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ABSTRACT 
 
Most solid tumors are intrinsically resistant to immune rejection due to 
immunosuppressive mechanisms operative within the tumor microenvironment. 
Cancer patients frequently harbor elevated numbers of regulatory T cells (Tregs), 
which inhibit efficient anti-tumor T cell responses. We employed different mouse 
models for Treg depletion in order to study the mechanisms that control tumor 
rejection. Depletion of about 99% Tregs in Foxp3
DTR
 knock-in mice resulted in 
complete rejection of transplanted HCmel 1274 and B16 melanomas in a CD8
+
 T cell-
dependent way. In contrast, about 90% Treg depletion in BAC transgenic 
Foxp3.LuciDTR4 mice failed to induce complete rejection of HCmel 1274 and B16, 
demonstrating that low numbers of Tregs were able to control CD8
+
 T cell responses 
against the tumor. Treg depletion provoked drastic changes within tumor 
microenvironment, such as cytokine storm and strong infiltration of CD8
+
 T cells. In 
addition, substantial infiltration of basophils was observed. This study reported for the 
first time that tumor-associated basophils play a crucial role in tumor rejection. These 
intratumoral basophils produced large amounts of chemokines such as CCL3 and 
CCL4 that were found to be responsible fo the infiltration of tumor-specific CD8
+
 T 
cells into the tumor. IFN-γ produced by these CD8+ T cells resulted in skewing of 
tumor-associated macrophages from a M2-like phenotype to a M1-like phenotype. In 
a feedback mechanism, the M1-like macrophages potentiated infiltration of CD8
+
 T 
cells by secreting potent CD8
+
 T cell chemoattractants, including CCL2, CXCL9 and 
CXCL10, and by inducing normalization of the tumor vasculature. 
 
The mechanisms of tumor rejection were also investigated in a second tumor 
model. Rip1-Tag5 (RT5) mice develop spontaneously pancreatic cancer, which 
precisely reflects the clinical development of pancreatic neuroendocrine tumors. Like 
almost all human and rodent tumors, these insulinomas contain an abnormal tumor 
vasculature, which acts as a barrier for T cell migration into the tumor. Thus, 
treatment of Rip1-Tag5 mice with adoptively transferred T cells failed to eradicate the 
tumors.  However, when T cell transfer was combined with CpG-ODN as an inducer 
of pro-inflammatory signals, upregulation of T cell adhesion molecules such as 
VCAM-1 on the tumor endothelium was observed, as well as strong infiltration of T 
  
cells, prolonged survival of tumor-bearing mice. Of note, CpG-ODN was found to 
bind to CD206
+
 iNOS
-
 M2-like macrophages and to polarize them into CD206
-
 iNOS
+
 
M1-like macrophages. Depletion of macrophages and blockade of iNOS revealed that 
the iNOS activity by the M1-skewed tumor macrophages was responsible for the 
increased VCAM-1 expression on the tumor endothelium and for the subsequent T 
cell infiltration and tumor rejection. Notably, transfer of pre-activated iNOS
+
 
macrophages in combination with tumor-specific CD8
+
 T cells, in the absence of 
additional CpG-ODN, was also able to promote VCAM-1 expression and T cell 
infiltration. In contrast, iNOS-deficient macrophages failed to do so, highlighting the 
critical role of NO production by M1-polarized tumor macrophages. In vitro, 
incubation of human endothelial cells with iNOS-expressing human macrophages or 
with the NO donor GTN induced expression of adhesion molecules, such as VCAM-
1, ICAM-1 and E-selectin, but only with low doses of GTN, whereas higher doses 
resulted in inhibition. Thus, these results indicate that NO production by M1-
polarized tumor macrophages is a critical step in tumor therapy.  
 
Together, the data from both mouse models show that adoptive T cell 
therapy and basophil/macrophage targeting strategies, or co-transfer of M1-polarized 
macrophages are able to evoke efficient T cell infiltration and tumor rejection. These 
findings have implications for immunotherapeutic interventions in cancer patients. 
 
  
ZUSAMMENFASSUNG 
 
Der Großteil solider Tumoren besitzt aufgrund immunsuppressiver 
Mechanismen, die ihre Aktivitäten in der Mikroumgebung des Tumors entfalten, eine 
intrinsische Resistenz gegenüber immunologischen Abstoßungsmechanismen. 
Tumorpatienten weisen häufig eine erhöhte Anzahl an regulatorischen T-Zellen auf, 
die effiziente T-Zell-Reaktionen gegenüber dem Tumor verhindern. Um die 
Mechanismen zu untersuchen, die die Tumorabstoßung kontrollieren, wurden von uns 
unterschiedliche Mausmodelle zur Depletion regulatorischer T-Zellen eingesetzt. In 
Foxp3
DTR
 knock-in Mäusen, deren Tregs zu circa 99 % entfernt worden waren, konnte 
eine vollständige CD8
+
 T-Zell abhängige Abstoßung transplantierter HCmel 1274 und 
B16 Melanoma erzielt werden. Im Gegensatz dazu gab es, nach einer circa 90%igen 
Depletion der Tregs in BAC transgenen Foxp3.LuciDTR4 Mäusen, keine vollständige 
Abstoßung der HCmel 1274 und B16 Tumore. Dies zeigt, dass bereits eine geringe 
Anzahl an Tregs genügt, um die CD8
+
 T-Zell-Antworten gegen den Tumor zu 
kontrollieren. Durch die Depletion der Tregs kam es zu sehr großen Veränderungen in 
der Tumormikroumgebung, die durch durch eine enorme Zytokinausschüttung und 
einer vermehrten Infiltration an CD8
+
T-Zellen ausgelöst wurde. Zusätzlich konnte 
eine erhebliche Infiltration basophiler Granulozyten beobachtet werden. 
 
In dieser Forschungsarbeit konnte zum ersten Mal gezeigt werden, dass die 
tumorassoziierten Basophilen eine signifikante Rolle bei der Tumorabstoßung 
besitzen. Diese im Tumor vorhandenen Basophile produzierten große Mengen an 
Zytokinen wie CCL3 und CCL4. Wir konnten nachweisen, dass diese Zytokinen für 
die Infiltration tumorspezifischer CD8
+ 
T-Zellen verantwortlich sind. Das von den 
CD8
+
 T-Zellen produzierte IFN-γ verursacht eine Änderung bei den tumorassoziierten 
Makrophagen vom M2-ähnlichen hin zum M1-ähnlichen Phänotyp. Über einen 
Rückkopplungsmechanismus verstärken die M1-ähnlichen Makrophagen die 
Infiltration der CD8
+
 T-Zellen indem sie stark chemotaktisch auf CD8
+
 T-Zellen 
wirkende Stoffe, einschließlich CCL2, CXCL9 und CXCL10, sezernieren und eine 
Normalisierung der Gefäßversorgung des Tumors induzieren. 
 
  
Die Mechanismen der Tumorabstoßung wurden in einem weiteren 
Tumormodell untersucht. Rip1-Tag5 Mäuse entwickeln spontan 
Bauchspeicheldrüsenkrebs, was sich auch in der klinischen Entwicklung 
neuroendokriner Pankreastumoren wiederspiegelt. Wie nahezu alle Tumoren bei 
Mensch und Nager, besitzen auch diese Insulinome eine veränderte Gefäßstruktur, 
welche sich als Barriere für die Infiltration von T-Zellen in dem Tumor auswirkt. 
Demzufolge führt eine Behandlung der Rip1-Tag5 Mäuse durch einen adoptiven T-
Zell Transfer zu keiner Tumoreradikation. Wurde aber der T-Zell Transfer mit CpG-
ODN, einem Auslöser proinflammotorischer Signale, kombiniert, konnte im 
endothelialen Tumorgewebe eine Hochregulation von T-Zell Adhäsionsmolekülen 
wie zum Beispiel VCAM-1 beobachtet werden, sowie eine starke Infiltration von T-
Zellen und eine verlängerte Überlebenszeit der tumortragenden Mäuse. 
Bemerkenswerterweise stellte sich heraus, dass CpG-ODN an CD206
+
 iNOS
+ 
M2-
ähnlichenMakrophagen bindet und sie zu CD206
-
 iNOS
+
 M1-ähnlichen Makrophagen 
polarisiert. Durch die Depletion der Makrophagen und die Blockade von iNOS wurde 
gezeigt, dass die iNOS Aktivität der zu M1-gewandelten Tumor Makrophagen für die 
vermehrte Expression vonVCAM-1 auf dem Tumorendothelien sowie die 
nachfolgende T-Zell Infiltration und Tumorabstoßung verantwortlich waren. 
Beachtenswert ist ebenfalls, dass der Transfer voraktivierter iNOS
+
 Makrophagen 
zusammen mit tumorspezifischen CD8
+
 T-Zellen, auch in Abwesenheit von CpG-
ODN, in der Lage waren die VCAM-1 Expression und die Einwanderung der T-
Zellen zu fördern. Im Gegensatz dazu fehlte diese Eigenschaft iNOS defizienten 
Makrophagen, was die wesentliche Rolle der NO Produktion durch M1-polarisierte 
Tumor Makrophagen hervorhebt. Mittels in vitro Experimenten konnte demonstriert 
werden, dass die Inkubation humaner Endothelzellen mit iNOS exprimierenden 
humanen Makrophagen oder mit dem NO Spender Glyceroltrinitrat (GTN) die 
Expression von Adhäsionsmolekülen wie VCAM-1, ICAM-1 und E-Selectin 
induzierte. Allerdings konnte dieser Effekt nur mit niederen Dosen GTN erzielt 
werden. Höhere Dosen führten zu einer Inhibition. Diese Ergebnisse machen deutlich, 
dass die NO Produktion durch M1-polarisierte Tumor Makrophagen einen kritischen 
Punkt einer Tumortherapie darstellt. 
 
Zusammengefasst zeigen die Daten beider Mausmodelle, dass adoptive T-
Zelltherapie und zielgerichtete Strategien bezüglich Basophile/ Makrophagen oder 
  
auch der Transfer von M1-polarisierten Makrophagen eine effiziente T-Zell 
Infiltration und Tumorabstoßung bewirken. Diese neuen Erkenntnisse können die 
immuntherapeutischen Behandlungsstrategien bei Tumortherapien beeinflussen. 
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INTRODUCTION 1 
 
1 INTRODUCTION 
 
1.1 Tumor Immunity 
 
Cancer is one of the biggest health problem in the world. In 2012, there were 
an estimated 14.1 million new cancer cases diagnosed and 8.2 million cancer deaths 
worldwide
1
. Cancer is characterized by the accumulation of mutations in various 
genes that results in the loss of normal cellular regulatory processes and, consequent 
transformation of normal cells into malignant cells with unlimited proliferation 
capacity. Nevertheless, the host develops various defenses against the growth of 
transformed cells. These defenses include the immune system.  
 
More than a five decades ago, Lewis Thomas and Frank Macfarlane Burnett 
proposed the “immune surveillance” theory stating that the immune system can confer 
protection against cancer by recognizing and eliminating transformed cells
2, 3, 4, 5
. 
Since then, the idea that the immune system can control cancer has been a matter of 
great debate. Over the last two decades, findings from gene-targeted mouse models 
that selectively lack key components of the immune system have reinforced the 
immune surveillance theory. Recombination activating gene 2 (RAG2)-deficient mice 
that lack both T and B cells were shown to be more susceptible to spontaneous or 
carcinogen-induced carcinomas
6. In addition, mice lacking γδ T cells showed 
increased susceptibility to developing cutaneous tumors
7
. Strikingly, mice deprived of 
cytokines interferon-α/β (IFN-α/β) or IFN-γ were found to be more susceptible to 
spontaneous tumor induction as well as tumor induction by chemical carcinogen
5, 6, 8,9
. 
Further evidence for the immunosurveillance theory was provided by the mice 
deficient of perforin
10
, which is used by cytotoxic T cells to kill target cells. These 
mice exhibited elevated incidence of spontaneous lymphoma
10
. All together, these 
data indicate that the immune system does indeed confer protection against cancer in 
mice. However, a study, showing the importance of IFN- γ in tumor rejection, 
suggested that the immune system can also promote tumor progression by shaping 
tumor immunogenicity
6
. This caused a considerable revision of immunosurveillance 
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hypothesis and gave rise to a relatively extended hypothesis termed “cancer 
immunoediting”, which is divided into three sequential phases. The first phase is 
called “elimination” phase in which the immune system acts to destroy transformed 
cells long before they develop to clinically apparent tumors. If the elimination is 
complete, this phase represents the full extent of the process. However, if rare tumor 
cell variants survive the elimination phase, they may enter the “equilibrium” phase in 
which the immune system is still able to control the outgrowth of tumor cells but, 
meanwhile, shapes the tumor immunogenecitiy. The constant immune selection 
pressure placed on genetically unstable tumor cells in the equilibrium phase may yield 
variants with new mutations that confer them escape mechanisms, including antigen 
loss, defects in antigen processing and presentation (i.e. loss of major 
histocompatibility complex (MHC) expression), and induction of anti-apoptotic 
mechanisms. Alternatively, tumors may escape immune attacks by establishing 
immunosupressive tumor microenvironment. Then, these tumor cells in “escape” 
phase may multiply to generate clinically apparent tumors.  
 
In addition to evidence compiled in mice, there are clear indications that the 
human immune system does indeed naturally protect against cancer. The main 
evidence in human comes from observations that primary (inborn) 
immunodeficiencies are correlated with increased risk of malignancy. For example, 
patients with common variable immunodeficiency (CVID), who have defective 
humoral immunity, are far more susceptible than the general population to lymphoma, 
stomach, breast, bladder and cervix cancer
11, 12
. Patients with immunoglobulin A 
(IgA) deficiency showed higher incidence of gastric carcinoma
12
. Furthermore, 
patients, who have a mutation in the CD40 ligand molecule, had an increased 
incidence of developing pancreas and liver tumors
13
. All these findings reveal a 
consistent correlation between primary immunodeficiency and elavated risk of 
developing various types of tumors. 
 
Histopathologic data has demonstrated that many solid tumors are infiltrated 
by immune cells including T and B lymphocytes, natural killer (NK) cells and 
macrophages. Several studies indicate an association between immune cell infiltrates 
and the clinical outcome for many cancer types. For instance, the presence of CD3
+
 T 
cells in ovarian and colorectal cancers was shown to be correlated with increased 
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survival of patients
14, 15
. CD4
+
 T cell infiltrates were found to predict positive clinical 
outcome in non-small cell lung cancer
16
. CD8
+
 T cell infiltration into colon, lung and 
breast tumors represents a positive prognostic marker
16, 17, 18, 19
. CD4
+  
and CD8
+
 T 
infiltrates, together, were shown to be associated with prolonged survival in 
esophageal squamous cell carcinoma and non-small cell lung cancer
20, 21
. As 
compared to other subsets of CD4
+
 T cells, T-helper (Th)-1 phenotype was reported 
to be beneficial for colorectal, liver and breast cancer patients
14, 22, 23, 24
. Infiltration by 
NKp46
+
 NK cells was also found to predict positive clinical outcome  in patients with 
gastrointestinal stromal tumors (GIST)
25
. Moreover, the number of intratumoral 
CD68
+
 macrophages was demonstrated to be linked to longer survival of patients with 
prostate, lung and colon cancers
17, 25, 26, 27, 28
. This association between immune cell 
infiltration and clinical outcome is intriguing but does not provide a direct evidence 
for the generation of an effective anti-tumor immune responses in cancer patients.  
 
Today, it is well established that tumor cells can express antigens that can be 
recognized by B and T lymphocytes. So far, a variety of tumor antigens have been 
discovered in both mouse and human cancers, especially ones recognized by 
cytotoxic CD8
+
 T cells. Tumor antigens can be classified into two group based their 
expression patterns. Antigens that are expressed solely on tumor cells are called 
“tumor-specific antigens” and have the potential to induce tumor-specific immune 
responses. This class of antigens includes viral antigens, antigens that result from 
mutations, deletions, chromosomal translocations or viral gene insertions affecting 
proto-oncogens and tumor-suppressor genes, and antigens that are encoded by cancer-
germline genes. The majority of these antigens is unique to individual tumors, 
whereas few of them are shared by different tumors. Another class of antigens are 
called “tumor-associated antigens” which are expressed on both normal and tumor 
cells. Most of these antigens are strongly overexpressed in tumor cells in comparison 
to normal cells. Besides, some antigens are unique to particular lineage but expressed 
on both malignant and normal cells. 
 
The molecular identification of human tumor antigens has provided the basis 
for the development of immunotherapies for cancer patients. In principle, two 
treatment concepts have emerged on the basis that tumors express antigens, which can 
be recognized by T cells. Antigen-specific “vaccination therapy” is designed to 
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stimulate and augment anti-tumor activity of patient’s T cells whereas “adoptive T 
cell therapy” involves infusion of ex vivo-expanded tumor antigen-specific T cells 
into cancer patients for elimination of cancer cells.  
 
1.1.1 Evasion of immune responses by tumors 
 
The generation of an anti-tumor immune response is a multi-step process that 
involves several components of the immune system. In the first step, antigens released 
from tumor cells are taken up by antigen-presenting cells (APCs). APCs, mainly 
dendritic cells, process the tumor antigens and present them to CD4
+
 T cells or CD8
+
 
T cells on MHC-II or MHC-I molecules, respectively, in regional lymph nodes. This 
step results in priming and activation of effector T cells directed against tumor 
antigens. Next, activated T cells have to traffic to the tumor site and cross the tumor 
endothelial barrier in order to obtain access to the tumor bed, where they can kill the 
tumor cells.  
 
Tumors possess multiple mechanisms to evade and resist T cell-mediated 
immune attacks. These mechanisms enable tumor cells to interfere with almost every 
step needed for effective immune responses, from  deregulation of APCs that prevents 
efficient T cell priming to establishment of aberrant endothelial barrier that blocks T 
cell infiltration and to generation of immunosuppresive microenvironment that 
abolishes T cell activity in the tumor. 
 
1.1.1.1 Progressive loss of tumor-specific T cells 
 
Central tolerance mechanism presents a challange to the generation of anti-
tumor T cell responses while protecting against autoimmunity. Medullary thymic 
epithelial cells (mTECs) contribute to central tolerance through expression of a broad 
range of self antigens, which is largely dependent on autoimmune regulator (AIRE).  
During thymic maturation, developing T cells that responds to self-antigens on 
mTECs are deleted by negative selection or assume regulatory T (Treg) cell 
phenotype. Since many tumor antigens are self-antigens, many tumor-specific T cells 
are potentially deleted as well. However, central tolerance is sometimes incomplete, 
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allowing maturation and survival of low numbers of tumor-specific T cells with T cell 
receptors (TCRs) that have low-to-intermediate affinity for antigen recognition
29
. In 
fact, transient depletion of mTECs or modulation of AIRE ecpression were shown to 
enhance anti-tumor immunity by increasing the pool and affinity of effector T cells 
recognizing tumor/self-antigens
30, 31
.  
 
1.1.1.2 Inefficient priming of tumor-reactive T cells 
 
Tumors can impair tumor antigen presentation to T cells mainly by 
modulating dendritic cells (DCs), which are the most efficient APCs. DCs capture 
tumor-derived antigens, process them into peptides, migrate into the tumor-draining 
lymph nodes, where they present peptide-MHC complexes to T cells, thereby 
generating antigen-specific T cell responses. Antigens may also directly travel to 
draining lymph nodes through lymph and can be taken up by lymph node-resident 
DCs
32
. Non-activated (immature) DCs are highly phagocytic and can process antigens 
for presentation to T cells but often induce immune tolerance through T cell deletion, 
T cell anergy or expansion of regulatory T cells
33, 34, 35, 36
. In contrast, mature DCs, 
which are activated by a variety of factors including pathogen-associated molecular 
patterns (PAMPs)
37, 38, 39
, danger-associated molecular patterns (DAMPs)
40, 41, 42, 43
, 
cytokines
44, 45
 and CD40 ligand
46, 47, 48, 49
, elicit effective T cell responses. Typically, 
tumor microenvironment lacks the factors required for DC activation, and, therefore, 
tumor-infiltrating DCs often show functionally impaired phenotype
50
. In addition, 
tumors produce factors that prevent DC maturation. Such factors include vascular 
endothelial growth factor (VEGF)
51, 52, 53
, interleukin (IL)-10
54
, transforming growth 
factor (TGF)-β55. Hypoxia and lactic acid, which are frequently present in the tumor 
microenvironment, can also influence DC maturation
56, 57
. Immature DCs or 
incompletely matured DCs assume regulatory phenotype and secrete 
immunosuppresive molecules, including  IL-10, indoleamine 2,3-dioxygenase (IDO) 
and prostagladin E2 (PGE2)
56, 57, 58, 59, 60
. Moreover, tumors affect differentiation of DC 
precursors. For example, tumor-derived IL-6 and macrophage colony-stimulating 
factor (M-CSF) have been reported to promote differentiation of monocytes to 
macrophages rather than DCs
61
, hence contributing to reduced APC activity in cancer 
patients.  
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1.1.1.3 Impaired infiltration of tumor-reactive T cells into the tumor 
 
The control of T-cell trafficking to tumors are coordinated by chemokines. It 
seems that inefficient levels of intratumoral chemokine expression contribute to tumor 
escape from T cell responses. Of note, tumors with high-level T cell infiltration are 
characterized by high-level expression of T cell-attracting chemokines, including  
chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL4, CCL5, chemokine (C-X-C 
motif) ligand 9 (CXCL9) and CXCL10
62
. Chemokine activity can be  disrupted by 
abnormal post-translational modifications, and alterations in proteolytic cleavage, 
glycosylation, or deamination
63, 64
, which are common processes in the tumor 
microenvironment. For instance, reactive nitrogen species (RNS) in the tumor 
microenvironment cause nitrosylation of CCL2, which, therefore loses the ability to 
recruit tumor-specific T cells into tumor bed
65
.  
 
T cells must cross the tumor endothelium in order to be able to recognize and 
kill tumor cells. However, accumulating evidence indicates that the tumor 
endothelium actually represents a physical barrier to T cell penetration into the 
tumor
66, 67, 68
.  
 
The angiogenic switch is a critical step in tumor progression. It induces 
formation of new vessels from pre-existing capillaries  and post-capillary venules to 
provide oxygenation, nutrition and waste disposal for the growing tumor mass. 
Importantly, the angiogenic switch leads to an aberrant tumor vasculature that is 
characterized by structural abnormalities, including heterogenous distribution, 
tortuosity, dilation, inadequate perivascular cell coverage and funtional abnormalities, 
such as insufficient blood flow and leakiness
69
.  This aberrant phenotype is driven via 
production of angiogenic factors, such as VEGF, by tumor itself
70, 71
 and/or by tumor-
infiltrating macrophages
72, 73
 and/or by tumor-infiltrating Tregs
74
. Our group has 
shown that the abnormal tumor vasculature itself  can also act as a major barrier to T 
cell infiltration
75
. Gene expression profiling data demonstrated that regulator of G-
protein signaling (RGS)-5 was overexpressed in aberrant tumor vasculature
76
. Genetic 
deletion of RGS-5 resulted in normalization of the vasculature, pericyte maturation 
and striking decreases in tumor hypoxia and vessel leakiness
75
. These vascular 
changes, in turn, augmented the influx of tumor-specific effector T cells into tumor 
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and enhanced survival of tumor-bearing mice
75
. Angiogenic factors in the tumor 
microenvironment, such as VEGF and fibroblast growth factor (FGF), were shown to 
hinder the endothelial expression of intracellular adhesion molecule (ICAM)-1/2 and 
vascular cell adhesion molecule (VCAM)-1
77, 78
, which are critical for adhesion of T 
cells to tumor endothelium. T cell infiltration-blocking nature of tumor endothelium 
might be determined by the quantity of these adhesion molecules. Moreover, an 
aberrant vasculature causes a tumor microenvironment, which is a hostile milieu for T 
cells. For example, an abnormal tumor vasculature is associated with hypoxia in the 
tumor
69
, which is known to limit T cell functions
79, 80, 81
. Tumor endothelial cells can 
also produce immunosuppressive molecules, including programmed death ligand 
(PD-L) 1 and 2
82, 83, 84
, B7-H3
85
, T cell immunoglobulin mucin (TIM)-3
86
, IL-10
87, 88
, 
TGF-β87, 88 and PGE2
87, 88
. A recent study demonstrated that Fas ligand (FasL) 
expression on tumor endothelial cells induces the death of effector T cells, thus 
limiting T cell infiltration into tumor
89
. 
 
1.1.1.4 Immunosuppressive mechanisms in the tumor microenvironment 
 
Upon penetration into tumors, T cells will encounter an immunosuppressive 
microenvionment characterized by tumor stroma and immunosuppresive immune 
cells such as Tregs, tumor-associated macrophages (TAMs) and myeloid-derived 
suppressor cells (MDSCs). The tumor stroma is composed of  fibroblasts, myeloid-
lineage cells and endothelial cells with variable extent of extracellular matrix (ECM). 
They all appear to play crucial roles in tumor progression by providing an 
environment for tumor grrowth
90, 91, 92
 or by curbing anti-tumor immune 
responses
93,94
. Carcinoma-associated fibroblasts (CAFs) comprises a major portion of 
tumor stroma and exhibit altered functions in comparison to normal 
fibroblasts
91,92,95,96,97,98
. Elimination of fibroblasts with a genetic model that lacks 
fibroblast-activating protein (FAP) was shown to induce tumor regression by a 
mechanism that relied on host IFN-γ and tumor necrosis factor (TNF) production94. 
 
CD4
+
 CD25 
+
 (IL-2 receptor
+
) forkhead box P3
+
 (Foxp3
+
) Tregs are enriched 
in the tumors of several cancer types, including melanoma
99
, ovarian
100
, breast
101
, 
colorectal
102
, lung
100
, gastric
103
 and pancreatic
101
 cancers. Of particular interest is the 
observation that elevated numbers of Tregs in tumors predict poor clinical outcome in 
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some cancers, such as breast
104
, gastric
103
 and ovarian
105, 106
 cancers.  Natural Tregs 
(nTregs), which originate in the thymus like other T cells, can be recruited to tumors 
via several factors. CCL22 production by tumors and TAMs was reported to induce 
infiltration of chemokine (C-C motif) receptor (CCR)4
+
 Tregs in ovarian cancer
105
 
and Hodgkin’s lymphoma107. Recently, hypoxia was found to favor CCR10+ Treg 
recruitment into ovarian tumors by upregulating CCL28 expression in the tumor 
microenvironment
74
. In addition to chemokine-mediated attraction of Tregs, tumors 
promote the expansion nTregs
108
 and the generation of inducible Tregs (iTregs) from 
naive CD4
+
 T cell precursors
109
. This conversion can be achieved by enhanced 
expression of IL-10
110
, TGF-β111 and adenosine112 in the tumor microenvironment. 
Tregs exert immunosuppresive functions that result in immunologic tolerance and 
ignorance of tumors. Tregs are known to inhibit efficient priming of T cells in lymph 
nodes
113, 114
, thereby preventing expansion of tumor-specific CD8
+ 
T
 
cell clones. This 
is probably the most important mechanism by which Tregs block efficient T cell 
responses against tumors. Tregs also secrete IL-10, TGF-β, IL-35, which are known 
to inhibit immune responses by supressing expansion of T cells and cytokine 
production by T cell 
115, 116
. Of importance, IL-10 and TGF-β have been shown to 
mediate tumor progression by limiting anti-tumor immunity
117, 118
. An additional 
mechanism of Treg-mediated immunosuppression is the induction of effector T cell 
apoptosis, which is executed via expression of granzyme B
119, 120
, tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL)
121
 and galectin-1
122
. Tregs induce 
effector T cell apoptosis also by depleting local resources of IL-2
123
, which is 
essential for survival of both Tregs and effector T cells. Further, Tregs suppress T cell 
functions through the generation of adenosine
124, 125
. Tregs can limit anti-tumor 
immune responses not only by acting on effector T cells but also by acting on DCs, 
impairing antigen presentation to tumor-specific T cells. They can engage in crosstalk 
with DCs through cell-cell interaction mediated by cytotoxic T lymphocyte antigen 
(CTLA)-4 on Tregs and CD80 and/or CD86 on DCs
126
. This interaction induces IDO 
expression by DCs, which, in turn, suppress T cell functions through tryptophan 
catabolism
126. Tregs have been shown to restrict DCs’ ability to stimulate T cell 
priming and activation by some other mechanisms, including inhibition of 
costimulatory molecules, tolerogenic polarization of DCs by IL-10 and TGF-β127 and 
Treg-DC interactions via lymphocyte-activation gene (LAG)-3
128
. A recent study has 
defined a new role for Tregs in tumor progression
74
. Beyond their immunosuppressive 
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activities, Tregs have been demonstrated to promote angiogenesis in ovarian cancer 
by VEGF expression
74
. 
 
Macrophages and MDSCs are abundantly present in solid tumors and can 
contribute to immune evasion. Macrophages are specialized phagocytic cells that 
engulf and digest invading microbes, cell debris and foreign substances
129
. In 
addition to their phagocytic activity, they can modulate adaptive immune responses 
through antigen presentation or  through the release of various cytokines and 
chemokines
129
. Macrophages can acquire distinct phenotypes depending on the 
local tissue microenvironment
129
. The conventional classification divides activated 
macrophages into M1 macrophages (classically activated macrophages) and M2 
macrophages (alternatively activated macrophages)
129
. Importantly, macrophage 
polarization is usually temporary and can be altered by changes in the tissue 
microenvironment
129
, indicating a high degree of plasticity. M1 polarization can be 
driven by bacterial moeties, such as toll-like receptor (TLR) ligands and Th1 
cytokines, including IFN-γ and TNF-α129. Upon activation, M1-polarized 
macrophages secrete pro-inflammatory cytokines that orchestrate Th1-type immune 
responses, and chemokines that attract other Th1-related immune cells
129
. In 
contrast, M2 macrophages are mainly induced by Th2 cytokines IL-4, IL-13 and 
IL-10
129
. Upon activation, they produce cytokines and chemokines that are 
involved in Th2-type immune responses
129
. M2 macrophages can also exert 
immunoregulatory functions and take part in tissue homeostasis
129
.  Importantly, 
macrophage polarization in vivo rarely results in pure M1 or M2 populations but 
usually into populations that are skewed only to a certain extend towards the M1 or 
M2 phenotype. For instance, tumor macrophages show M2-like phenotype due to 
abundant presence of cytokines and growth factors, such as IL-4, IL-13, IL-10 and 
M-CSF, in the tumor microenvironment
130, 131, 132, 133
.  Clinical evidence show that 
increased numbers of TAM is associated with poor prognosis and resistance to 
therapies in many cancer types, such as breast cancer
134, 135, Hodgkin’s 
lymphoma
136, 137
, T cell lymphoma
138, 139
, B cell lymphoma
140
, cervical cancer
141
, 
uveal melanoma
142
 and lung cancer
143
.  
 
TAMs also play an essential role in regulating tumor angiogenesis. Clinical 
studies have reported a positive correlation between blood vessel density and the 
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number of TAMs in vessel areas in human tumors
144, 145
. Mouse models further 
supported the role of TAMs in tumor angiogenesis. It has been shown that TAM 
depletion in mice reduced tumor angiogenesis
146, 147
 whereas TAM enrichment 
augmented tumor angiogenesis
148
. Moreover, hypoxia in the tumor microenvironment 
modulates macrophages to produce large amounts of VEGF via hypoxia-inducible 
factor (HIF)-1 and HIF-2 signaling
149, 150, 151
. Indeed, VEGF production by TAMs has 
been demonstrated to regulate angiogenesis in the spontaneous mammary carcinoma 
model and in some transplantable tumor models
73, 152
.  TAMs also produce and 
secrete number of other pro-angiogenic factors such as placental growth factor 
(PlGF), basic-fibroblast growth factor (b-FGF), M-CSF, platelet-derived growth 
factor (PDGF), heparin-binding epidermal growth factor (HB-EGF), macrophage-
inhibitory factor (MIF), platelet activating factor (PAF), semaphorin 4D (Sema4D) 
and TGF-β153, 154, 155. 
 
TAMs release a variety cytokines that can suppress effector T cells. TAMs 
have been reported to produce IL-10 and TGF-β in human and animal cancers156, 
which are implicated in tumor progression by hindering anti-tumor immune 
responses. In addition, macrophages have been shown to cause Treg recruitment to 
tumors by chemokine production
105, 157
 and induce conversion of naive CD4
+
 T cell 
into iTregs in the tumor
158
. TAM-derived arginase I (ARGI) can curb T cell activity 
by depleting local L-arginine resources in the tumor microenvironment
81, 159, 160, 161
. 
 
MDSCs are immature myeloid-cell lineage cells, which are often found in 
large numbers in cancer patients and correlated with tunor progression
58
. They can 
potently suppress effector T cells through functional activity of ARGI
160
 and 
nitrosylation of TCR on infiltrating T cells by RNS
162
.  
 
T cell-mediated tumor killing requires the recognition of target tumor antigen 
through MHC-TCR interactions. However, many tumors develop resistance to T cell 
attacks through loss of antigen and MHC expression, and deregulation of antigen-
processing
163, 164, 165, 166, 167
. These resistance mechanims possibly stem from selection 
pressures of host immunity and can be acquired by mutations, genetic loss or  
epigenetic silencing
164
. In fact, loss of MHC expression is linked to poor clinical 
outcome in cancer patients
163
. Tumors may produce molecules, such as FasL and 
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TRAIL
168
, that can directly kill T cells. They can also express surface molecules PD-
L1 and PD-L2
169
, which, in turn, binds to programmed death receptor (PD)-1 receptor 
on activated T cells and prevents T cell proliferation, cytokine production and 
cytolytic activity
170
. Of importance, PD-L1 and PD-L2 are also highly expressed on 
tumor-infiltrating DCs and macrophages
171, 172, 173
. 
 
In summary, tumors employ a variety of intrinsic and extrinsic strategies to 
impair immune responses and to promote their progression. In the  field of tumor 
immunology, major efforts now concentrate on attenuating immune escape 
mechanims of tumor to improve efficacy of immunotherapies against cancer.   
 
1.1.2 Clinical immunotherapies for cancer 
 
The potential for treating cancer patients by immunotherapies is now 
becoming a clinical reality. Current therapies for cancer, including chemotherapy and 
radiotherapy, are designed to block cell division or kill proliferating cells but they 
may have severe side effects on normal cells. In contrast, immunotherapy has the 
potential of being the most tumor-restricted treatment modality since immune 
responses to tumors are usually against the antigens that are specific to tumors.  
 
The earliest attempts to boost cancer patient’s immune responses against 
tumor cellls include antigen-based vaccination. Cancer vaccines are typically 
composed of tumor antigens and adjuvants, such as toll-like receptor (TLR) ligands 
poly I:C, monophoshoryl lipid A (MPL), flagellin, Aldara (Imiquimod), Resiquimod 
and CpG
174
. They are designed to stimulate antigen-specific T cell responses to 
eliminate tumors and to generate memory T cells that will serve to impede relapse. 
Indeed, vaccination of cancer patients based on purified tumor antigen-associated 
peptides or whole tumor cells leads to expansion of antigen-specific CD4
+
 and/or 
CD8
+
 T cells in the blood
175, 176, 177, 178, 179, 180
, however the clinical success is limited 
(objective response rate = 3.8%)
177, 180, 181
.  
 
The adoptive transfer of tumor-specific T cells into cancer patients is one of 
the main treatment modalities within cancer immunotherapy. In this therapy, T cells 
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are isolated from patients’ blood or tumor, and then expanded in vitro in the presence 
of appropriate T cell growth factors such as IL-2. T cell populations that are reactive 
against tumor antigens can be specifically selected and expanded, then adoptively 
infused into cancer patients. When combined with lymphodepletion by chemotherapy 
alone or chemotherapy in combination with total body irradiation, adoptive T cell 
therapy (ACT) of patients with metastaic melanoma resulted in objective response 
rate around 48%
182, 183, 184
. It seems that the availability of naturally occuring tumor-
infiltrating cells for ACT is restricted to melanoma
185
. Therefore, in order to expand 
the range of cancers potentialy susceptible to ACT therapy, T cells are engineered to 
express appropriate T cell receptor that is specific for particular tumor antigen by 
several techniques. The most developed technique is the use of chimeric antigen 
receptors (CARs), in which T cells from patients are transfected or transduced with a 
construct encoding a single chain variable fragment of an antibody that specifically 
recognize target tumor antigen
185
. Thanks to CAR technology, the range of cancer 
amenable to ACT now includes B-cell acute lymphoblastic leukemia (against 
CD19)
186
, renal carcinoma (against carbonic anhydrase)
187
 and neuroblastoma 
(against L1 adhesion molecule)
188
. The most promising results have been achieved in 
blood cancers
189, 190
, where T cells do not have to penetrate a stromal barrier to 
recognize and kill tumor cells. 
 
Despite the considerable successes with vaccination and ACT, some patients 
fail to respond favourably to these treatments, probably due to the presence of 
immunosuppresive elements within the tumor microenvironment. The tumors in these 
patients may have tumor vasculature that is nonpermisive for entry by T cells. 
Proangiogenic signals are known to drive abnormalization of tumor vasculature that is 
characterized by reduced expression of adhesion molecules for T cell penetration
191, 
192
. In addition, dysregulated tumor angiogenesis creates a hostile microenvironment 
for T cells
191
. Interestingly, treatment of tumor-bearing mice and cancer patients with 
anti-angiogenic agents resulted in a normalized vasculature and a more 
immunosupportive tumor microenvironment
191
. The United States Food and Drug 
Administration (FDA)-approved anti-VEGF antibody, bevacizumab,  has shown its 
effectiveness in normalizing tumor vasculature in several clinical trials
193, 194, 195
. 
Several animal studies have shown that vessel-targeted therapies improve the efficacy 
of immunotherapies by augmenting T cell infiltration into the tumor
75, 196, 197, 198
.  
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One of the immunosuppresive mechanisms present in the tumor 
microenvironment is the negative regulation of T cell activation by cytotoxic T 
lymphocyte activation marker 4 (CTLA-4), which is an coinhibitory receptor 
expressed on activated T cells and binds to costimulatory molecules B7.1 and B7.2 on 
antigen presenting cells
199
. The use of ipilimumab, a monoclonal antibody directed 
against CTLA-4, in clinical trials has shown an overall survival benefit for patients 
with advanced melanoma
200, 201
. Programmed death (PD)-1 is another coinhibitory 
receptor expressed on T cells and binds to PD-L1 and PD-L2 expressed on tumor 
cells, stromal cells or other immune cells
202
. Blocking of PD-1 signaling has been 
shown to enhance T cell responses against tumors in animal studies
173, 203
. In addition, 
clinical trials using either anti-PD-1 or or anti-PD-L1 antibodies resulted in objective 
clinical responses in patients with melanoma, renal cell cancer or lung cancer
204, 205
.  
Importantly, dual blockade of PD-1 and CTLA-4 were demonstrated to further 
augment T cell responses in a preclinical model with transplantable tumors
206
 whereas 
clinical trials with dual blockade is underway (trial number NCT01024231).  
 
In summary, multiple approaches to cancer immunotherapy exist and few are 
able to generate significant clinical responses. One attractive approach is to combine 
potent vaccines or adoptive T cell therapy with therapeutic agents targeting 
immunosuppressive cells or molecules in the tumor microenvironment.  
 
1.2 Treg Depletion as A Model to Study Anti-Tumor 
Immune Responses 
 
The role of Tregs in cancer progression has mentioned above in section 
1.1.1.4. Several groups have examined whether Treg depletion can improve anti-
tumor immunity. It was reported that Treg depletion with PC-61 antibody (anti-CD25 
antibody), before tumor inoculation, caused tumor regression
207, 208, 209, 210, 211, 212
 
whereas PC-61-mediated Treg depletion after tumor establishment had no effect in 
tumor growth
207, 213, 214
.  The limited therapeutic efficacy of PC-61 antibody treatment 
is attributed to fact that the degree of depletion is not sufficient and PC-61 antibody 
also removes CD25
+
 effector T cells.  In some clinical trials, denileukin diftitox 
(ONTAK), which is a fusion protein between active domain of diphtheria toxin (DT) 
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and IL-2,  is employed to reduce Treg number in cancer patients
215, 216, 217
. Although 
ONTAK was indeed able to decrease the number of Tregs in patients but the 
therapeutic efficacy was hampered, probably because of unwanted effects on tumor-
specific T cells
218
. 
 
To test a more specific Treg ablation in pathological settings, including 
cancer, various groups have developed genetic models that allow selective depletion 
of Tregs by targeting only the cells expressing Foxp3, which is a transcription factor 
required for the development and function of Tregs. For this group, Alexander 
Rudensky’s group has generated Foxp3DTR mice harboring knock-in human diphtheria 
toxin receptor (DTR), and enhanced green fluorescent protein (eGFP) downstream of 
the internal stop codon of foxp3 gene
219
. In this model, DT application results in 
transient depletion of almost all Tregs
219
. However, continuous DT administration in 
this model induces fatal autoimmunity
219
. Our group established Foxp3-LuciDTR4 
mice, which contain  a bacterial artificial chromosome (BAC) construct, composed of 
eGFP, human DTR and CBGr99 luciferase,  which was inserted at the start codon of 
foxp3 gene
220
. DT administration in  these mice ablates DTR-expressing Tregs 
without inducing any autoimmune responses but DTR
-
 Tregs, which represent the 
very little portion of whole Treg population in mice, persist
220
. Another published 
Foxp3-DTR strain of mice, designated DEREG mice, also contains a BAC construct 
encoding human DTRand GFP
221
. 
 
Using the Foxp3-LuciDTR4 model, my group showed that Treg depletion 
induced activation of tumor-specific T cells and rejection of ovalbumin-expressing 
B16 (B16-OVA) tumors
222
. In the present study, I made use of Foxp3
DTR
 and Foxp3-
LuciDTR4 mouse models to study anti-tumor immune responses against melanoma. I 
found that basophils are specifically enriched in melanomas following Treg depletion 
in Foxp3
DTR
 mice, enabling us to define a new role for basophils in anti-tumor 
immunity. 
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1.2.1 Basophils 
 
Basophils are circulating basophilic granulocytes that comprise less than 1% 
of peripheral blood leukocytes. They were discovered by Paul Ehrlich in 1879 and 
named after their metachromatic granules that stain with basic dyes. Human basophils 
are 7-10 μm in size and have a segmented nucleus.  
 
Basophils share several aspects with mast cells, such as expression of the 
high-affinity immunoglobulin E receptor FcεRI on cell surface and the secretion of 
chemical mediators that are associated with allergic responses
223, 224
.  Therefore, they 
have often been mistakenly considered as minor and possibly redundant relatives of 
mast cells or as blood-circulating progenitors of mast cells. However, basophils can 
also be distinguished from mast cells by their segmented nuclei, mast cell protease 8 
(mMCP8, also known as Basoph8) production and the lack of mast/stem cell growth 
factor receptor (c-Kit) expression
225
.  Basophils enter the blood circulation in a steady 
state after they complete their maturation in the bone marrow. They infilrate into 
peripheral tissues upon various stimuli linked to pathological settings, including 
allergic reactions and parasitic infections
223, 224
. In contrast, mast cell circulate in the 
blood in an immature form and complete their maturation in the peripheral tissues in 
which they reside
223, 224
. Basophils do not proliferate after their maturation whereas 
mast cells can further proliferate in the periphery
223, 224
. In addition, the lifespan of 
basophils (~60 hour
226
) is much shorter than that of mast cells (weeks to months)
223, 
224
. These differences between basophils and mast cells indicate that they may have 
distinct functions. 
 
1.2.1.1 Basophil development 
 
All blood cells emerge from hematopoietic stem cells (HSC) in the bone 
marrow. HSCs mature into common lymphoid progenitors (CLPs) that can give rise 
to T, B and NK cells or mature into common myeloid progenitors (CMPs) that are 
antecedents of erythrocytes, monocytes and granulocytes. Eosinophils, basophils and 
mast cells originate from the granulocyte-monocyte progenitor (GMP), descending 
from the CMP
227
.   
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Commitment to eosinophil, basophil and mast cell lineages relies on the 
stimulation of specific transcriptional regulators in response to signals received from 
the cell surface. A model has been proposed that complex interplay between 
transcriptional factors GATA-2 and CEBP/α drives a GMP to specifically acquire 
eosinophil, basophil or mast cell properties, respectively
228
. Co-expression of GATA-
2 and CEBP/α in GMPs leads to eosinophil development whereas GATA-2 
expression in the absence of CEBP/α promotes GMPs to differentiate into basophil-
mast cell common progenitors (BMCPs)
228
. BMCPs can then give rise to basophils by 
re-expression of CEBP/α or to mast cells if CEBP/α remains not expressed228. These 
findings indicate a tight developmental link between basophils, mast cells and 
eosinophils. 
 
The precise extrinsic signals that guide timed expression of GATA-2 and 
CEBP/α and coordinated development of basophils, mast cells and eosinophils remain 
to be determined. It has been shown that IL-3, IL-5, granulocyte macrophage colony-
stimulating factor (GM-CSF) and thymic stromal lymphopoietin (TSLP) are not 
necessary for basophil development in steady-state conditions because mice that lack 
receptors for these cytokines still harbor the same level of basophils compared to wild 
type mice
229
. 
 
1.2.1.2 Basophil homeostasis 
 
Pathological conditions, such as parasitic infections, can induce a rise in 
basophil numbers. For instance, helminth infection of mice resulted in basophilia, 
which was shown to be dependent on IL-3
230
. Further studies demonstrated that T 
cells are a major source of IL-3 for induction of basophilia during helminth 
infection
231
. Direct evidence that IL-3 induces basophilia by augmenting 
differentiation of basophils in the bone marrow originates from in vitro studies where 
basophil precursors, purified from bone marrow of mice, were shown to develop into 
mature basophils in the presence of IL-3
229, 232
. In addition, survival of basophils can 
be enhanced by IL-3 via stimulation of NF-κB pathway233, 234.  
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Another cytokine that has been described to cause basophilia is TSLP.  
Administration of recombinant TSLP into mice was shown to induce an increase in 
basophil numbers in the blood
235
 and in the spleen
229
, probably by enhancing the 
lifespan of basophils. TSLP-induced basophils differ from those stimulated with IL-3 
in several aspects
229
. First of all, they are smaller in size compared to IL-3-elicited 
basophils
229
. They also express different array of genes and may assume different 
roles
229
. Studies are being carried out to analyze whether IL-3- and TSLP-stimulated 
basophils represent distinct subsets of basophils. 
 
1.2.1.3 Tissue recruitment of basophils 
 
Basophils can be selectively recruited to inflamed tissues in response to 
injury, assault or infection. Several human allergic diseases, including atopic 
dermatisis, asthma and rhinitis, are characterized by immense basophil infiltrates
236
.  
 
Tissue-specific recruitment of basophils is mediated by both activation and 
chemotactic factors. IL-3 was shown to induce infiltration basophils into lymph nodes 
after helminth infection
231, 237
, whereas TSLP was observed to mediate accumulation 
of basophils in the skin in a model of atopic dermatitis
229
. Interestingly, IL-3 
activation has been shown to enhance CD11b and CD18 expression on the surface of 
basophils, thereby augmenting adherence to endothelium
238, 239
.  Besides, it was 
demonstrated that IL-3 stimulation of endothelial cells promotes selective adhesion 
and rolling of resting basophils in vitro
240
.  The same study also showed that human 
basophils express CCR1, CCR2, CCR3, CCR7, CXCR1 and CXCR4 but only CCR7 
is involved in IL-3 induced recruitment
240
. Other studies have shown that basophils 
can migrate in response to CCL2, CCL5, CCL7 and CCL11
241, 242
. 
 
After arriving in the tissue, basophils may receive several cues that enhance 
their survival and assume effector functions. These cues include cytokines, DAMPs, 
PAMPs and complement factors that originate from the tissue microenvironment 
itself, other infiltrating immune cells, or pathogens.   
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1.2.1.4 Basophil effector functions 
 
Basophils have been shown to release histamine, proteoglycans (chondroitin 
and chondroitin sulphate etc.), several proteolytic enzymes, (elastase and 
lysophospholipase etc.) and lipid mediators such as leukotrienes and prostaglandins 
(LTC4, PGD2) from their cytoplasmic granules in a process called “degranulation”
224, 
243
. Basophil degranulation usually takes place in response to crosslinking of 
immunoglobulin E (IgE) bound to FcεRI on their cell surface after exposure to 
allergens
224
. Moreover, the complement factors 3a (C3a) and C5a, bacterial peptide 
N-formyl-methionine-leucine-phenylanaline (fMLP) and IgD induce basophils to 
degranulate
244, 245
. The release of these preformed mediators has been linked to 
development of immediate hypersensitivity reactions
246
. 
 
Basophils also produce several cytokines in response to various stimuli, 
including FcεRI crosslinking and IL-3 stimulation. For example, basophils are a 
major source of Th2 cytokines, mainly IL-4 and IL-13, in several pathologic settings 
such as allergy and parasitic infections
226, 247, 248, 249
. Interestingly, they can synthesize 
more IL-4 and IL-13 per cell than other leukocytes
250, 251, 252, 253
. Moreover, it  was 
demonstrated that IL-4, derived from basophils, induce Th2 polarization of CD4
+
 T 
cells in vitro
254
. However, recent in vivo studies have shown that Th2 polarization in 
response to papain, alum/ovalbumin, or nippostrongylus brasiliensis is not dependent 
on basophils
255
. Recent studies have shown that, in the presence of IL-3, IL-33 and 
IL-18 can activate basophils to produce and secrete large amounts of cytokines and 
chemokines, including IL-4, IL-6, IL-9, IL-13, CCL2, CCL3, CCL4, CCL5 and GM-
CSF, but bot IL-17, IL-5 and IFN-γ256, 257, 258. 
 
Basophils have been implicated in protective immunity against multicellular 
parasites such as helminthes and ticks, and in allergic reactions such as anaphylaxis, 
asthma and skin disorders
259, 260
. However, the real biological functions of basophils 
in these pathologic settings are not clear. 
 
The precise role of basophils in cancer is also largely unclear. Several reports 
have demonstrated that patients diagnosed with myelodysplastic syndrome (MDS) 
harbor increased number of circulating basophils
261, 262, 263
. Moreover, a study 
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examining the prognostic significance of basophils showed that basophilia predicted 
reduced survival in MDS patients
264
. Basophilia is also common in patients with acute 
myeloid leukemia and accelerated chronic myeloid leukemia
265, 266
. The number of 
basophils and their activity was found to be augmented in some cohorts of patients 
with solid tumors. One group found increased degranulation of blood basophils in 
patients with stomach cancer
267
, suggesting enhanced activity of basophils in those 
patients. Another group showed increased number of basophils in peripheral blood of 
lung cancer patients, but this basophilia in those lung cancer patients was also 
associated with increased levels of monocytes and eosinophils in the blood
268
. In 
mice, IL-4-transduced tumors exhibited marked infiltration of eosinophils, basophils, 
mast cells, macrophages
269
, which, in turn, may initiate a pro-inflammatory cascade 
that favours influx of cytotoxic T cells and finally tumor rejection. Interestingly, 
immunohistochemical analysis of IL-4-transduced tumors showed that cells 
morphologically similar to basophils and mast cells produce TNF-α269.   
 
1.3 Rip1-Tag5 as A Model to Study Anti-Tumor Immune 
Responses 
 
Preclinical tumor studies often utilize mouse tumor models that resemble the 
clinical situation as closely as possible. Rip1-Tag5 (RT5) mice is a transgenic mouse 
model of sponatenous pancreatic islet carcinogenesis, where the oncogene, simian 
virus 40 large T antigen (SV40-Tag) is specifically expressed in islet β cells under the 
control of the rat insulin promoter (RIP)
270
. RT5 mice exhibit multi-step 
carcinogenesis, which starts with hyperproliferation of pancreatic β cells in response 
to the induction of Tag oncogene expression at 10-12 weeks of age, continues with 
development of angiogenic islets and results in formation of highly vascularized, 
invasive solid tumors within 20 weeks
270
. This multi-step carcinogenesis precisely 
reflects clinical pancreatic neuroendocrine tumors (PanNET)
270
. Tag expression in 
transformed β cells leads to Tag antigen-specific immunity, characterized by T cell 
infiltrates in hyperproliferative islets
271, 272
. However, the T cell infiltration is lost 
during the transition from angiogenic islets to solid tumors
272
. 
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The “angiogenic switch” during RT5 tumorigenesis induces conversion of 
the quiescent vasculature in early neoplastic lesions into an aberrant tumor 
vasculature which is characterized by dilated and tortous blood vessels
273
. 
Futhermore, adhesion of leukocytes to tumor endothelium is dramatically reduced in 
angiogenic islets and solid tumors and linked to changes in the tumor vasculature 
following induction of angioegenesis
272
. Treatment of RT5 tumors with antigen-based 
vaccination or adoptive T cell transfer causes only modest leukocyte infiltration into 
the tumors but with little effect on tumor progression
274
, implying that aberrant tumor 
vasculature creates a physical barrier for T cell infiltration. The ultimate proof that an 
aberrant tumor vasculature indeed formed a barrier against T cell infiltration was 
provided in a recent from our laboratory, in which knock-out of Rgs5 gene resulted in 
normalization of the tumor vasculature, that now permitted increased T cell 
infiltration and tumor rejection in the absence of additional danger signals
75
.  
 
Severeal years, our laboratory has attempted to design strategies to overcome 
the tumor endothelial barrier and to create permissive tumor microenvironment for 
effector T cells It was shown that whole body irradiation or application of a TLR9 
ligand, cytosine-phosphorothioate-guanine (CpG) containing oligodeoxynucleotides 
(ODN), induced changes in the tumor microenvironment, which allowed the 
recruitment of T cells into the tumor
274, 275
. These changes included the normalization 
of the tumor vasculature and an increase in intratumoral expression of adhesion 
molecules, such as VCAM-1 and ICAM-1
274, 275
. These findings were further 
supported by a recent study conducted with collaborator Philip Beckhove (DKFZ, 
Heidelberg, Germany) where it was shown that local irradiation of RT5 tumors 
induces tumor vasculature normalization as well as VCAM-1 expression on tumor 
endothelium, resulting in strong infiltration of T cells into the tumors
276
. Interestingly, 
the study showed also that inducible nitric oxide synthase (iNOS) expression by 
macrophages is required for alterations in the tumor vasculature and subsequent T cell 
recruitment
276
. However, the precise role of iNOS
+
 macrophages for tumor rejection 
remained unclear. 
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1.4 Aims of The Study 
 
The success of clinical caner immunotherapy is hampered by many factors 
within the tumor microenvironment, including aberrant vasculature, Tregs and 
immunosuppressive tumor macrophages. The lack of T cell infiltration into tumors is 
a major limitation. For example, tumors usually exhibit an aberrant vasculature that 
prevents T cell infiltration. Another major obstacle is due by Tregs, which block 
generation of efficient T cell responses. Tumor macrophages promote many inportant 
characteristics of tumor progression, including supression of T cell responses, 
angiogenesis and tumor cell invasion. 
 
Main aim of thesis was to define mechanisms of T cell infiltration into the 
tumor and the respective inhibitory mechanism, so that strategies for improved 
immunotherapy of cancer can be developed. 
 
In a first approach, we set out to study the role of Tregs  in tumor immunity. 
In previous studies, Our group has demonstrated that ~90% Treg depletion in tumor-
bearing Foxp3.LuciDTR4 mice unleashed CD8
+
 T cell responses against the tumor 
and resulted in complete rejection of melanomas expressing ovalbumin (OVA) as a 
surrogate tumor antigen whereas ~70% Treg depletion with anti-CD25 antibody was 
ineffective
222
. In the present study, I planned to investigate the effect of Treg 
depletion on the immune reaction against non-modified melanoma tumors, which 
were of lower immunogenicity than the OVA-modified B16 melanoma and, therefore, 
more difficult to reject. For this purpose, two different Foxp3DTR strains of mice 
were available, namely Foxp3
DTR 
mice in which ~99% Tregs can be depleted, and 
Foxp3.LuciDTR4 mice in which ~90% of Tregs can be depleted. As in previous 
studies, Treg depletion was found to increase T cell infiltration into tumors, the 
precise composition of the infiltrating leukocyte subpopulations, status of tumor-
associated macrophages (TAMs), presence of other innate subpopulations that may 
contribute to tumor rejection, and the underlying mechanism of leukocyte infiltration  
should be analyzed. 
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As a second model for the investigation of T cell infiltration, Rip1-Tag5 
(RT5) mice were used, which develop spontaneous pancreatic islet tumors. These 
tumors are characterized by a typical aberrant tumor vasculature. In previous studies, 
our laboratory has found that this aberrant vasculature forms a barrier against 
infiltration of tumor-specific T cells
75
.However, application of “danger signals” such 
as the TLR9 ligand CpG-ODN modified the aberrant vasculature in such a way that it 
became permissible for T cell infiltration
274
. CpG-ODN is known to bind to tumor 
macrophages
274
. The RT5 mice seemed to represent a promising model to explore the 
role of tumor macrophages for modulation of the tumor vasculature and T cell 
infiltration. 
 
Finally, the two tumor models described here should be compared in order to 
see if there are common pathways for tumor rejection that could be exploited for 
novel therapeutic strategies.    
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2 MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Mice 
 
Mice (listed in Table1) were bred at the central animal facility of the 
German Cancer Research Center (DKFZ) and held under specific pathogen free 
conditions. Experiments were carried out according to governmental and institutional 
guidelines and regulations (Regierungspräsidium Karlsruhe, permit no. 35-
9185.81/G98/08, 35-9185.81/G206/12 and 9185.81/G205/13). 
 
Table 1: Mouse strains 
Strain Source 
C57BL/6N (B6) Charles River Laboratories 
C3H/HeJ (C3H) Charles River Laboratories 
CD45.1 (B6 background) Charles River Laboratories 
Foxp3.LuciDTR4 (B6 background) established in the laboratory 
Foxp3
DTR 
(B6 background) provided by Alexander Rudensky 
(Memorial Sloan Kettering Cancer 
Center, New York, USA) 
OT-I (B6 background) Charles River Laboratories 
Rip1-Tag5 (RT5) (C3H background) Provided by Douglas Hanahan 
(Swiss Institute for Experimental Cancer 
Research, Lausanne, Switzerland)  
TCR8 (C3H background) Provided by Richard A Flavell 
(School of Medicine, Yale University, 
Yale, USA)  
 
 
MATERIALS AND METHODS 24 
 
2.1.2 Tumor cell lines 
 
HCmel 1274 melanoma, B16 melanoma and ovalbumin-expressing B16 
melanoma (B16-OVA) were used. The HCmel 1274 melanoma cell line is derived 
from genetically modified HGF-CDK4 mice that spontaneously develop cutaneous 
melanoma
277
.  
 
2.1.3 Antibodies and reagents for cell depletion 
 
Table 2: Antibodies and reagents used for cell depletion 
Name Clone Company 
α-CD4 antibody (Ab) GK1.5 BioXCell 
α-CD8 Ab 2.43 BioXCell 
α-NK1.1 Ab PK163-3-6 BioXCell 
α-FcεRI Ab MAR-1 eBiosciences 
α-Siglec-F Ab 238047 R&D Systems 
Diphtheria toxin (DT) Sigma-Aldrich 
Clodronate-loaded liposomes (CLIP) Nico Van Rooijen, Vrije 
Universiteit, Netherlands 
 
2.1.4 Antibodies and reagents for blocking experiments 
 
Table 3: Antibodies and reagents used for blocking experiments 
Name Clone Company 
α-IFN-γ Ab XMG1.2 BioXCell 
α-CCL3 Ab 39626 R&D Systems 
α-CCL4 Ab 46907 R&D Systems 
N6-(1-iminoethyl)-L-lysine, dihydrochloride 
L-NIL 
Cayman Chemical 
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2.1.5 Buffers and Solutions 
 
Table 4: Buffers and solutions 
Buffer/Solution Composition 
Phosphate buffered saline (PBS) 130 mM NaCl 
2.6 mM KCl 
1.5 mM KH2PO4 
4 mM Na2HPO4 
pH 7.2 
Dulbecco’s PBS (dPBS) 0.9 mM CaCl2 
2.7 mM KCl 
1.2 mM KH2PO4 
0.5 mM MgCl2 
137 mM NaCl 
8.1 mM Na2HPO4 
pH 7.4 
PBS-Tween PBS 
0.01% Tween 20 (Sigma-Aldrich) 
FACS buffer dPBS 
3% (v/v) Fetal calf serum (FCS) 
0.01% (w/v) NaN3 
FACS blocking buffer FACS buffer 
1% Normal immunoglobulin (Privigen®, 
CSL Behring) 
IF blocking buffer PBS-Tween 
5% (v/v) Goat serum (Sigma-Aldrich) 
MACS buffer dPBS 
3% (v/v) FCS 
2 mM EDTA 
Heparin buffer dPBS 
2% (v/v) FCS 
0.01% (w/v) NaN3 
5 U/ml Heparin (Ratiopharm) 
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ACK buffer 150 mM NH4Cl 
10 mM KHCO3 
0.1 mM EDTA 
pH 7.2-7.4 
Tissue digestion solution dPBS 
1 mg/ml Collagenase IV (Sigma-Aldrich) 
50 U/ml DNase I (Sigma-Aldrich) 
RT5 tumor digestion solution dPBS 
0.2 mg/ml Collagenase D (Roche) 
0.025 mg/ml DNase I (Sigma-Aldrich) 
0.08 mg/ml Dispase (Roche) 
Trypsin-EDTA solution 0.025% (w/v) Trypsin (Sigma-Aldrich) 
0.01% EDTA 
StemPro® Accutase® cell dissociation 
solution (Life Technologies) 
 
 
2.1.6 Cytokines and NO donor 
 
Table 5: Recombinant cytokines and NO donor 
Name Company 
Mouse IL-2 eBiosciences 
Mouse IL-3 PeproTech 
Mouse IL-3 R&D Systems 
Mouse IFN-γ PeproTech 
Mouse M-CSF Sigma-Aldrich 
Human IFN-γ PeproTech 
Human M-CSF PeproTech 
Human TNF PeproTech 
Glyceryl trinitrate (GTN) Sigma-Aldrich 
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2.1.7 Commercial Kits 
 
Table 6: Commercial kits 
Kit name Company  
CD4
+
 CD25
+
 regulatory T cell isolation 
kit, mouse 
Miltenyi 
CD49b (DX5) microbeads, mouse Miltenyi 
Foxp3 staining kit, mouse/rat eBiosciences 
Griess reagent kit Sigma-Aldrich 
RNeasy mini kit Qiagen 
RNeasy micro kit Qiagen 
iScript™ cDNA synthesis kit Bio-Rad 
LightCycler® 480 SYBR Green I Master Roche 
Bio-Plex® Multiplex Assays Bio-Rad 
 
2.1.8 Cell culture media 
 
Table 7: Cell culture media 
Medium Supplements 
RPMI-1640 (Gibco®, Invitrogen) 
Roswell park memorial institute-1640 
10% (v/v) FCS heat-inactivated 
2 nM glutamine (Sigma-Aldrich) 
100 U/ml penicilin (Sigma-Aldrich) 
100 μg/ml streptomycin (Sigma-Aldrich) 
0.05 mM 2-ME (Sigma-Aldrich) 
DMEM (Gibco®, Invitrogen) 
Dulbecco’s modified eagle’s medium 
10% (v/v) FCS heat-inactivated 
2 nM glutamine (Sigma-Aldrich) 
100 U/ml penicilin (Sigma-Aldrich) 
100 μg/ml streptomycin (Sigma-Aldrich) 
0.05 mM 2-ME (Sigma-Aldrich) 
ENDOPAN-3 (Pan-BioTech) 3%  (v/v) FCS 
FGF-2, VEGF, R3-IGF-1, ascorbic acid, 
heparin, gentamicin sulfate amphotericin 
B, hydrocortisone 
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2.1.9 Antibodies and reagents for flow cytometry 
 
Table 8: Antibodies and reagents for flow cytometry 
FITC, fluorescein isothiocyanate; PE, R-phycoerythrin; PerCP/Cy5.5, peridinin chlorophyll/cyanine (Cy5.5); 
PE/Cy7, PE/cyanine (Cy7); APC, allophycocyanin; AF647, Alexa Fluor 647; APC/Cy7, APC/cyanine (Cy7); 
APC/eF780, APC/eFluor® 780; PB, pacific blue; BV421, brilliant violet™ 421, BV650, brilliant violet™ 650 
 
Name Clone Reactivity Conjugate Company 
α-CD3ε Ab 145-2C11 Mouse FITC BDBiosciences 
α-CD4 Ab GK1.5 Mouse APC/Cy7 BioLegend 
α-CD4 Ab GK1.5 Mouse PB BioLegend 
α-CD8a Ab 53-6.7 Mouse PE BDBiosciences 
α-CD8a Ab 53-6.7 Mouse PE/Cy7 BDBiosciences 
α-CD8a Ab 53-6.7 Mouse AF647 BioLegend 
α-CD11b Ab M1/70 Mouse PB BioLegend 
α-CD11c Ab HL3 Mouse PE/Cy7 BDBiosciences 
α-CD19 Ab 1D3 Mouse PE BDBiosciences 
α-CD45 Ab 30-F11 Mouse PB BioLegend 
α-CD45 Ab 30-F11 Mouse BV606 BioLegend 
α-CD45.2 Ab 104 Mouse APC/Cy7 BioLegend 
α-CD49b Ab DX5 Mouse APC/eF780 eBiosciences 
α-CD117 Ab 
(c-Kit) 
2B8 Mouse PE/Cy7 eBiosciences 
α-CD200R3Ab Ba13 Mouse PE BioLegend 
α-CD206 Ab 
(MRC1) 
C068C2 Mouse PE BioLegend 
α-F4/80 Ab BM8 Mouse PerCP/Cy5.5 eBiosciences 
α-F4/80 Ab BM8 Mouse PE/Cy7 eBiosciences 
α-F4/80 Ab BM8 Mouse AF647 BioLegend 
α-FcεRI Ab MAR-1 Mouse PE eBiosciences 
α-Gr-1 Ab RB6-8C5 Mouse FITC BDBiosciences 
α-Gr-1 Ab RB6-8C5 Mouse PE/Cy7 BioLegend 
α-Gr-1 Ab RB6-8C5 Mouse APC BDBiosciences 
α-IgE Ab R35-72 Mouse FITC BDBiosciences 
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α-iNOS Ab CXNFT Mouse FITC eBiosciences 
α-MHC-II Ab 
(I-A/I-E) 
M5/114.15.2 Mouse FITC BioLegend 
α-MHC-II Ab 
(I-A/I-E) 
M5/114.15.2 Mouse APC/Cy7 BioLegend 
α-NK1.1 Ab PK136 Mouse PE/Cy7 BDBiosciences 
α-Siglec-F Ab E50-2440 Mouse PE BDBiosciences 
α-Siglec-F Ab E50-2440 Mouse APC BDBiosciences 
α-Ter119 Ab TER119 Mouse PerCP/Cy5.5 BioLegend 
α-CD90.1 Ab 
(Thy1.1) 
OX-7 Mouse PB BioLegend 
α-CD62E Ab 
(E-Selectin) 
 Human   
α-CD54 Ab 
(ICAM-1) 
 Human   
α-CD106 Ab 
(VCAM-1) 
 Human   
α-vWF  Human   
Fixable viability dye APC/eF780 eBiosciences 
Propidium iodide (PI) Fluka 
 
2.1.10 Antibodies and reagents for immunofluorescene 
 
Table 9 Antibodies and reagents for immunofluorescence 
Name Clone Conjugate Company 
α-CD31 Ab 2H8  AbD Serotec 
α-VCAM-1 
(CD106) Ab 
429  BD Biosciences 
α-Armenian 
hamster IgG 
Poly4055 DyLight™ 488 BioLegend 
α-Armenian 
hamster IgG 
Poly4055 DyLight™ 594 BioLegend 
α-Rat IgG Poly4054 DyLight™ 488 BioLegend 
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α-Rat IgG Poly4054 Cy3 BioLegend 
VectaShield® mounting medium with DAPI Vector 
 
2.1.11 Primers for quantitive real-time polymerase chain reaction 
(qRT-PCR) 
 
Table 10: Primers for qRT-PCR 
Gene Sequence (5’3’) 
Angpt2 CCTCGACTACGACGACTCAGT 
TCTGCACCACATTCTGTTGGA 
Ccl2 TTAAAAACCTGGATCGGAACCAA 
GCATTAGCTTCAGATTTACGGGT 
Ccl3 TTCTCTGTACCATGACACTCTGC 
CGTGGAATCTTCCGGCTGTAG 
Ccl4 TTCCTGCTGTTTCTCTTACACCT 
CTGTCTGCCTCTTTTGGTCAG 
Ccl5 GCTGCTTTGCCTACCTCTCC 
TCGAGTGACAAACACGACTGC 
Ccl7 GCTGCTTTCAGCATCCAAGTG 
CCAGGGACACCGACTACTG 
Ccl11 GAATCACCAACAACAGATGCAC 
ATCCTGGACCCACTTCTTCTT 
Ccl19 GGGGTGCTAATGATGCGGAA 
CCTTAGTGTGGTGAACACAACA 
Ccl20 GCCTCTCGTACATACAGACGC 
CCAGTTCTGCTTTGGATCAGC 
Ccl22 AGGTCCCTATGGTGCCAATGT 
CGGCAGGATTTTGAGGTCCA 
Ccl24 ATTCTGTGACCATCCCCTCAT 
TGTATGTGCCTCTGAACCCAC 
Cxcl9 TCCTTTTGGGCATCATCTTCC 
TTTGTAGTGGATCGTGCCTCG 
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Cxcl10 CCAAGTGCTGCCGTCATTTTC 
GGCTCGCAGGGATGATTTCAA 
Fgf1 CCCTGACCGAGAGGTTCAAC 
GTCCCTTGTCCCATCCACG 
Gapdh AGGTCGGTGTGAACGGATTTG 
TGTAGACCATGTAGTTGAGGTCA 
Gm-Csf GGCCTTGGAAGCATGTAGAGG 
GGAGAACTCGTTAGAGACGACTT 
Icam-1 GTGATGCTCAGGTATCCATCCA 
CACAGTTCTCAAAGCACAGCG 
Ifn-α TACTCAGCAGACCTTGAACCT 
CAGTCTTGGCAGCAAGTTGAC 
Ifn-β CAGCTCCAAGAAAGGACGAAC 
GGCAGTGTAACTCTTCTGCAT 
Ifn-γ ATGAACGCTACACACTGCATC 
CCATCCTTTTGCCAGTTCCTC 
Il-1β GCAACTGTTCCTGAACTCAACT 
ATCTTTTGGGGTCCGTCAACT 
Il-2 TGAGCAGGATGGAGAATTACAGG 
GTCCAAGTTCATCTTCTAGGCAC 
Il-3 GGGATACCCACCGTTTAACCA 
AGGTTTACTCTCCGAAAGCTCTT 
Il-4 GGTCTCAACCCCCAGCTAGT 
GCCGATGATCTCTCTCAAGTGAT 
Il-5 CTCTGTTGACAAGCAATGAGACG 
TCTTCAGTATGTCTAGCCCCTG 
Il-6 TAGTCCTTCCTACCCCAATTTCC 
TTGGTCCTTAGCCACTCCTTC 
Il-9 ATGTTGGTGACATACATCCTTGC 
TGACGGTGGATCATCCTTCAG 
Il-10 GCTCTTACTGACTGGCATGAG 
CGCAGCTCTAGGAGCATGTG 
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Il-12 CTGTGCCTTGGTAGCATCTATG 
GCAGAGTCTCGCCATTATGATTC 
Il-13 CCTGGCTCTTGCTTGCCTT 
GGTCTTGTGTGATGTTGCTCA 
Il-18 GACTCTTGCGTCAACTTCAAGG 
CAGGCTGTCTTTTGTCAACGA 
Il-25 ACAGGGACTTGAATCGGGTC 
TGGTAAAGTGGGACGGAGTTG 
Il-33 TCCAACTCCAAGATTTCCCCG 
CATGCAGTAGACATGGCAGAA 
Mcpt8 CCACTCCCGGCCCTATATG 
TGCTGTCATTACGATGTCTCTTG 
Mhc-II (H2-2α) TCAGTCGCAGACGGTGTTTAT 
GGGGGCTGGAATCTCAGGT 
Nos2 GTTCTCAGCCCAACAATACAAGA 
GTGGACGGGTCGATGTCAC 
Pdgf-α GAGGAAGCCGAGATACCCC 
TGCTGTGGATCTGACTTCGAG 
Rgs5 CGCACTCATGCCTGGAAAG 
TGAAGCTGGCAAATCCATAGC 
Tnf CCCTCACACTCAGATCATCTTCT 
GCTACGACGTGGGCTACAG 
Tslp ACGGATGGGGCTAACTTACAA 
AGTCCTCGATTTGCTCGAACT 
Vcam-1 AGTTGGGGATTCGGTTGTTCT 
CCCCTCATTCCTTACCACCC 
Vegf-α CTGCCGTCCGATTGAGACC 
CCCCTCCTTGTACCACTGTC 
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2.1.12 Equipments 
 
Table 11: Equipments 
Name Company 
FACSCanto II  BD Biosciences 
FACSAria II BD Biosciences 
Axio Observor.Z1 Zeiss 
FastPrep® FP120 cell disrupter Qbiogene 
NanoDrop 2000™ spectrophotometer Thermo Fisher Scientific 
PTC-200 thermal cycler MJ Research Inc. 
Light Cycler® 480 II Roche 
Minifuge-2 Heraeus Christ 
BB 6220 CO2 incubator Heraeus Christ 
 
2.1.13 Software 
 
Table 12: Software 
Name  Company 
FACSDiva v. 6.1.2 BD Biosciences 
FlowJo v. 9.8 Tree Star 
ZEN 2011 lite (blue edition) Zeiss 
Light Cycler® 480 software v.1.5.0 Roche 
Excel 2008 v. 12.3.6 Microsoft 
Power Point 2008 v. 12.3.6 Microsoft 
Prism 6 v. 6.0d GraphPad Software 
EndNote v. X7.2.1 Thomson Corporation 
MATERIALS AND METHODS 34 
 
2.2 Methods 
 
2.2.1 Mouse Studies 
 
2.2.1.1 Tumor challenge  
 
1x10
6
 tumor cells were injected intradermally (i.d.) at the right flank of mice. 
Tumor sizes were measured with a caliper every 2-3 days and tumor volume was 
calculated according to the formula: V= 0.5 x Length x Width
2
. Mice were sacrificed 
when tumors reached a size of 2000 mm
3
.  
 
2.2.1.2 Cell depletion 
 
For Treg depletion, Foxp3
DTR
 and Foxp3.LuciDTR4 mice received two 
consecutive injections with 20 ng/g DT (Sigma-Aldrich, Steinheim, Germany) 
intraperitoneally (i.p.). Treg depletion was initiated when the tumors displayed a 
volume of 250-500 mm
3
.  
 
For the depletion of CD8
+
 T cells, mice were injected intraperitoneally (i.p.) 
with 500 μg anti-CD8 antibody (BioXCell, West Lebanon, USA, Clone 2.43) 0, 3, 6 
days after Treg depletion. CD4
+
 T cells were depleted by i.p. injection of 1 mg anti-
CD4 antibody (BioXCell, West Lebanon, USA, Clone GK1.5) 0, 3, 6 days after Treg 
depletion. Natural killer (NK) cells were depleted by i.p. injection of 1 mg anti-NK1.1 
antibody (BioXCell, West Lebanon, USA, Clone PK163-3-6) 0, 3, 6 days after Treg 
depletion. 
 
Basophils were depleted by i.p. injection of 10 μg anti-FcεRI antibody 
(eBiosciences, Frankfurt am Main, Germany, Clone: MAR-1) 0, 2,3,4 and 6 days 
after Treg depletion for tumor growth experiments. For population analyses, MAR-1 
was injected i.p. 0 and 2 days after Treg depletion.  
 
For macrophage depletion in Foxp3
DTR
 mice bearing intradermal HCmel 
1274 tumors, clodronate-loaded liposomes (CLIP) (VUMC, Amsterdam, Netherlands) 
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were first injected 200 μl i.p and 100 μl intratumorally (i.t) 2 days following Treg 
depletion, then every 5 days 100 μl i.t until the end of the experiment. PBS-loaded 
liposomes (PLIP) (VUMC, Amsterdam, Netherlands) were used as control. For 
population analyses, CLIP or PLIP was injected 200 μl i.p and 100 μl i.t 2 days after 
Treg depletion. 
 
Macrophages in Rip1-Tag5 (RT5) mice were depleted by i.p. injections of 
100 μl CLIP every 5 days after an inital injection with 200 μl CLIP. PLIP was used as 
control.  
 
2.2.1.3 Preparation of cell suspensions from mouse tissues 
 
Cell suspension were prepared from tumor-draining lymph nodes (td-LN), 
spleen, lung, bone marrow and tumor. Tumor-draining lymph nodes were axillary, 
branchial and inguinal lymph nodes on the right flank of the mice. 
 
For T cell preparations, spleens from OT-I or TCR8 mice were minced using 
a scalpel. Respective tissue fragments were meshed through 40 μm nylon cell strainer 
into a petri dish using the plunger end of the syringe. The cell strainer was then rinsed 
with ice-cold dPBS. The suspended cells were transferred into a 15 ml conical 
centrifugation tubes and spun at 4°C at 1200 rpm for 8 minutes and the supernatant 
was discarded. The cell pellet was resuspended in 2 ml of ACK buffer and incubated 
at room temperature for 3 minutes to lyse erythrocytes. After the incubation, 8 ml 
RPMI-1640 was added and the cells were centrifuged as mentioned above. The 
supernatant was again discarded and the pellet was resuspended in 2 ml RPMI-1640 
medium.  
 
For macrophage preparations, femurs and tibias were taken and both ends 
were cut with a scissor. Bone marrow cells were flushed out with a syringe and 25G 
needle using ice-cold dPBS. Cell suspension was next filtered into 50 ml falcon tubes 
through a 40 μm filter to remove crude tissue particles.  
 
For flow cytometric stainings, tumors, td-LNs, spleens and lungs from mice 
were isolated from mice and placed in 3 ml of dPBS containing 1 mg/ml of 
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collagenase IV (Sigma-Aldrich, Steinheim, Germany)  and 50 U/ml of Dnase I 
(Sigma-Aldrich, Steinheim, Germany). Tissue was disrupted using forceps and 
transferred into 5 ml round-bottom polystyrene tubes. Samples were then incubated at 
room temperature with gentle stirring by a magnet (100 rpm). Enzymatic digestion of 
the tissues was supported by mechanical disruption via pipetting up and down 10 
times every 10 minutes. After 30 minutes, samples were filtered through a 40 μm 
nylon cell strainer. Erythrocytes were removed by incubating with ACK buffer for 2 
minutes. After the centrifugation at 1400 rpm for 8 minutes, samples were incubated 
in FACS blocking buffer (FACS buffer with 1% normal immunoglobulin (Privigen®, 
CSL Berling, Hattersheim am Main, Germany) for 15 minutes. Finally, samples were 
stained for flow cytometry. RT5 tumors were first homogenized with small scissors 
and placed into 1.5 ml eppendorf tubes containing 1 ml of dPBS with 0.2 mg/ml of 
collagenase D (Roche, Mannheim, Germany), 0.08 mg/ml of dispase I (Roche, 
Mannheim, Germany) and 0.025 mg/ml of DNase I (Sigma-Aldrich, Steinheim, 
Germany). Samples were incubated at 37°C for 30 minutes. Samples were filtered 
through a 40 μm nylon cell strainer into a 5 ml round-bottom polystyrene tubes and 
then centrifuged at 1400 rpm for 8 minutes. The pellet was resuspended in FACS 
blocking buffer. After 15 minute-incubation, the samples were stained for flow 
cytometry. 
 
2.2.1.4 Preparation of monouclear cells from whole blood 
 
Whole blood was collected from the submandibular facial vein into dPBS 
including heparin in order to avoid clotting and then spun at 5000 rpm for 4 minutes. 
The supernatant was discarded and the cell pellet was resuspended in 1ml of ACK 
buffer to kill erythrocytes. After 7 minute-incubation at  room temperature, samples 
were centrifuged at 5000 rpm for 4 minutes and the supernatant was discarded. The 
pellet was resuspended in FACS blocking buffer. Samples were then stained for flow 
cytometry analysis.  
 
2.2.1.5 Adoptive transfer of CD8+ T cells 
 
Spleens were harvested from naive OT-I or TCR8 mice and disrupted to 
obtain single-cell suspensions as mentioned above. Splenic cells were resuspend at 
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1x10
6
 cells/ml in RPMI-1640 medium supplemented with 10% FCS, 2 nM glutamine, 
100 U/ml penicilin, 100 μg/ml streptomycin, 0.05 mM 2-ME, 10U/ml of recombinant 
IL-2 (eBiosciences, Frankfurt am Main, Germany). OT-I splenic cells were cultured 
in the presence of 25 nM SIINFEKL peptide (PSL, Heidelberg Germany). TCR8 
splenic cells were cultured in the presence of 25 nM Tag peptide 560-568 (PSL, 
Heidelberg Germany). Cells were used for adoptive transfer 3 days after incubation at 
37°C. B16-OVA-bearing mice received intravenous (i.v.) injections of 2.5x10
6
 
activated OT-I CD8
+
 T cells in 200 μl dPBS 1 day after macrophage transfer or 3 days 
after mouse recombinant IL-3 injection. RT5 mice were adoptively transferred with 
2.5x10
6
 activated TCR8 CD8
+
 T cells in 200 μl dPBS 1 day after CpG-ODN injection 
and 10 days after the first injection. For survival experiment, TCR8 CD8
+
 T cell 
transfer was repeated every 10 days. 
 
2.2.1.6 Adoptive transfer of macrophages 
 
Bone marrow-derived cells were prepared  from wild-type or NOS2
-/-
 mice 
(received from Christian Bogdan, Universitätsklinikum, Erlangen) as mentioned 
above and cultured at 3.5x10
6 
cells/ml in RPMI-1640 medium supplemented with 
10% FCS, 2 nM glutamine, 100 U/ml penicilin, 100 μg/ml streptomycin and 10 ng/ml 
mouse recombinant macrophage-colony stimulating factor (M-CSF) (Sigma-Aldrich, 
Steinheim, Germany). 5 days later, culture medium was changed to fresh medium 
with the same supplements. 3 days after the medium change, macrophages were 
activated with 20 ng/ml LPS (Sigma-Aldrich, Steinheim, Germany) and 20 ng/ml 
mouse recombinant IFN-γ (PeproTech, Hamburg, Germany) or left untreated. 18 
hours later, macrophages were harvested using StemPro® Accutase® cell dissciation 
reagent (Life Technologies, Darmstadt Germany). For adoptive transfer, 5x10
6 
activated and non-activated macrophages in 200 μl dPBS were injected i.v. when 
tumors reached a size of 300-500 mm
3
.  
 
2.2.1.7 Adoptive transfer of Tregs 
 
Spleens were harvested from naive wild-type mice and dissociated to obtain 
single-cell suspensions as mentioned above. Splenic cells were resuspend in MACS 
buffer and CD4
+ 
CD25
+ 
Tregs were sorted using the Treg magnetic isolation kit 
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(Miltenyi, Bergisch Gladbach, Germany) in a two-step procedure. First, CD4
+
 T cells 
were negatively selected by depleting other cells over a MACS® column (LS 
column) with a cocktail of biotin-conjugated antibodies against CD8 (Ly-2), CD11b 
(Mac-1), CD45R (B220), CD49b (DX5), Ter-119 and anti-biotin magnetic 
microbeads. In the second step, negatively selected untouched CD4
+
 T cells are 
labeled with CD25 microbeads, which allow positive selection of 
CD4
+
CD25
+
regulatory T cells. The magnetic cell sorting was performed on a 
Miltenyi MACS Multi Stand with MACS magnet (Miltenyi, Bergisch Gladbach, 
Germany) using LS columns. Purified CD4
+
 CD25
+
 Tregs were then injected i.t. into 
HCmel 1274-bearing Foxp3
DTR
 mice 2 days after Treg depletion.  
  
2.2.1.8 Oligonucleotide treatment 
 
24 week-old RT5 mice were injected with phosphothioate-stabilized CpG-
ODN 1668 (TCCATGACGTTCCTGATGCT) (TIB-MOLBIOL, Berlin, Germany) 
and 6 and 10 days after the first injection.   
 
2.2.1.9 Cytokine injection 
 
10 μg IL-3 (PeproTech, Hamburg, Germany) was mixed with 5 μg anti-IL-3 
antibody (BD Biosciences, Heidelberg, Germany, Clone MP2-8F8) at room 
temperature for one minute. The cytokine and antibody mixture in 200 μl dPBS was 
injected into mice i.v. when tumors reached a size of 200-400 mm
3
. 
 
2.2.1.10 Cytokine, chemokine and inducible nitric oxide synthase (iNOS) 
blocking 
 
For in vivo IFN-γ blockade, 500 μg anti- IFN-γ (BioXCell, West Lebanon, 
USA, Clone XMG1.2) or 500 μg isotype control, rat IgG1 (BioXCell, West Lebanon, 
USA), was injected into Foxp3
DTR
 mice i.p. 2, 5 and 8 days after Treg depletion.   
 
For in vivo blockade of CCL3 and CCL4, 250 μg of anti-CCL3 (R&D 
Systems, Abingdon, UK, Clone 39624) and anti-CCL4 (R&D Systems, Abingdon, 
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UK, Clone 46907) antibodies or appropriate isotype control, rat IgG2a, were injected 
into mice 0, 3, 6 days after OT-I CD8
+
 T cell transfer.    
 
iNOS activity in mice was blocked by 2 mM N6-(1-iminoethyl)-L-lysine, 
dihydrochloride (L-NIL) in the drinking water. The water bottles containing L-NIL 
was replaced every 2 days until the end of experiment. 
 
2.2.2 Cell biology methods 
 
2.2.2.1 Flow cytometric stainings and cell sorting 
 
Antibodies used for flow cytometry are listed in Table 8. Single cell 
suspensions from the tissues were prepared as mentioned above and incubated with 
FACS blocking buffer for 15 minutes in 96-well plates with U-shaped wells to 
minimize non-specific binding. For extracellular staining, samples were incubated 
with a cocktail of fluorochrome-conjugated anti-mouse antibodies in FACS blocking 
buffer for 20 minutes at 4°C. Afterwards, samples were washed twice with FACS 
Buffer. To exclude dead cells, samples were then resuspended in 200 μl of FACS 
buffer containing 1 μg/ml propidium iodide (PI) (BD Biosciences, Heidelberg, 
Germany). For staining of intracellular molecules, samples were first stained with 
fixable viability dye (eBiosciences, Frankfurt am Main, Germany) for 15 minutes at 
4°C and then fixed with fixation/permeabilization buffer from Foxp3-staining kit 
(eBiosciences, Frankfurt am Main, Germany) for 30-60 minutes. Samples were 
permeabilized with 1X permeabilization buffer from Foxp3-staining kit 
(eBiosciences, Frankfurt am Main, Germany) and then stained with a mixture of 
antibodies or isotype controls in 1X permeabilization buffer for 30 minutes at 4°C. 
After washing twice with 1X permeabilization buffer, samples were resuspended in 
FACS buffer. Stained samples were acquired using a BD FACSCanto II (BD 
Biosciences, Heidelberg, Germany) with BDFACSDiva software (BD Biosciences, 
Heidelberg, Germany). Data were analyzed with FlowJo software (Tree Star, 
Ashland, USA). For analysis of cells purified from tumors, 1-5x10
4
 cells were sorted 
with a FACSAria II (BD Biosciences, Heidelberg, Germany) running with FACSDiva 
Software (BD Biosciences, Heidelberg, Germany). 
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2.2.2.2 Cryosectioning and immunofluorescence analysis 
 
Tumors were carefully excised from euthanized mice and placed into 
cryomolds containing OCT gel (Tissue-Tek®, Sakura, Staufen, Germany). Samples 
were first incubated in ice-cold isopentane for 10 minutes and then placed in liquid 
nitrogen-cooled isopentane for 10 minutes. Afterwards, samples were slowly exposed 
to liquid nitrogen. Frozen samples were stored at -80°C.  
 
7 μm sections were prepared from OCT-embedded frozen tumors using 
Leica CM3050S cryotome (Wetzlar Germany) and placed onto silane-coated slides. 
After drying overnight, sections were fixed with 10 minute-incubation in ice-cold 
acetone. Samples were again air-dried for 20 minutes to allow acetone to evaporate 
from the tumor tissues. Sections were then used for immunofluorescent staining 
immediately or stored at -30°C for later use.  
 
A hydrophobic wax pen used to create a boundary around the tissue sections 
on the slide. The immunofluorecent staining was performed in  a humid chamber to 
prevent sections from drying. Sections were rehydrated in PBS containing 0.01% 
Tween20 (PBS-Tween) for 10 minutes and incubated in immunofluorescent (IF) 
blocking buffer (PBS-Tween containing 5% goat serum (Sigma-Aldrich, Steinheim, 
Germany) for 15 minutes. After draining off the blocking buffer from slides, the 
sections were incubated at room temperature for 60 minutes with 100 μl of primary 
antibodies in IF blocking buffer (listed in Table 9). Excess antibody was removed by 
washing the slides 3 times in PBS-Tween, 5 minutes each. 200 μl of secondary 
antibodies (listed in Table 9) in IF blocking buffer was added and samples were 
incubated in the dark at room temperature for 60 minutes. Excess antibody was 
removed by washing the slides 3 times in PBS-Tween, 5 minutes each. Thereafter, 
sections were mounted in VectaShield® mounting medium with DAPI (Vector, 
Peteborough, UK).  
 
Stained sections were visualized under Zeiss Axio Observor.Z1 microscope 
(Zeiss, Jena, Germany). Zeiss blue software (Zeiss, Jena, Germany) was used to 
analyze the tumor vasculature. 
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2.2.2.3 Giemsa Staining 
 
Morphology of sorted basophils was analyzed by Giemsa staining. Sorted 
basophils were first placed in a cuvette which was already assembled with a slide and 
a cardboard filter. After the centrifugation at 700 rpm for 4 minutes, cells on the slides 
were fixed with 100% methanol for 5 minutes. The slides were rinsed off in the water 
and allowed to air-dry. The cells were then stained with freshly prepared  Giemsa 
solution (10% v/v Giemsa stain (Sigma-Aldrich, Steinheim, Germany) in deionized 
water) for 30 minutes. The slides were again rinsed in the water and air-dried. 
Thereafter, sections were mounted in Permount™ mounting medium (Thermo Fisher 
Scientific Karlsruhe, Germany). Giemsa-stained cells were then visualized under 
Zeiss Axioplan widefiled microscope (Zeiss, Jena, Germany). Zeiss blue software was 
used to analyze the tumor vasculature. 
 
2.2.3 Cell culture methods 
 
Cell culture was conducted under sterile conditions at 37°C in a CO2 
incubator (5%). 
 
2.2.3.1 Culture of tumor cell lines 
 
The growth medium for tumor cell lines, B16, B16-OVA and HCmel 1274, 
was DMEM supplemented with 10% FCS, 2 nM glutamine, 100 U/ml penicilin, 100 
μg/ml streptomycin and 0.05 mM 2-ME. When the cells were 80-90% confluent, they   
were passaged.  
 
2.2.3.2 Culture of human umbilical vein endothelial cells (HUVECs)  
 
HUVECs were supplied from pooled donors (PromoCell, Heidelberg, 
Germany). Upon arrival, frozen HUVECs were immediately thawn and cultured in 
ENDOPAN 3 endothelial cell growth medium (Pan-Biotech, Aidenbach, Germany) 
supplemented with 3% FBS,  0.1% FGF-2, 0.1% VEGF, 0.1% R3-IGF-1, 0.1% 
ascorbic acid, 0.1% heparin, 0.12% gentamicin sulfate amphotericin B, 0.02% 
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hydrocortisone. Once they have reached 70-90% confluency, the cells were 
subcultured. 
 
2.2.3.3 Isolation and culture of human macrophages 
 
To obtain human macrophages, first of all, mononuclear cells were isolated 
from human peripheral blood by density gradient centrifugation using Ficoll-Paque™ 
(GE Healthcare, Freiburg, Germany). During centrifugation, erythrocytes and 
polynucleated cells pass through the Ficoll due to their higher density, while 
mononuclear cells accumulated as a white band on the top the Ficoll layer. This white 
band was carefully pipetted and washed twice with PBS. Isolated mononuclear cells 
were then plated at 2x10
8
/175 cm
2
 in RPMI-1640 medium supplemented with 10% 
FCS, 2 nM glutamine, 100 U/ml penicilin, 100 μg/ml streptomycin and incubated for 
90 minutes at 37°C. Thereafter, suspension cells were discarded and adherent cells, 
which mainly contains monocytes, were removed using StemPro® Accutase® cell 
dissociation reagent. Monocytes were next seeded at 2x10
6
 cells/ml in RPMI-1640 
medium supplemented with 10% FCS, 2 nM glutamine, 100 U/ml penicilin, 100 
μg/ml streptomycin and 25 ng/ml human recombinant M-CSF (PeproTech, Hamburg, 
Germany). After 6 day-incubation at 37°C, monocytes were differentiated into 
macrophages, confirmed by FACS staining with CD14 and CD68. Macrophages were 
left untreated (M0 macrophages) or activated in the presence of 100 ng/ml LPS and 
20 ng/ml human recombinant IFN-γ (PeproTech, Hamburg, Germany) for 18 hours to 
generate M1 macrophages. 
 
2.2.3.4 Co-culture of HUVECs and human macrophages 
  
Human macrophages were isolated from circulating blood monocytes, and 
were left untreated (M0 macrophages) or activated (M1 macrophages) as mentioned 
above. Macrophages were then harvested using StemPro® Accutase® cell 
dissociation reagent. 1x10
6
 M1 or M0 macrophages were added to HUVECs, which 
had been cultured at 1x10
5
 cells/ml 3 days ago in 6-well plates, in the presence or 
absence of iNOS inhibitor L-NIL (1mM). 18 hours later, cells were harvested and the 
expression of adhesion molecules on HUVECs such as VCAM-1, ICAM-1 and E-
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Selectin was measured by FACS. HUVECs were distinguished from macrophages by 
their expression of von willebrand factor (vWF).  
 
2.2.3.5 Culture of HUVECs with NO donor 
 
HUVECs were cultured at 1x10
5
 cells/ml into 6 well plates. 3 days later, NO 
donor, glycerel trinitrate (GTN) (Sigma-Aldrich, Steinheim, Germany) with different 
doses were added to the cultures. After 18 hour-incubation, cells were harvested and 
the expression of adhesion molecules on HUVECs such as VCAM-1, ICAM-1 and E-
Selectin was measured by FACS.  
 
2.2.3.6 Detection of nitric oxide (NO) as nitrite (NO2
-
) 
 
The level of NO in the cell culture was measured by Griess reagent (Sigma-
Aldrich, Steinheim, Germany) as NO2
-
 according to manufacturer’s instructions. 
 
2.2.3.7 Generation and isolation of mouse basophils from bone marrow 
 
Bone marrow cells were prepared as mentioned above and cultured RPMI-
1640 medium supplemented with 10% FCS, 2 nM glutamine, 100 U/ml penicilin, 100 
μg/ml streptomycin and 2 ng/ml mouse recombinant IL-3 (R&D Systems, Abingdon, 
UK) for 10 days to yield basophils and mast cells. Basophils were then purified by 
magnetic sorting based on CD49b expression. Sorted basophils were then activated by 
50 ng/ml mouse recombinant IL-18 (R&D Systems, Abingdon, UK) and 100 ng/ml 
mouse recombinant IL-33 (R&D Systems, Abingdon, UK)  in the presence of 2 ng/ml 
IL-3.   
 
2.2.3.8 In vitro migration assay 
 
Migration of activated OT-I CD8
+
 T cells were analyzed using 96-well 
transwell plates with a 5 μm-pore size (Corning Life Sciences, Amsterdam, 
Netherlands). The lower chamber was loaded with 100 μl migration medium (RPMI-
1640 supplemented with 0.2% FCS, 2 nM glutamine, 100 U/ml penicilin, 100 μg/ml 
streptomycin and 0.05 nM 2-ME) containing different doses (1x10
5
-1x10
6
) of 
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basophils. 1x10
5
 activated OT-I CD8
+
 T cells were added in 50 μl to the upper 
chamber. As a positive control, OT-I CD8
+
 T cells were placed directly into the lower 
chamber. As a  negative control, migration medium alone was placed in the upper 
chamber. As a control group, OT-I CD8
+
 T cells were added to the upper chamber 
and migration medium alone was added to the lower chamber. After 18 hour-
incubation at 37°C, the transwell inserts were removed and the content of the lower 
compartment carefully pipetted and transferred into 96-well plates for FACS staining. 
The number of OT-I CD8
+
 T cells were measured by flow cytometry in the presence 
of a particular number of microbeads. Migration rate was calculated using the 
formula: migration rate = 100 x (number of CD8
+
 cells from lower chamber/number 
of beads) / (number of CD8
+
 T cells from input sample/number of beads). For 
experiments with chemokine blockade, neutraziling antibodies against CCL3 (R&D 
Systems, Abingdon, UK) and CCL4 (R&D Systems, Abingdon, UK) were added to 
the lower chamber before the migration assay. 
 
2.2.4 Molecular biology methods 
 
2.2.4.1 Quantitive PCR (qRT-PCR)   
 
Tumors were collected from mice and cut into samples of approximately 25 
mg. Each sample was placed in a tube containing 450 μl of lysis buffer (RLT buffer) 
and 1.4 mm zirconium oxide beads (Peqlab, Erlangen, Germany). Samples were then 
mechanistically disrupted by FastPrep® FP120 cell disrupter (Qbiogene, Cedex, 
France) running at 6.5 m/s for 15 seconds. RNA was extracted using the RNeasy Mini 
Kit (Qiagen, Düsseldorf, Germany) according to manufacturer’s instructions. RNA 
from sorted cells was isolated using the RNeasy Micro kit  (Qiagen, Düsseldorf, 
Germany). The concentration of RNA was determined by a NanoDrop 2000™ 
spectrophotometer (Thermo Fischer Scientific, Karlsruhe, Germany). cDNA synthesis 
was performed using iScript cDNA synthesis kit (Bio-Rad, München, Germany) 
according to the protocol below. 
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Components 
5x iScript reaction mix 
iScript reverse transcriptase 
Nuclease-free water 
RNA template (100 fg to 1 µg total RNA) 
Total volume 
Volume per reaction 
4 µl 
1 µl 
x µl 
x µl 
20 µl 
 
Complete reaction mix was incubated at 25ºC for 5 minutes, at 42ºC for 30 minutes at 
85ºC for 5 minutes in a thermal cycler.  
 
Gene expression was determined using real-time PCR with LightCycler® 
480 SYBR Green I Master (Roche, Mannheim, Germany) in a Light Cycler® 480 
(Roche, Mannheim, Germany) according to the protocol below. 
 
Components 
SYBR Green I Master 
Primer mix (each 500nM) 
Nuclease-free water 
cDNA sample (100 fg to 1 µg) 
Total volume 
Volume per reaction 
5 µl 
1 µl 
1.5 µl 
2.5 µl 
10 µl 
 
Pre incubation (1 cycle): 95°C 5 minutes 
Amplification (45 cycles): 95°C 10 seconds 
    60°C 15 seconds 
    72°C 20 seconds  
Melting curve (1 cycle): 95°C 5 seconds 
                                             60°C 1 minutes 
Cooling (1 cycle):                40°C 10 seconds 
 
Dissociation curves were used to confrim specificity of the PCR. Results are 
expressed as –ΔΔCt. –ΔΔCt = 2-ΔCtsample-ΔCtbiggest Ct, ΔCt = Cttarget mRNA – CtGapdh. The 
primers used are shown in Table 10. 
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2.2.4.2 Protein level analysis  
 
Tumor tissue and purified basophils were lysed using the Bio-Plex Cell Lysis 
Kit (Bio-Rad, München, Germany). Chemokines were quntified using the multiplex 
protein array system technology (Bio-Rad, München, Germany) according to 
manufacturer’s instructions. 
 
2.2.4.3 Microarray analysis 
 
Total RNA was isolated from untreated HUVECs or from HUVECs treated 
with NO donor (GTN) or TNF, and hybridized to Human HT-12 v4 expression 
beadchip (Illumina, San Diego, USA) in DKFZ Genomics and Proteomics Facility. 
Normalized gene expression intensities were compared, and genes were considered to 
be differentially expressed between different groups if their fold change was greater 
than 2 or less than -2.  
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3 RESULTS 
 
3.1 Treg Depletion as a Model to Study Immune Rejection 
of Tumors 
 
Tumors harbor several mechanisms that impair the efficacy of cancer 
immunotherapy. One of the major obstacles is created by CD4
+
 CD25
+
 Foxp3
+
 Tregs, 
which are known to promote tumor progression by limiting anti-tumor T cell 
response. Tregs are often found at elevated frequencies in the peripheral blood and 
tumors of cancer patients, and their accumulation is associated with poor disease 
outcome for many cancers
103, 104, 105, 106
. Various groups have established mouse 
models, which allow high-level depletion of Tregs. For example, Alexander 
Rudensky’s group generated Foxp3DTR mutant mice, which express knocked-in 
human diptheria toxin receptor (DTR) and enhanced green fluorescent protein (eGFP) 
under the control of foxp3 locus
219
. In these mice, diptheria toxin (DT) administration 
results in almost complete Treg depletion
219
. In addition, our group established 
bacterial artificial chromosome (BAC)-transgenic Foxp3.LuciDTR4 mice, in which 
Tregs express luciferase and eGFP for the detection and human DTR for the 
depletion
220
. DT application in these mice led to about 90-95% depletion of Tregs
220
. 
The presence of these two mouse models displaying different degrees of Treg 
depletion allowed me to study whether the extent of Treg depletion would be 
important for anti-tumor immune responses.    
 
3.1.1 Treg depletion in Foxp3DTR knock-in mice is more efficient 
than in BAC transgenic Foxp3.LuciDTR4 mice 
 
The degree of Treg depletion in Foxp3
DTR
 and Foxp3.LuciDTR4 models was 
compared one day after intraperitoneal DT (20 ng/g) application. For this purpose, 
Foxp3 expression in CD4
+
 T cells was measured by flow cytometry in the tumor, 
tumor-draining lymph nodes (td-LNs), spleen and blood of wild type, Foxp3
DTR
 and 
RESULTS 48 
 
Foxp3.LuciDTR4 mice. DT application in Foxp3.LuciDTR4 mice resulted in about 
92% depletion in the tumor, 95% depletion in td-LNs, 92% depletion in spleen and 
80% depletion in blood (Figure 1A, B). DT treatment of Foxp3
DTR
 mice led to about 
99% depletion in the tumor, 99% depletion in td-LNs, 99% depletion in spleen and 
90% depletion in blood (Figure 1A, B). These findings show that Treg depletion is 
significantly more effective in Foxp3
DTR
 mice as compared to Foxp3.LuciDTR4 mice, 
probably because in knock-in Foxp3
DTR
 mice the DTR is expressed presumably in all 
Foxp3
+
 Tregs. In contrast, BAC-transgenic Foxp3.LuciDTR4 mice contain a small 
percentage of Foxp3
+
 Tregs that do not express DTR
220
.  
 
3.1.2 A small number of Tregs  can obstruct the CD8+ T cell-
dependent complete rejection of tumors  
 
To examine the role of differential Treg depletion in anti-tumor immune 
responses, HCmel 1274 and B16 melanomas were utilized. HCmel 1274 is a 
melanoma cell line recently derived from HGF-CDK4 mice which spontaneosuly 
develop melanoma due to transgenic overexpression of hepatocyte growth factor 
(HGF) and impaired p16
Ink4a
-dependent cell cycle regulation resulting from an 
oncogenic CDK4 (R24C) germline mutation
277
. Similar to B16 cells, HCmel 1274 
cells express natural melanoma antigens, including tyrosinase, tyrosine-related protein 
(TRP)-1, TRP-2 and glycoprotein 100 (gp100), which can induce T cell responses. 
The B16 cell line was isolated from a chemically induced melanoma in C57BL/6 
mice more than 60 years ago. Although this cell line is still widely used by various 
laboratories, it should be noted that B16 can change within a laboratory due to 
continuous in vivo and in vitro passaging over time. Cell lines from genetic models of 
melanoma may better reflect the human disease when compared to B16 cells. 
Therefore, in the present study, mainly the HCmel 1274 melanoma was used. 
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Figure 1: DT application in Foxp3DTR and Foxp3.LuciDTR4 mice results in different degree of Treg 
depletion.  
Wild-type (WT, C57BL/6N), Foxp3.LuciDTR4 and Foxp3DTR mice were injected with 1x106 HCmel 1274 cells 
i.d. When tumors reached a size of 250-500 mm3, Treg were depleted in Foxp3.LuciDTR4 and Foxp3DTR mice 
by i.p. injection of 20 ng/g bodyweight diphtheria toxin (DT). Analysis was performed 1 day after DT application. 
(A) Representative flow cytometric analysis of CD4+ Foxp3+ Treg in tumor, tumor draining-lymph nodes (td-
LN), spleen and blood. (B) Summary of data presented in  (A).  Bars indicate mean±SEM of 6 mice per group. 
The experiment was repeated with similar results. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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To analyze the effect of differential Treg depletion on the tumor growth, DT 
was injected twice into Foxp3
DTR 
and Foxp3.LuciDTR4 mice when tumors had 
reached a size of about 250-500 mm
3
, usually on days 12-14. ~92% Treg depletion in 
Foxp3-LuciDTR4 mice resulted in partial regression of HCmel 1274 tumors (Figure  
2A) and significantly prolonged the survival of tumor-bearing mice as 
compared to tumor-bearing wild type (WT) mice (Figure 2B). Interestingly, ~99% 
Treg depletion in Foxp3
DTR
 mice led to complete regression of HCmel1274 tumors 
(Figure 2A) and, all of the tumor-bearing Foxp3
DTR
 mice were completely cured and 
survived until the experiment is terminated (Figure 2B). In the case of  B16 tumors, 
~92% Treg depletion did not have an impact on tumor growth and survival (Figure 
2C, D) whereas 99% Treg depletion improved the survival of tumor-bearing mice by 
inducing complete tumor rejection (Figure 2C, D). These results show that the 
remaining ~8% Tregs in Foxp3.LuciDTR4 mice are able to prevent complete 
rejection of tumors.  
 
Figure 2: ~99% Treg depletion in Foxp3DTR mice, but not ~92% Treg depletion in Foxp3.LuciDTR4 mice, 
induced complete rejection of established HCmel 1274 and B16 tumors. 
(A) Growth of HCmel 1274 tumors in wild-type (WT, C57BL/6N), Foxp3.LuciDTR4 and Foxp3DTR mice treated 
with diphtheria toxin (DT) on the indicated days. (B) Kaplan-Meier survival curves of mice shown in (A). (C) 
Growth of B16 tumors in wild-type (WT, C57BL/6N), Foxp3.LuciDTR4 and Foxp3DTR mice treated with 
diphtheria toxin (DT) on the indicated days. (D) Kaplan-Meier survival curves of mice shown in (C). Results are 
shown as mean±SEM of 6 mice per group. Shown is 1 representative out of 3 independent experiments. *=p<0.05, 
*=p<0.01, *=p<0.001, ns=not statistically significant. 
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To identify the effector immune cell subpopulation that is required for 
HCmel 1274 tumor rejection after Treg depletion in Foxp3
DTR
 mice, CD8
+
 T, CD4
+
 T 
or NK cells were removed by depleting antibodies 2.43, GK1.5 or PK163-3-6, 
respectively. Figure 3 shows that ablation of CD8
+
 T cells abolished Treg depletion-
mediated tumor eradication, whereas CD4
+
 T cell and NK cell depletion had no effect 
on the tumor regression. These results indicate that CD8
+
 T cells are pivotal in HCmel 
1274 rejection following Treg depletion, which is in agreement with a previous 
finding that the rejection of ovalbumin-expressing B16 in Foxp3.LuciDTR4 mice is 
dependent on CD8
+
 T cells
222
.      
Figure 3: CD8+ T cells are responsible for HCmel 1274 tumor rejection following ~99% Treg depletion in 
Foxp3DTR mice. 
Growth of HCmel 1274 tumors in wild-type (WT, C57BL/6N), Foxp3.LuciDTR4 and Foxp3DTR mice treated with 
diphtheria toxin (DT) and respective depleting antibodies on the indicated days. CD8+ T cells, CD4+ T cells and 
natural killer (NK) cells were depleted by i.p. injections of 0.5 mg anti-CD8 antibody 2.43, 1 mg anti-CD4 
antibody GK1.5, 1 mg anti-NK1.1 antibody PK163, respectively. Rat IgG was used as isotype control antibody. 
Data are mean±SEM of 6 mice per group. Shown is 1 representative out of 2 independent experiments. *=p<0.05, 
*=p<0.01, *=p<0.001, ns=not statistically significant. 
 
To confirm the observation that small numbers of Tregs can block complete 
rejection of tumors, Tregs were prepared from C57BL/6 splenic cells via magnetic 
sorting of CD4
+
 CD25
+
 cells and intratumorally transferred into Foxp3
DTR
 mice 2 
days after DT treatment. The adoptive transfer of 2x10
3
 Tregs was found to prevent 
complete eradication of HCmel 1274 tumors following Treg depletion in 3 out of 6 
mice (Figure 4A), while the adoptive transfer of 2x10
4 
Tregs was found to impede 
complete tumor rejection in all 6 mice (Figure 4A). In addition, all of the Foxp3
DTR
 
mice, which had been injected with 2x10
5
 Tregs after DT application, exhibited tumor 
growth similar to WT mice without any sign of tumor rejection (Figure 4A).  
Adoptive Treg reconstitution was also shown to reduce the surival of tumor-bearing 
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mice, depending on the number of tranferred cells (Figure 4B). This data further 
verifies that small numbers of Tregs can still block the host’s response against 
growing tumors, However, it should be noted that the transferred Tregs may expand 
rapidly due to homeostatic factors and that, therefore, transferred numbers do not 
reflect the actual Treg numbers in the tumor.       
 
 
Figure 4: Adoptive cell reconstitution of Treg-depleted Foxp3DTR mice with purified CD4+ CD25+ Tregs 
isolated from wild-type mice impaired rejection of HCmel1274 tumors. 
(A) Growth of HCmel 1274 tumors in wild-type (WT, C57BL/6N), Foxp3DTR mice treated with diphtheria toxin 
(DT) and Foxp3DTR mice treated with DT and adoptively transferred with purified CD4+ CD25+ Tregs isolated 
from wild-type mice. 2x103, 2x104 or 2x105 purified Tregs were injected intratumorally into HCmel 1274-bearing 
mice 2 days after DT application. (B) Kaplan-Meier survival curves of mice shown in (A). Results are shown as 
mean±SEM of 6 mice per group. Shown is 1 representative out of 2 independent experiments. *=p<0.05, 
*=p<0.01, *=p<0.001, ns=not statistically significant. 
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3.1.3 Treg depletion in Foxp3DTR mice promotes basophil 
recruitment into the tumor 
 
Next, the immune cell infiltrates in HCmel 1274 tumors were investigated 
following Treg depletion in Foxp3
DTR
 and Foxp3.LuciDTR4 mice. Single-cell 
suspensions were prepared from tumors on day 16-18 (4 days after DT 
administration), when the size of tumors from wild-type (WT), Foxp3
DTR
 and 
Foxp3.LuciDTR4 mice were still in the same range, namely size of about 250-500 
mm
3
. Flow cytometric analysis showed that infiltration of CD45
+
 leukocytes was 
enhanced in both models after Treg depletion (Figure 5B). Among the leukoctye 
population in the tumor, CD8
+
 T cells are specifically enriched in both 
Foxp3.LuciDTR4 and Foxp3
DTR
 models, but the level of infiltration was much 
stronger in the latter (Figure 5C). Despite the fact that CD4
+
 Tregs are removed after 
Treg depletion, it was found that the percentage of CD4
+
 T cells in tumor-infiltrating 
leukocytes was similar between wild-type and Treg-depleted mice (Figure 5C), 
indicating that conventional CD4
+
 T cells infiltrated into the tumor after Treg 
depletion. In contrast to CD8
+
 and CD4
+
 T cells, the number of intratumoral B cells 
were reduced after Treg depletion (Figure 5C). The percentage of innate cells, 
including natural killer (NK) cells, NKT cells, dendritic cells (DCs) and macrophages, 
in the intratumoral leukocytes were not changed following Treg depletion (Figure 
5D) but it should be noted that the number of these cells is actually increased due to 
the general increase in leukocyte infiltration. Interestingly, Treg depletion induced 
tumor eosinophilia in both mouse models but tumor basophilia in only Foxp3
DTR
 mice 
(Figure 5E). Treg depletion had no effect on the percentage of neutrophils in the 
leukocyte compartment of the tumor (Figure 5E). In addition, tumors in wild-type, 
Foxp3.LuciDTR4 and Foxp3
DTR
 mice showed little mast cell infiltration (Figure 5E). 
In conclusion, Treg depletion was found to induce infiltration of several leukocyte 
subpopulations in both mouse models, especially CD8
+
 T cells, but basophils were 
only enriched in the tumors of Foxp
DTR 
mice.  
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Figure 5: Treg depletion in Foxp3DTR mice led to strong infiltration of leukocytes into tumors, notably 
CD8+T cells and basophils. 
(A) Wild-type (WT, C57BL/6N), Foxp3.LuciDTR4 and Foxp3DTR mice were injected with 1x106 HCmel 1274 
cells i.d. When tumors reached a size of 250-500 mm3, Treg were depleted in Foxp3.LuciDTR4 and Foxp3DTR 
mice by DT application on the indicated days. Analysis was performed 4 days after first DT application. (B) 
Quantification by flow cytometry of total CD45+ leukocyte infiltration into HCmel 1274 tumors in the indicated 
mice treated with DT. (C) Percentage of lymphocytes in leukocytes infiltrating into HCmel 1274 tumors in the 
indicated mice treated with DT. (D) Percentage of innate cells in leukocytes infiltrating into HCmel 1274 tumors 
in the indicated mice treated with DT. (E) Percentage of granulocytes in leukocytes infiltrating into HCmel 1274 
tumors in the indicated mice treated with DT. Analysis of tumor-infiltrating cells was performed by flow 
cytometry. Data are mean±SEM of 12 mice per group. Shown is all data from 2 independent experiments. 
*=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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Basophils were identified in the tumor by dissecting the intratumoral CD45
int
 
population observed after Treg depletion in Foxp3
DTR
 mice (Figure 6B). Flow 
cytometric analysis showed that most of the CD45
int
 cells in the tumor are 
characterized as FcεRI+ (high affinity IgE receptor) CD49b+ cells (Figure 6B). These 
markers are expressed on both basophils and mast cells, but basophils can be 
differentiated from mast cells by the lack of c-Kit (CD117) expression (Figure 6B). 
In addition, tumor-infiltrating basophils are IgE
+ 
(Figure 6B), indicating the activated 
status of basophils in Treg-depleted tumors because IgE is known to be a potent 
stimulator for effector functions of basophils. For a more comprenhensive 
characterization, The tumor-infiltrating CD45
+
 FcεRI+ CD49b+ cells, CD45+ FcεRI- 
CD49b
-
 cells and CD45
-
 cells were sorted by flow cytometry. RT-PCR analysis on 
sorted cells demonstrated that CD45
+
 FcεRI+ CD49b+ cells expressed high levels of 
mast cell protease 8 (Mcpt8) mRNA, today also known as Basoph8, bacause it is a 
marker specific for basophils but not for mast cells. CD45
+
 FcεRI- CD49b- cells and 
CD45
-
 cells displayed no Mcpt8/Basoph8 transcripts (Figure 6C). Moreover, sorted 
intratumoral CD45
+
 FcεRI+ CD49b+ cells showed characteristic basophil morphology 
with a lobulated nucleus and basophilic granules after Giemsa staining (Figure 6D). 
In addition, after Treg depletion in Foxp3
DTR
 mice, basophils were enriched only in 
the tumor, but not in the blood, spleen, td-LN and lung (Figure 6E). The observation 
that basophils were only enriched in 99% Treg-depleted tumors suggested that 
basophils may be involved in tumor rejection in Foxp3
DTR
 mice. 
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Figure 6: Characterization of tumor-infiltrating basophils after Treg depletion in Foxp3DTR mice. 
(A) Wild-type (WT, C57BL/6N) and Foxp3DTR mice were injected with 1x106 HCmel 1274 cells i.d. When tumors 
reached a size of 250-500 mm3, Treg were depleted in Foxp3.LuciDTR4 and Foxp3DTR mice by DT application on 
the indicated days. Analysis was performed 4 days after first DT application. (B) Flow cytometric analysis of 
HCmel 1274-infiltrating basophils which were characterized as CD45int FcεRI+ CD49b+ IgE+ c-Kit- cells. Results 
are shown as mean±SEM of 12 mice per group. Shown is all data from 2 independent experiments. (C) qRT-PCR 
analysis of CD45+ FcεRI+ CD49b+ cells sorted from HCmel 1274 tumors after Treg depletion for basophil-specific 
marker Mcpt8. Data are shown as mean±SEM of 12 mice per group. Shown all data from 2 independent 
experiments. (D) Representative giemsa staining of basophils (CD45+ FcεRI+ CD49b+ cells) sorted from HCmel 
1274 tumors after Treg depletion. (E) Percentage of basophils (CD45+ FcεRI+ CD49b+ cells) in leukocytes in 
blood, lung, spleen, tumor draining-lymph nodes (td-LN) and tumor. Results are shown as mean±SEM of 12 mice 
per group. Shown is all data from 2 independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically 
significant. 
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3.1.4 Basophils are essential for efficient tumor rejection in 
Foxp3
DTR
 mice 
 
The selective enrichment of  basophils in Foxp3
DTR
 mice following Treg 
depletion prompted us to study the role of basophils in anti-tumor immune responses 
following Treg depletion, a FcεRI-specific monoclonal antibody (MAR-1) was 
employed, which is known to deplete basophils in mice
249
. Following intravenous 
injection (i.v.) of MAR-1, basophils were efficiently ablated in the tumor of Foxp3
DTR
  
mice (Figure 7B and C). Importantly, basophil depletion substantially impaired the 
rejection of HCmel 1274 tumors obtained by Treg depletion and reduced survival of 
tumor-bearing mice (Figure 7D and E). These data exhibit that basophils are required 
for Treg depletion-mediated tumor eradication. 
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Figure 7: Basophil depletion curbs rejection of HCmel 1274 tumors obtained after Treg depletion in 
Foxp3DTR mice.   
(A) Wild-type (WT, C57BL/6N) and Foxp3DTR mice were injected with 1x106 HCmel 1274 cells i.d. When tumors 
reached a size of 250-500 mm3, Treg were depleted in Foxp3DTR mice by DT on the indicated days. Basophils 
were depleted by i.p. injection of 10 μg/mice anti-FcεRI antibody MAR-1 on the indicated days. (B) 
Representative flow cytometric analysis of CD45+ CD200R3+ CD49b+ basophils in the tumor before and after 
basophil depletion with anti-FcεRI antibody MAR-1. (C) Summary of data presented in  (B).  Results are 
mean±SEM of 17 mice per group. Shown is all data from 3 independent experiments. (D) Growth of HCmel 1274 
tumors in wild-type (WT, C57BL/6N), Foxp3DTR mice after Treg depletion with DT and Foxp3DTR after Treg 
depletion combined with ablation of basophils by anti-FcεRI antibody MAR-1. Isotype indicates isotype-matched 
irrelevant antibody as control for anti-FcεRI antibody MAR-1 (E) Kaplan-Meier survival curves of mice shown in 
(D). Data are shown as mean±SEM of 6 mice per group. Shown is 1 representative out of 3 independent 
experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
 
 
Next, immune cell infiltrates in Treg-depleted HCmel 1274 tumors were 
analyzed before and after basophil depletion. Basophil depletion was found to lead to 
a marked reduction in infiltration of CD8
+
 T cells (Figure 8B). In addition, number of 
CD4
+
 T cells, NK cells and macrophages in the tumor was significantly decreased 
after basophil depletion (Figure 8B). In contrast, basophil ablation had no significant 
effect on the number of intratumoral B cells, DCs, eosinophils and neutrophils 
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(Figure 8B). These findings show that basophils play a role in anti-tumor immune 
responses, probably by promoting CD8
+
 T cell infiltration into tumors.  
 
Figure 8: Basophil depletion hampered infiltration of several leukocyte subpopulations, including CD8+ T 
cells, CD4+ T cells, NK cells and macrophages, into Treg-depleted HCmel 1274 tumors in Foxp3DTR mice. 
(A) Wild-type (WT, C57BL/6N), Foxp3.LuciDTR4 and Foxp3DTR mice were injected with 1x106 HCmel 1274 
cells i.d. When tumors reached a size of 250-500 mm3, Treg were depleted in Foxp3.LuciDTR4 and Foxp3DTR 
mice by DT application on the indicated days. Basophils were depleted by anti-FcεRI antibody MAR-1 on the 
indicated days. Analysis was performed 4 days after first DT application. (B) Quantification by flow cytometry of 
leukocyte subpopulation infiltration into HCmel 1274 tumors in the indicated mice. Results are shown as 
mean±SEM of 17 mice per group. Shown is all data from 3 independent experiments. *=p<0.05, *=p<0.01, 
*=p<0.001, ns=not statistically significant. 
 
The effect of basophil depletion on tumor rejection was investigated at the 
molecular level. For this purpose, RT-PCR was performed on total RNA isolated 
from HCmel 1274 tumor lysates for analysis of  the cytokine and chemokine profile 
of tumors in the presence and absence of basophils. Treg depletion was found to cause 
a cytokine storm in the tumor with strong upregulation of Th1 response-related 
cytokines, including interferon (Ifn)-α, Ifn-β, Ifn-γ, tumor necrosis factor (Tnf)-α, 
Interleukin (Il)-1β, Il-12, and Th2 response-related cytokines, such as Il-3, Il-4, Il-5, 
Il-9, Il-10 and Il-13 (Figure 9B). These data suggest that Treg depletion induced both 
Th1 and Th2 responses against the tumor but Th1 cytokines seemed to be dominant 
over Th2 cytokines.  Interestingly, with the exception of Il-12, Il-5 and Il-9, the 
upregulation of these genes was remarkably curbed after basophil depletion (Figure 
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9B). This data suggests that basophils enhance the cytokine storm observed after Treg 
depletion. 
Figure 9: Changes in cytokine expression within the tumor microenvironment after Treg and basophil 
depletion. 
(A) Wild-type (WT, C57BL/6N), Foxp3.LuciDTR4 and Foxp3DTR mice were injected with 1x106 HCmel 1274 
cells i.d. When tumors reached a size of 250-500 mm3, Treg were depleted in Foxp3.LuciDTR4 and Foxp3DTR 
mice by DT application on the indicated days. Basophils were depleted by anti-FcεRI antibody MAR-1 on the 
indicated days. Analysis was performed 4 days after first DT application. (B) qRT-PCR analysis of 
proinflammatory cytokines in tumors of the indicated mice. Results are shown as mean±SEM of 17 mice per 
group. Shown is all data from 3 independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically 
significant. 
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Similar to cytokines, intratumoral expression of several chemokines such as 
chemokine C-C motif ligand (Ccl)2, Ccl3, Ccl4, Ccl7, Ccl11, Ccl20, chemokine C-X-
C motif ligand (Cxcl)9 and Cxcl10 was augmented following Treg depletion (Figure 
10B). However, expression levels of Ccl5, Ccl19, Ccl22 and Ccl24 were not changed 
in the tumor after Treg depletion (Figure 10B). CCL2, CCL3, CCL4, CCL5, CXCL9 
and CXCL10 are known to be potent chemoattractants for tumor-infiltrating T and 
NK cells
62
, thereby upregulation of the genes encoding CCL2, CCL3, CCL4, CXCL9 
and CXCL10 may explain the increased infiltration of T and NK cells into HCmel 
1274 tumors after Treg depletion. In addition, CCL2, CCL3, CCL4, CCL5 and CCL7 
are implicated in infiltration of monocytes/macrophages into tumors
153
, indicating that 
enhanced macrophage infiltration may result from the upregulation of the expression 
of CCL2, CCL3, CCL4 and CCL7 in the tumor microenvironment. CCL11 and 
CCL24 are powerful chemoattractants for eosinophils
278
, strong activation of the gene 
encoding CCL11 could be the reason for enhanced infiltration of eosinophils into the 
tumor after Treg depletion. CCL20 and CCL22 has been shown to recruit Tregs into 
the tumor
105, 279
, but CCL20 can also attract DCs into the tumors
280
. Importantly, 
basophil depletion resulted in a decreased expression of chemokines, Ccl2, Ccl3, 
Ccl4, Cxcl9 and Cxcl10 (Figure 10B). These results indicate that basophils may a 
play a role in T cell migration into the tumor through chemokine production. 
 
The requirement for basophils in Treg depletion-mediated tumor rejection 
was confirmed in an additional tumor system, B16 melanoma. Basophil depletion 
following DT treatment in B16-bearing mice was shown to yield comparable results 
(Figure 11A, B, D and E). Basophils ablation impaired the rejection of B16 tumors 
obtained after Treg depletion (Figure 11A),  resulting in reduced survival of tumor-
bearing mice (Figure 11B). Basophil-depleted tumors displayed diminished 
infiltration of CD8
+
 T cells, CD4
+
 T cells and macrophages (Figure 11D) and 
decreased expression of Ifn-γ, Ccl2, Ccl3, Ccl4, Cxcl9 and Cxcl10 within the tumor 
microenvironment (Figure 11E).   
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Figure 10: Changes in chemokine expression within the tumor microenvironment after Treg and basophil 
depletion. 
(A) Wild-type (WT, C57BL/6N), Foxp3.LuciDTR4 and Foxp3DTR mice were injected with 1x106 HCmel 1274 
cells i.d. When tumors reached a size of 250-500 mm3, Treg were depleted in Foxp3.LuciDTR4 and Foxp3DTR 
mice by DT application on the indicated days. Basophils were depleted by anti-FcεRI antibody MAR-1 on the 
indicated days. Analysis was performed 4 days after first DT application. (B) qRT-PCR analysis of 
chemoattractants in tumors of the indicated mice. Results are shown as mean±SEM of 17 mice per group. Shown 
is all data from 3 independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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Figure 11: Basophil depletion impaired infiltration of leukocyte subpopulations into Treg-depleted B16 
tumors and rejection of B16 tumors observed after Treg depletion in Foxp3DTR mice. 
(A) Growth of HCmel 1274 tumors in wild-type (WT, C57BL/6N), Foxp3DTR mice after Treg depletion with DT 
and Foxp3DTR after Treg depletion combined with ablation of basophils by anti-FcεRI antibody MAR-1. Isotype 
indicates isotype-matched irrelevant antibody as control for anti-FcεRI antibody MAR-1. DT and antibodies were 
injected on the indicated days (B) Kaplan-Meier survival curves of mice shown in (A). Data are shown as 
mean±SEM of 6 mice per group. Shown is 1 representative experiment. (C) Wild-type (WT, C57BL/6N), 
Foxp3.LuciDTR4 and Foxp3DTR mice were injected with 1x106 HCmel 1274 cells i.d. When tumors reached a size 
of 250-500 mm3, Treg were depleted in Foxp3.LuciDTR4 and Foxp3DTR mice by DT application on the indicated 
days. Basophils were depleted by anti-FcεRI antibody MAR-1 on the indicated days. Analysis was performed 4 
days after first DT application. (D) Quantification by flow cytometry of leukocyte subpopulation infiltration into 
HCmel 1274 tumors in the indicated mice. (E) qRT-PCR analysis of cytokines and chemokines in tumors of the 
indicated mice. Results are shown as mean±SEM of 6 mice per group. Shown is all data from 1 experiment. 
*=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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3.1.5 Basophils promote CD8+ T cell recruitment into the tumor 
through production of chemokines CCL3 and CCL4 
 
So far analysis of tumor microenvironment was performed on day 4 after 
Treg depletion. In order to check whether basophils migrate into the tumor before 
CD8
+
 T cells, immune cell infiltrates in HCmel 1274 tumors were analyzed by flow 
cytometry at an earlier time point, namely 2 days after DT treatment. Tumors in wild-
type, Foxp3.LuciDTR4 and Foxp3
DTR
 mice were found to exhibit similar level of 
CD45
+
 leukocyte infiltration 2 days after DT application (Figure 12B). Accordingly, 
similar CD8
+
 T cell and B cell frequencies were observed in wild-type and Treg-
ablated tumors (Figure 12C). As expected, the density of CD4
+
 T cells were reduced 
in the tumors of mice depleted of CD4
+
 Tregs (Figure 12C). In addition, the 
intratumoral infiltration of NK cells, NKT cells, DCs, macrophages, eosinophils, 
neutrophils and mast cells was not altered after Treg depletion (Figure 12D and E). 
Strikingly, Treg-depleted tumors in Foxp3
DTR
 mice were strongly infiltrated by 
basophils already 2 days after DT administration (Figure 12E). These data show that 
basophils were the first immune cell population that infiltrated into the tumor 
following Treg depletion in Foxp3
DTR 
mice.  
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Figure 12: Basophils are the earliest leukocyte subpopulation that infiltrated HCmel 1274 tumors after Treg 
depletion in Foxp3DTR mice. 
(A) Wild-type (WT, C57BL/6N), Foxp3.LuciDTR4 and Foxp3DTR mice were injected with 1x106 HCmel 1274 
cells i.d. When tumors reached a size of 250-500 mm3, Treg were depleted in Foxp3.LuciDTR4 and Foxp3DTR 
mice by DT application on the indicated days. Analysis was performed 2 days after first DT application. (B) 
Quantification by flow cytometry of total CD45+ leukocyte infiltration into HCmel 1274 tumors in the indicated 
mice treated with DT. (C) Percentage of lymphocytes in leukocytes infiltrating into HCmel 1274 tumors in the 
indicated mice treated with DT. (D) Percentage of innate cells in leukocytes infiltrating into HCmel 1274 tumors 
in the indicated mice treated with DT. (E) Percentage of granulocytes in leukocytes infiltrating into HCmel 1274 
tumors in the indicated mice treated with DT. Analysis of tumor-infiltrating cells was performed by flow 
cytometry. Data are mean±SEM of 12 mice per group. Shown is all data from 2 independent experiments. 
*=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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Kinetic studies on tumor infiltration by immune cell subpopulations 
confirmed that basophil infiltration preceded CD8
+
 T cell infiltration (Figure 13A 
and B). Basophils were enriched in the tumor 2 days after Treg depletion (Figure 
13A) whereas the number of intratumoral CD8
+
 T cells peaked 4 days after Treg 
depletion (Figure 13B).  
 
Figure 13: Basophil infiltration preceded CD8+ T cell infiltration into Treg-depleted HCmel 1274 tumors. 
(A) Infiltration kinetics of basophils and (B) CD8+ T cells into the tumor after Treg depletion in Foxp3DTR mice 
calculated by by flow cytometry. Results are mean±SEM of 12 mice per group. Shown is all data from 2 
independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
 
Next, the chemokine profile of the tumor microenvironment was examined 2 
days after Treg depletion, when basophil population peaked in the tumor. RT-PCR 
data revealed that the expression of chemokines Ccl3 and Ccl4 but not Ccl2, Ccl5, 
Ccl7, Ccl11, Ccl12, Ccl19, Ccl20, Ccl22, Ccl24, Cxcl9 and Cxcl10 was significantly 
upregulated 2 days following Treg depletion (Figure 14B). Basophils (CD45
+
 FcεRI+ 
CD49b
+
 cells) sorted from Treg-depleted tumor were found to express high levels of 
Ccl3 and Ccl4 but not Ccl2, Cxcl9 and Cxcl10 as compared with CD45
+ FcεRI- 
CD49b
-
 cells and CD45
-
 cells (Figure 14C), suggesting that basophils are a critical 
source of CCL3 and CCL4 in the tumor microenvironment. Moreover, the production 
of CCL3 and CCL4 was observed only in tumoral basophils but not in splenic 
basophils (Figure 14D). These observations show that basophils are a major source of 
chemokines CCL3 and CCL4 in the tumor microenvironment. 
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Figure 14: Basophils in Treg-depleted tumors produce CCL3 and CCL4 that are known to attract CD8+ T 
cells. 
(A) Wild-type (WT, C57BL/6N) and Foxp3DTR mice were injected with 1x106 HCmel 1274 cells i.d. When tumors 
reached a size of 250-500 mm3, Treg were depleted in Foxp3DTR mice by DT application on the indicated days. 
Analysis was performed 2 days after first DT application. (B) qRT-PCR analysis of chemoattractants in tumors of 
the indicated mice 2 days after Treg depletion. (C) qRT-PCR analysis of chemokines in CD45+ FcεRI+ CD49b+ 
basophils, CD45+ FcεRI- CD49b- cells and CD45= cells sorted from HCmel 1274 tumors 2 days after Treg 
depletion. (D) qRT-PCR analysis of chemokines in CD45+ FcεRI+ CD49b+ basophils sorted from the tumor or the 
spleen 2 days after Treg depletion. Results are mean±SEM of 12 mice per group. Shown is all data from 2 
independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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Based on these results, I investigated the possibility that CD8
+
 T cells were 
attracted into tumors by basophil-derived CCL3 and CCL4. Bone marrow-derived 
basophils were generated in the presence of IL-3. Fully differentiated basophils were 
shown to secrete elavated amounts of CCL3 and CCL4 but did not increase CCL2, 
CXCL9 and CXCL10 production when stimulated with a combination of IL-3, IL-18 
and IL-33 (Figure 15A), in agreement with previous findings
257, 258
. Using a two-
chamber system in vitro, it was observed that basophils activated with IL-3+IL-
18+IL-33 induced migration of activated CD8
+
 T cells whereas basophils activated 
with IL-3 alone failed to do so (Figure 15B). Blocking of CCL3 and CCL4 with a 
cocktail of specific antibodies markedly abrogated CD8
+
 T cell migration (Figure 
15C). These findings demonstrate that basophils attract CD8
+
 T cells by secreting 
CCL3 and CCL4, thereby providing an explanation for the decreased infiltration of 
CD8
+
 T cells into Treg-depleted tumors in the absence of basophils. 
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Figure 15: Basophil-derived chemokines induce CD8+ T cell migration. 
(A) Multiplex analysis of chemokines produced by basophils cultured in vitro with IL-3 only or with IL-3 plus IL-
18 plus IL-33. Data are shown as mean±SEM of 4 samples. Shown is 1 representative experiment. (B) Basophils 
treated with IL-3 IL-18 plus IL-33 induce migration of CD8+ T cells in a two-chamber system. (C) Inhibition of 
migration by specific antibodies against CCL3 and CCL4. Data are shown as mean±SEM of 6 samples. Shown is 
all data from 2 independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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3.1.6 Basophilia-induced CD8+ T cell infiltration stimulates tumor-
associated macrophages to produce chemokines CCL2, 
CXCL9 and CXCL10  
 
As shown before, in addition to increased Ccl3 and Ccl4 levels,  tumors 
displayed abundant Ccl2, Cxcl9 and Cxcl10 mRNAs 4 days after Treg depletion 
(Figure 10B). Furthermore, basophil depletion was found to impair the upregulation 
of the genes encoding these chemokines (Figure 10B). RT-PCR analysis revealed 
that sorted intratumoral basophils did not produce these chemokines (Figure 14C). 
Thus, these findings suggested that basophils may act on other leukocyte 
subpopulations to stimulate production of these chemokines in the tumor 
microenvironment. Several studies have reported that CCL2, CXCL9 and CXCL10 
are produced by macrophages, eosinophils or other myeloid cells in the tumor, mainly 
in response to IFN-γ and TNF-α281, 282, 283. Following Treg depletion in Foxp3DTR 
mice, the main source of these chemokines was shown to be macrophages sorted from 
the tumors (Figure 16B). IFN-γ is known to be largely produced by CD8+ T cells, 
indicating that activated CD8
+
 T cells may control the production of CCL2, CXCL9 
and CXCL10 by macrophages via IFN-γ. Indeed, basophil depletion, CD8+ T cell 
depletion and IFN-γ blockade with respective antibodies were shown to cause a 
reduction in CCL2, CXCL9 and CXCL10 expression by intratumoral macrophages 
(Figure 16D). These data indicate that decrease in intratumoral levels of CCL2, 
CXCL9 and CXCL10 after basophil depletion can be attributed to a reduced level of 
CD8
+
 T cell infiltration and IFN-γ production by these CD8+ T cells. Thus, it can be 
hypothesized that basophils first induce CD8
+
 T cell migration into tumors through 
production of CCL3 and CCL4. The infiltrating CD8
+
 T cells will polarize 
macrophages into M1-like CCL2-, CXCL9- and CXCL10- producing macrophages, 
which, in turn, are likely to amplify CD8
+
 T cell trafficking into tumors.  
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Figure 16: Tumor-associated macrophages produce CCL2, CXCL9 and CXCL10, which is dependent on 
IFN-γ produced by CD8+ T cells. 
(A) Foxp3DTR mice were injected with 1x106 HCmel 1274 cells i.d. When tumors reached a size of 250-500 mm3, 
Treg were depleted in Foxp3DTR mice by DT application on the indicated days. Analysis was performed 4 days 
after first DT application. (B) qRT-PCR analysis of chemokines in CD45+ CD11b+ Gr-1low F4/80+ Siglec-F- 
macrophages, CD45+ CD11b+ Gr-1low F4/80+ Siglec-F+ eosinophils, other CD45+ cells and CD45= cells sorted 
from HCmel 1274 tumors 4 days after Treg depletion. (C) Wild-type (WT, C57BL/6N) and Foxp3DTR mice were 
injected with 1x106 HCmel 1274 cells i.d. When tumors reached a size of 250-500 mm3, Treg were depleted in 
Foxp3DTR mice by DT application on the indicated days. Basophils and CD8+ T cells were depleted by i.p. 
injections of 10 μg anti-FcεRI antibody MAR-1 and 0.5 mg anti-CD8 antibody 2.43, respectively, 2 days after DT 
application. IFN-γ was blocked by i.p. injection of 0.5 mg anti-IFN-γ antibody XMG1.2  2 days after first DT 
application. Analysis was performed 4 days after first DT application. (D) qRT-PCR analysis of chemokines in 
CD45+ CD11b+ Gr-1low F4/80+ Siglec-F- macrophages sorted from Treg-depleted HCmel 1274 tumors after 
basophil depletion, CD8+ T cell depletion or IFN-γ blockade. Results are mean±SEM of 12 mice per group. Shown 
is all data from 2 independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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For examination of a role for M1-like polarization in tumor rejection, 
macrophages were depleted by administration of clodronate-loaded liposomes (CLIP), 
and IFN-γ activity was blocked by XMG1.2 antibody. Interestingly, tumor rejection 
after Treg depletion was shown to be completely abrogated by macrophage ablation 
and by IFN-γ blockade (Figure 17A), indicating that macrophages are essential for 
Treg-mediated tumor rejection. Furthermore, macrophage ablation and IFN-γ 
blockade diminished the positive impact of Treg depletion on the survival of tumor-
bearing mice (Figure 17B).  Figure 17D displayed that CLIP efficiently depleted the 
macrophages in the tumor whereas IFN- γ blockade did not have an effect on the 
number of macrophages. In addition, both macrophage depletion and IFN-γ blockade 
resulted in severely reduced CD8
+
 and CD4
+
 T cell infiltration into tumors 
concomitant with a dramatic decrease in expression of CCL2, CXCL9 and CXCL10 
in the tumor (Figure 17D and E). 
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Figure 17: Macrophage depletion and IFN-γ blockade obstruct chemokine production within the Treg-
depleted tumor microenvironment, thereby preventing T cell infiltration and tumor rejection observed after 
Treg depletion in Foxp3DTR mice. 
(A) Growth of HCmel 1274 tumors in wild-type (WT, C57BL/6N), Foxp3DTR mice after Treg depletion with DT, 
Foxp3DTR after Treg depletion combined with ablation of macrophages by 200 μl of clodronate-loaded liposomes 
(CLIP) and Foxp3DTR after Treg depletion combined with blocking of IFN-γ by anti-IFN-γ antibody XMG1.2. DT, 
CLIP and antibody were injected on the indicated days. (B) Kaplan-Meier survival curves of mice shown in (A). 
Data are shown as mean±SEM of 6 mice per group. Shown is 1 representative out of 2 independent experiments. 
(C) Wild-type (WT, C57BL/6N) and Foxp3DTR mice were injected with 1x106 HCmel 1274 cells i.d. When tumors 
reached a size of 250-500 mm3, Treg were depleted in Foxp3DTR mice by DT application on the indicated days. 
Macrophages were depleted by CLIP and IFN-γ was blocked by anti-IFN-γ antibody XMG1.2 2 days after Treg 
depletion. Analysis was performed 4 days after first DT application. (D) Quantification by flow cytometry of 
leukocyte subpopulation infiltration into HCmel 1274 tumors in the indicated mice. (E) qRT-PCR analysis of 
chemoattractants in tumors of the indicated mice. Results are shown as mean±SEM of 12 mice per group. Shown 
is all data from 2 independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
 
In a recent study, we have shown that depletion of Tregs in 
Foxp3.LuciDTR4 mice induced tumor eosinophilia, which were required for efficient 
rejection of ovalbumin-expressing B16 melanoma (B16-OVA) following Treg 
depletion
283
. In the present study, flow cytometry demonstrated that after Treg 
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depletion in Foxp3
DTR
 mice, infiltration of eosinophils into HCmel 1274 tumors was 
also enhanced (Figure 5E). The potential role of eosinophils in rejection of HCmel 
1274 tumors after Treg ablation was analyzed, using a Siglec-F specific monoclonal 
antibody that deplete eosinophils. However, in Foxp3
DTR 
mice, eosinophil depletion 
had no effect on tumor growth (Figure 18A), showing that eosinophils are not 
essential for the regression of HCmel 1274 melanoma observed after Treg depletion. 
Kinetic studies of infiltration of tumors by leukocyte subpopulations revealed that 
after Treg depletion eosinophil and CD8
+
 T infiltration into HCmel 1274 tumors in 
Foxp3
DTR 
mice occured simultaneously (Figure 13B and 18B) whereas in 
Foxp3.LuciDTR4 mice eosinophil infiltration preceded CD8
+
 infiltration into B16-
OVA tumors following ablation of Tregs
283
.   
 
Figure 18: Eosinophil depletion has no effect on growth of HCmel 1274 tumors after Treg depletion in 
Foxp3DTR mice. 
(A) Growth of HCmel 1274 tumors in wild-type (WT, C57BL/6N), Foxp3DTR mice after Treg depletion with DT 
and Foxp3DTR after Treg depletion combined with ablation of eosinophils by anti-Siglec-F antibody (15 μg/mice). 
DT and antibodies were injected on the indicated days. Data are shown as mean±SEM of 6 mice per group. Shown 
is 1 representative experiment. . (B) Infiltration kinetics of eosinophils into the tumor after Treg depletion in 
Foxp3DTR mice. Results are mean±SEM of 12 mice per group. Shown is all data from 2 independent experiments. 
*=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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3.1.7 IL-3 mediates tumor-specific recruitment of basophils after 
Treg depletion 
 
Next, the molecular mechanism of basophil infiltration into the tumor after 
Treg depletion in Foxp3
DTR
 mice was investigated. Figure 12E has shown that 
basophils were selectively recruited to the tumor 2 days after Treg depletion. 
Chemokine profiling on the same time point has revealed that the expression of CCL3 
and CCL4 were strongly upregulated (Figure 14B). However, further analysis 
demonstrated that these chemokines are actually produced by tumor-infiltrating 
basophils (Figure 14C), indicating that the increase in the expression of CCL3 and 
CCL4 in the tumor resulted from basophil migration into the tumor.  A large variety 
of cytokines, including IL-3, IL-5, IL-18, IL-25, IL-33, granulocyte macrophage 
colony-stimulating factor (GM-CSF) and thymic stromal lymphopoietin (TSLP), are 
implicated in the modulation of basophil development, homeostasis, recruitment and 
effector functions. Therefore, the intratumoral expression of these cytokines was 
analyzed by RT-PCR. The gene encoding IL-3 was strongly induced in tumors after 
Treg depletion in Foxp3
DTR
 mice but not after Treg depletion in Foxp3.LuciDTR4 
mice (Figure 19B). The expression level of other cytokines was not changed after 
Treg depletion in both models  (Figure 19B). A comprehensive analysis showed that 
intratumoral CD4
+
 T cells were a major source for IL-3 in the Treg-depleted tumor 
microenvironment in Foxp3
DTR
 mice (Figure 19C). Il-3 expression was only 
upregulated in the tumor but not in other organs such as spleen, td-LN and lung 
(Figure 19D), indicating tumor-specific production of IL-3 correlated with tumor-
specific recruitment of basophils. Together these findings suggest that Treg depletion 
causes tumor-infiltrating CD4
+
 T cells to secrete IL-3, which, in turn, attracts 
basophils into the tumor.  
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Figure 19: Tumor-specific recruitment of basophils after Treg depletion in Foxp3DTR mice via IL-3. 
(A) Wild-type (WT, C57BL/6N), Foxp3.LuciDTR4 and Foxp3DTR mice were injected with 1x106 HCmel 1274 
cells i.d. When tumors reached a size of 250-500 mm3, Treg were depleted in Foxp3.LuciDTR4 and Foxp3DTR 
mice by DT application on the indicated days. Analysis was performed 2 days after first DT application. (B) qRT-
PCR analysis of cytokines, implicated in stimulation of basophil effector functions, within the HCmel 1274 tumor 
microenvironment 2 days after Treg depletion. Data are shown as mean±SEM of 12 mice per group. Shown is all 
data from 2 independent experiments (C) qRT-PCR analysis of IL-3 in CD45+ CD3+ CD4+ T cells, CD45+ CD3+ 
CD8+ T cells, CD45+ FcεRI+ CD49b+ basophils and rest of the cells sorted from HCmel 1274 tumors 2 days after 
Treg depletion in Foxp3DTR mice. Data are shown as mean±SEM of 6 mice per group. Shown is 1 representative 
experiment. D) qRT-PCR analysis of IL-3 in tumors, spleens, tumor-draining lymph nodes (td-LN) and lung. Data 
are shown as mean±SEM of 6 mice per group. Shown is 1 representative experiment. *=p<0.05, *=p<0.01, 
*=p<0.001, ns=not statistically significant. 
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3.1.8 Systemic administration of IL-3/antibody causes tumor-
associated basophilia 
 
In a study by Ohmori et al., it was reported that injection of IL-3/antibody 
complex (IL-3 + anti-IL-3 Ab) into mice facilitated expansion of basophils in vivo
232
. 
Consistent with these findings, intravenous administration of IL-3/antibody complex 
into tumor-bearing mice was found to induce basophilia in the blood, in the lung, in 
the spleen and in the tumor, but not in td-LNs (Figure 20B). In addition, IL-
3/antibody complex had no effect on the number of eosinophils and mast cells 
(Figure 20B). As observed in the Treg depletion model, tumor-associated basophilia 
was correlated with an increased intratumoral expression of CCL3 and CCL4 (Figure 
20C). Since the IL-3/antibody complex mainly enhanced the levels of basophils, this 
approach enabled me to investigate more precisely the mechanism by which basophils 
support antitumor immunity.   
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Figure 20: IL-3/antibody complex injection induces basophilia in B16-OVA tumor, which correlates with 
intratumoral CCL3 and CCL4 production. 
(A) B16-OVA-bearing wild-type (WT, C57BL/6N) mice were injected i.v. with a mixture of mouse reombinant 
IL-3 (10 μg/mice) and anti-IL-3 antibody (5 μg/mice). 3 days later, mice were sacrificed for analysis. (B) 
Percentage of basophils and eosinophils in blood; percentage of basophils, eosinophils and mast cells in lung, 
spleen, tumor-draining lymph nodes (td-LN) and tumor in the indicated mice calculated by flow cytometry. Data 
are shown as mean±SEM of 10 mice per group. Shown is all data from 2 independent experiments. (C) Multiplex 
analysis of CC3 and CCL4 in tumor lysates of mice treated with IL-3/antibody complex or left untreated. Data are 
shown as mean±SEM of 5 mice. Shown is 1 representative experiment. *=p<0.05, *=p<0.01, *=p<0.001, ns=not 
statistically significant. 
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3.1.9 IL-3/antibody complex-induced basophilia enhances the 
infiltration of tumor-specific CD8
+
 T cells 
 
Immunotherapy based on the adoptive transfer of tumor-specific T cells is 
now a clinical therapy for cancer patients. However, its success is still limited
185
. 
Therefore, it was examined whether tumor-associated basophilia would be able to 
improve the efficacy of T cell therapy against B16 melanoma expressing ovalbumin 
as a surrogate tumor antigen (B16-OVA). As demonstrated in previous studies 
conducted in our laboratory, adoptive transfer of ovalbumin-specific CD8
+
 T cells 
alone, which are derived from TCR-transgenic OT-I mice, resulted in limited control 
of B16-OVA tumor growth (Figure 21A and B). Interestingly, when the transfer of 
OT-I CD8 T cells was combined with injection of IL-3/antibody complex, B16-OVA 
tumor growth was substantially inhibited and the survival of tumor-bearing mice 
prolonged (Figure 21A and B). Moreover, in vivo blockade of CCL3 and CCL4 by 
injection of a combination of antibodies against these chemokines impaired the tumor 
rejection observed after IL-3/antibody complex+OT-I CD8
+
 T cell therapy (Figure 
21A and B). These findings show that basophilia induced by the IL-3/antibody 
retarded tumor growth when combined with adoptive T cell therapy.  
 
 
Figure 21: Adoptive transfer of tumor-specific CD8+ T cells alone fails to control growth of B16-OVA 
tumors, whereas co-injection with IL-3/antibody complex leads to tumor rejection in a CCL3/4 dependent 
way. 
(A) B16-OVA tumor growth curves in Wild-type (WT, C57BL/6N) mice after i.v. injection of IL-3/antibody 
complex alone, activated OT-I CD8+ T cells alone, IL-3/antibody complex plus activated OT-I CD8+ T cells and 
IL-3/antibody complex plus activated OT-I CD8+ T cells in combination with a cocktail of antibodies against 
CCL3 and CCL4. (B) Kaplan-Meier survival curves of mice shown in (A). Data are shown as mean±SEM of 6 
mice per group. Shown is 1 representative out of 2 independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, 
ns=not statistically significant. 
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Analysis of the composition of immune cells revealed that CD8
+
 T cells and 
CD4
+ 
T cells only scarcely infiltrated the tumors after OT-I CD8
+ 
T cell transfer alone 
(Figure 22B). However, when combined with IL-3/antibody complex injection, 
tumors were strongly infiltrated by CD8
+
 T cells and CD4
+
 T cells (Figure 22B), but 
not with B cells (Figure 22B). In vivo blockade of basophil-derived chemokines 
CCL3 and CCL4 impaired the migration of CD8
+
 T cells, mainly including 
transferred OT-I CD8
+
 T cells, and CD4
+
 T cells into the tumor (Figure 22B and C). 
Combination therapy also led to a rise in the infiltration of innate immune cells into 
the tumor, including NK cells, DCs and macrophages but only the migration of NK 
cells and macrophages was affected by blocking of CCL3/4 (Figure 22D). Among the 
tumor infiltrating-granulocytes, only basophils were enriched after combination 
therapy in the tumor but not eosinophils, neutrophils and mast cells (Figure 22E). 
Importantly, CCL3/4 blocking was found to have no impact on IL-3/antibody 
complex-induced tumor-associated basophilia (Figure 22E). These results indicate 
that the IL-3/antibody complex-induced basophilia control recruitment of T cells and 
other leukocyte populations into tumors via production of  CCL3 and CCL4. 
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Figure 22: Combination of adoptive transfer of tumor-specific CD8+ T cells with IL-3/antibody complex 
results in strong T cell infiltration into B16-OVA tumors in a CCL3/4 dependent way. 
(A) B16-OVA-bearing wild-type (WT, C57BL/6N) mice were injected i.v. with IL-3/antibody complex 3 days 
before adoptive transfer of OT-I CD8+ T cells. 2 days after CD8+ T cell transfer, mice were sacrificed for analysis. 
Quantification by cytofluorometry of (B) lymphocyte infiltration, (C) transferred Thy1.1+ OT-I CD8+ T cell 
infiltration, (D) innate cell infiltration and (E) granulocyte infiltration into the tumor. Results are shown as 
mean±SEM of 10 mice per group. Shown is all data from 2 independent experiments. *=p<0.05, *=p<0.01, 
*=p<0.001, ns=not statistically significant. 
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3.1.10 IL-3/antibody complex+CD8 T cell transfer results in macro-
phage polarization and normalization of tumor vasculature 
 
Macrophages are abundantly present in tumors of cancer patients. Tumor-
associated macrophages (TAMs) usually present a protumoral  M2 phenotype that 
depends on the cues in the tumor microenvironment
284
. M2 TAMs promote many 
critical aspects of tumor progression, including angiogenesis, tumor cell motility and 
invasion as well as suppression of antitumor immune responses
284
. Therefore, M2 
TAMs represent a crucial target for cancer therapy. With appropriate therapeutic 
interventions, these cells might assume M1-like features. M1-like macrophages can  
induce direct killing of tumor cells, promote T cell-mediated inflammation, or 
decrease of angiogenesis
284
. Whereas TAMs isolated from untreated tumors displayed 
an M2-like phenotype, macrophages sorted from tumors after IL-3/antibody 
complex+CD8
+
 T cell transfer were skewed towards an M1-like phenotype, as 
demonstrated by higher expression of the genes encoding CCL2, CXCL9, CXCL10, 
TNF-α, inducible nitric oxide synthase (iNOS), and lower expression of the M2 
typical genes encoding arginase I (Arg1) and mannose receptor, c type 1 (MRC1) 
(Figure 23B). These findings indicate that the combination therapy used here caused 
macrophage polarization towards M1 probably due to basophilia-induced infiltration 
of T cells. These T cells can secrete cytokines such as IFN-γ and TNF-α which can 
further skew tumor-associated M2 macrophages towards M1 macrophages and further 
enhance T cell infiltration through production of chemokines and cytokines such as 
CCL2, CXCL9, CXCL10 and TNF-α by M1-like macrophages. 
 
In order to see if the combination of IL-3/antibody complex plus OT-I CD8
+
 
T cells is able to enhance normalization of the tumor vasculature, the tumor vessels 
were investigated by immunofluorescence. Results in Figure 23C and D show that 
untreated B16-OVA tumors were characterized by  aberrant tumor vasculature and 
combination therapy, consisting of basophils induction by IL-3/antibody complex and 
OT-I CD8
+
 T cells, promoted the normalization of tumor vasculature, as indicated by 
a reduction in the average CD31
+
 vessel size. Moreover, the normalized vessels 
showed enhanced expression of VCAM-1 (Figure 23C and D). In summary, 
combination therapy with IL-3/antibody complex and CD8
+
 T cells induced tumor 
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vasculature normalization and tumor endothelium activation through M1 skewing of 
tumor associated macrophages. 
Figure 23: Combination of adoptive transfer of tumor-specific CD8+ T cells with IL-3/antibody complex 
induces M1-like polarization of tumor-associated macrophages and normalization of the tumor vasculature.  
(A) B16-OVA-bearing wild-type (WT, C57BL/6N) mice were injected i.v. with IL-3/antibody complex 3 days 
before adoptive transfer of OT-I CD8+ T cells. 2 days after CD8+ T cell transfer, mice were sacrificed for analysis. 
(B) qRT-PCR analysis of cytokines, chemokines and markers for M1- and M2-like macrophages from sorted 
CD45+ CD11b+ Gr-1low F4/80+ Siglec-F- tumor macrophages from untreated mice, and mice injected with IL-
3/antibody complex and OT-I CD8+ T cells. Data are mean±SEM of 6 mice per group. Shown is 1 representative 
experiment. (C) Representative immunofluorescence microscopy analysis of tumor vessels of the indicated mice 
stained with antibodies against CD31 (red) and VCAM-1 (green). Yellow color shows colocalization. Size bar 
indicates 100 μm. (D) Quantification of individual CD31+ tumor vessel size, number of CD31+ tumor vessels and 
VCAM-1 expression on CD31+ tumor vessels. Tumors of comparable size were investigated. 3 random fields were 
analyzed from each tumor. Results are mean±SEM of 6 mice per group. Shown is 1 representative experiment. 
*=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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3.2 Rip1-Tag5 (RT5) as a Model to Study Immune 
Rejection of Tumors 
 
Previous studies have shown that treatment modalities such as vaccination 
against tumor antigens and adoptive T cell therapy failed to control tumor progression 
in RT5 mice due to inefficient T cell trafficking into tumors. This lack of T cell 
infiltration correlated with aberrant tumor vasculature
75, 274, 275
. However, the 
combination of adoptive T cell therapy with danger signals, such as irradiation and 
TLR9 agonist cytosine-phosphorothioate-guanine containing oligodeoxynucleotides 
(CpG-ODN), caused normalization of tumor vessels and recruitment of tumor-
specific T cells into tumors. In the present study, the underlying mechasim how the 
combination of CpG-ODN with pre-activated tumor-specific CD8
+
 T cells enhances T 
cell infiltration was investigated.  
 
3.2.1 Combination of CpG-ODN with adoptive T cell transfer 
prolongs the survival of RT5 mice 
 
Treatment of 24 week-old RT5 mice carrying large established pancreatic 
tumors with adoptive transfer of tumor antigen Tag-specific CD8
+
 T cells alone led 
only to a slight improvement in survival but eventually all the mice succumbed to 
death (Figure 24B). In contrast, treatment of mice with Tag-specific CD8
+
 T cells in 
combination with CpG-ODN resulted in rejection of RT5 tumors and prolonged 
survival of tumor-bearing mice (Figure 24B). CpG-ODN monotherapy had no impact 
on tumor growth in comparison with untreated mice (Figure 24B).  
 
In order to explore the mechanism underlying the successful combination 
therapy, tumor infiltration of 24 week-old RT5 mice by leukocyte subpopulations was 
examined by flow cytometry. It was observed that CpG-ODN alone was able to 
enhance tumor infiltration of CD8
+
 T cells, composed of endogenous and transferred 
CD8
+
 T cells, CD4
+
 T cells, B cells and macrophages but not of NK cells and DCs 
whereas adoptive CD8
+
 T cell therapy alone induced an increase only in the number 
of intratumoral CD8
+
 T cells and CD4
+
 T cells (Figure 24C). Strikingly, combination 
therapy strongly enhanced infiltration of CD8
+
 T cells, CD4
+
 T cells, B cells and NK 
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cells, DCs and macrophages into the tumor (Figure 24C), explaining the improved 
survival in RT5 mice treated with combination therapy.  
 
Figure 24: Combination of adoptive transfer of tumor-specific CD8+ T cells with CpG-ODN results in 
strong infiltration of leukocyte subpopulations, notably CD8+ T cells and macrophages, and tumor 
rejection.  
(A) 24 week-old Rip1-Tag5 (RT5) mice were injected with 25 μg of CpG-ODN 1668 i.v. on days 0, 6 and 10. If 
indicated, the same group of mice received adoptive transfers of activated TCR8 CD8+ T cells on day 1 and 11. 
Mice were sacrificed on day 13 and analyzed by flow cytometry. For survival experiments, mice were injected, as 
described above. CpG-ODN injection and adoptive transfers were repeated every 10 days until the end of 
experiment. (B) Kaplan-Meier survival curves of mice treated with CpG-ODN alone, adoptive transfer of TCR8 
CD8+ T cells alone and combination of CpG-ODN and adoptive transfer of TCR8 CD8+ T cells. Data are shown as 
10 mice per group. (C) Quantification by cytofluorometry of infiltration of leukocyte subpopulations into RT5 
tumors. Results are shown as mean±SEM of 10 mice per group. Shown is all data from 2 independent 
experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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3.2.2 CpG-ODN polarizes tumor-associated macrophages into M1-
like phenotype 
 
In a previous study, systemically injected CpG-ODN, that was fluorochrome 
labeled, was found to bind to macrophages in the tumor
274
.  Stimulated by this 
observation, the phenotype of tumor macrophages in RT5 mice was investigated for 
the expression of M1 marker iNOS and M2 marker CD206 (MRC1). In untreated 
tumors, the majority of macrophages were M2-like, as indicated by high level of 
CD206 expression and low level of iNOS expression (Figure 25B and C). CD8
+
 T 
cell transfer alone had no effect on the phenotype of macrophages whereas CpG-ODN 
polarized macrophages towards a M1-like phenotype, shown by an increase in iNOS 
production and a decrease in CD206 production (Figure 25B and C). Combination of 
CpG-ODN with adoptive CD8
+
 T cell transfer resulted in further augmented 
expression of iNOS in intratumoral macrophages (Figure 25B and C).  
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Figure 25: Combination therapy induces M1-like polarization of tumor-associated macrophages in RT5 
mice.  
(A) 24 week-old Rip1-Tag5 (RT5) mice were injected with 25 μg of CpG-ODN 1668 i.v. on days 0, 6 and 10. If 
indicated, the same group of mice received adoptive transfers of activated TCR8 CD8+ T cells on day 1 and 11. 
Mice were sacrificed on day 13 and analyzed by flow cytometry. (B) Representative flow cytometric analysis of 
iNOS (M1 marker) and CD206 (MRC1) (M2 marker) expression on CD11b+ Gr-1- F4/80+ tumor macrophages. 
(C) Summary of data presented in  (B). Bars indicate the percentage of respective population in total tumor-
infiltrating macrophages. Data are mean±SEM of 10 mice per group. Shown is all data from 2 independent 
experiments.  
 
 
3.2.3 iNOS-expressing macrophages are essential for tumor 
regression in RT5 mice  
 
In order to investigate the potential role of iNOS
+
 macrophages in tumor rejection 
after CpG-ODN plus adoptive CD8
+
 T cell transfer, CLIP was employed for selective 
depletion of macrophages. In addition, L-N6-(1-iminoethyl)lysine (L-NIL), was used 
to selectively inhibit iNOS activity in RT5 mice. Interestingly, CLIP treatment 
abrogated the increased lifespan of tumor-bearing RT5 mice observed after 
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combination therapy (Figure 26B). Flow cytometric analysis revealed that 
macrophages were efficiently depleted in the tumor by CLIP administration (Figure 
26C). Moreover, macrophage-depleted tumors displayed a reduced infiltration of 
CD8
+
 T cells, CD4
+
 T cells, NK cells and DCs (Figure 26C).  In contrast, iNOS 
blockade with L-NIL had a slight but not significant impact on the number of 
intratumoral macrophages, but also led to an reduction in the number of CD8
+
 T cells, 
CD4
+
 T cells, NK cells and DCs in the tumor (Figure 26C). B cell infiltration is not 
significantly affected by either macrophage depletion or iNOS blockade (Figure 
26C). Notably, the inhibition of leukocyte infiltration by macrophage ablation was 
stronger than that by iNOS blockade, leaving open the possibility that other 
macrophage-derived factors are involved or that iNOS blockade was not complete. 
Overall, these findings indicate that iNOS macrophages extend the lifespan of RT5 
mice by controlling T-cell trafficking into the tumor. 
RESULTS 89 
 
 
Figure 26: Macrophage depletion and iNOS blockade impairs T cell infiltration and RT5 tumor rejection 
(A) 24 week-old Rip1-Tag5 (RT5) mice were injected with 25 μg of CpG-ODN 1668 i.v. on days 0, 6 and 10. If 
indicated, the same group of mice received adoptive transfers of activated TCR8 CD8+ T cells on day 1 and 11. 
Mice were sacrificed on day 13 and analyzed by flow cytometry. Macrophages were depleted by i.p. injection of 
clodronate-loaded liposomes (CLIP) on day 0, 5 and 10. iNOS blockade was achieved by 2 mM L-NIL in the 
drinking water of mice. For survival experiments, mice were injected, as described above. CpG-ODN injection, 
adoptive transfers and CLIP injection were repeated every 10 days until the end of experiment. (B) Kaplan-Meier 
survival curves of mice treated with combination therapy, combination therapy accompanied with macrophage 
depletion by CLIP and combination therapy accompanied with iNOS blockade by L-NIL. Data are shown as 10 
mice per group. (C) Quantification by cytofluorometry of infiltration of leukocyte subpopulations into RT5 
tumors. Results are shown as mean±SEM of 10 mice per group. Shown is all data from 2 independent 
experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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3.2.4 iNOS activity in macrophages promotes normalization of the 
tumor vasculature 
 
As mentioned above, late-stage RT5 tumors are characterized by abnormal 
tumor vessels, which form a pyhsical barrier against T cell penetration into the tumor. 
Therefore, it was studied whether iNOS macrophages can modulate the tumor 
vasculature and thereby allow T cell infiltration into tumors. Immunofluorescence 
analysis showed that untreated RT5 tumors harbor large dilated vessels (Figure 27B 
and C), consistent with previous findings
75
. CpG-ODN alone or CD8
+
 T cell transfer 
alone caused partial normalization of tumor vasculature, as indicated by replacement 
of large dilated vessels with smaller and more homogeneous vessels (Figure 27b and 
C). Vessel normalization was further increased by combination of CpG-ODN and 
adoptive CD8
+
 T cell transfer (Figure 27B and C), suggesting that CpG-activated 
macrophages and pre-activated tumor-specific CD8
+
 T cells act together to normalize 
the aberrant tumor vasculature. Moreover, CpG-ODN alone and CD8
+
 T cell transfer 
alone induced vascular adhesion molecule-1 (VCAM-1) expression on the tumor 
endothelium, which was further enhanced by combination therapy (Figure 27B and 
C). Importantly, macrophage depletion and iNOS blockade inhibited normalization of 
tumor vasculature and VCAM-1 expression on  the tumor endothelium (Figure 27B 
and C).  
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Figure 27: Combination therapy leads to normalization of the RT5 tumor vasculature, which is dependent 
on iNOS activity in tumor-associated macrophages  
(A) 24 week-old Rip1-Tag5 (RT5) mice were injected with 25 μg of CpG-ODN 1668 i.v. on days 0, 6 and 10. If 
indicated, the same group of mice received adoptive transfers of activated TCR8 CD8+ T cells on day 1 and 11. 
Mice were sacrificed on day 13 and analyzed by flow cytometry. Macrophages were depleted by i.p. injection of 
clodronate-loaded liposomes (CLIP) on day 0, 5 and 10. iNOS blockade was achieved by 2 mM L-NIL in the 
drinking water of mice. (B) Representative immunofluorescence microscopy analysis of tumor vessels of the 
indicated mice stained with antibodies against CD31 (red) and VCAM-1 (green). Yellow color shows 
colocalization. Size bar indicates 100 μm. (C) Quantification of CD31+ tumor vessel area per square millimeter, 
average size of CD31+ tumor vessels and VCAM-1 expression on CD31+ tumor vessels. Tumors of comparable 
size were investigated. 3-6 random sections were analyzed from each tumor. Results are mean±SEM of 6 mice per 
group. Shown is all data from 2 independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically 
significant. 
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3.2.5 Adoptive transfer of iNOS-expressing macrophages 
promotes antitumor immunity 
 
In order to study in more detail the mechanism by which iNOS activity in 
macrophages support T cell-mediated antitumor immune responses, Nos2
-/-
 (iNOS-
deficient) macrophages were utilized. First, macrophages derived from wild type and 
NOS2
-/-
 bone marrow cells were activated lipopolysaccharide (LPS) and IFN-γ (M1) 
or left untreated (M0) compared for the expression of M1 and M2 markers. RT-PCR 
analysis showed that M1 polarization led to upregulation of the genes encoding Th1 
cytokines TNF-α, IL-1β, IL-12, chemokines CCL2, CCL5, CXCL9, CXCL10, and 
other M1 markers, such as MHC-II in both wild type and NOS2 macrophages (Figure 
28A). Moreover, M1 wild type and M1 Nos2
-/-
 macrophages displayed decreased 
expression of the genes encoding M2 markers, including Arginase I (ARGI), CD163, 
MRC1 and peroxisome-prolifeating receptor-γ (PPARG) and angiogenic factors, 
including vascular endothelial growth factor (VEGF)-α, angiopoeitin 2 (ANGPT2) 
and fibroblast growth factor 1 (FGF1) (Figure 28A). As anticipated, Nos2 expression 
is only induced in wt macrophages after LPS/IFN-γ-mediated polarization (Figure 
28A). This was further confirmed at the protein level by flow cytometry (Figure 
28B). In summary, wild type and NOS2
-/-
 macrophages displayed similar gene 
expression profiles. This indicates that lack of iNOS activity does not affect the gene 
expression in macrophages.  
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Figure 28: In vitro-activated wild-type (WT) and Nos2-/- macrophages displayed similar gene expression 
profiles.  
(A) qRT-PCR analysis of cytokines, chemokines, proangiogenic factors, M1 and M2 markers expressed by WT 
and Nos2-/- macrophages cultured in vitro with our without LPS and IFN-γ (M1 macrophages and M0 
macrophages, respectively). Data are shown as mean±SEM of 3 mice per group. Shown is 1 representative 
experiment. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant (B) Representative flow cytometric 
analysis of iNOS expression on WT and Nos2-/- macrophages cultured in vitro with our without LPS and IFN-γ 
(M1 macrophages and M0 macrophages, respectively). 
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Next, it was studied whether transfer of pre-activated macrophages would be 
able to replace CpG-ODN treatment and enhance recruitment of tumor-specific CD8
+
 
T cells into the tumor. To this end, macrophages, which were isolated from CD45.2 
congenic wt or Nos2
-/-
 mice, were activated with LPS and IFN-γ (M1) or left 
untreated (M0), and then injected into CD45.1 congenic mice bearing B16-OVA one 
day before the adoptive transfer of tumor-specific OT-I CD8
+
 T cells. The homing of 
adoptively transferred macrophages into the tumor was examined one day after 
macrophage transfer (before CD8
+
 T cell transfer) by staining for CD4.2 marker on 
the transferred macrophages. Most of the transferred wt and Nos2
-/-
 M1 macrophages 
reached the tumor whereas wt M0 macrophages showed lower migration capacity 
towards the tumor (Figure 29B and C). The higher infiltration capacity of M1 
macrophages probably resulted from increased chemokine receptor expression on 
activated macrophages. Of note, activated wt and Nos2
-/-
 macrophages displayed the 
same level of infiltration into the tumor (Figure 29B and C), suggesting that iNOS 
deficiency has no impact on migration capacity of macrophages.  
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Figure 29: Transferred macrophages reached the tumor 1 day after adoptive transfer into tumor-bearing 
mice.  
(A) CD45.2+ macrophages were isolated from wild-type and Nos2-/- mice and activated with LPS and IFN-γ (M1) 
or left untreated (M0). B16-OVA-bearing CD45.1 mice were injected i.v. with CD45.2+ macrophages as indicated. 
1 day later, mice were sacrificed for analysis. (B) Representative flow cytometric analysis of CD45.2+ transferred 
macrophages in tumors of CD45.1 mice. (C) Quantification by flow cytometry of CD45.2+ transferred 
macrophages and CD45.1+ endogenous macrophages in B16-OVA tumors. Results are shown as mean±SEM of 10 
mice per group. Shown is all data from 2 independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not 
statistically significant.  
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Examination of the subpopulations of immune cells in the tumor 2 days after 
CD8
+
 T cell transfer revelaed that wt M1 macrophages alone and CD8
+
 T cell alone 
were able to induce leukocyte infiltration into the tumor at low levels, which was 
strongly increased when the transfer of wt M1 macrophages were combined with the 
transfer of tumor-specific CD8
+
 T cells (Figure 30B). In contrast, co-transfer with 
M0 macrophages failed to enhance infiltration of leukocytes (Figure 30B), 
demonstrating that macrophages must be polarized to M1-like macrophages in order 
to support leukocyte infiltration. Interestingly, co-transfer of Nos2
-/- 
M1 macrophages 
with OT-I CD8
+
 T cells resulted only in low level of leukocyte migration into the 
tumor (Figure 30B). Analysis of respective leukocyte subpopulations showed that 
iNOS deficiency in the transferred macrophages led to an impaired migration of 
tumor-specific CD8
+
 T and NK cells, and macrophages into the tumor (Figure 30C, 
D and E).  
 
Suprisingly, CD45.2+ transferred macrophages were not observed in tumors 
3 days after macrophage transfer (Figure 31B), suggesting that transferred 
macrophages have short half-life. However, co-transfer of M1 macrophages with 
CD8+ T cells apparently induced polarization of CD45.1+ endogenous TAMs into 
M1-like phenotype, as characterized by high level of iNOS expression and low level 
of CD206 expression (Figure 31C and D). In contrast, M1 transfer alone, CD8+ T cell 
transfer alone or co-transfer with M0 macrophages had no effect on endogenous 
TAMs (Figure 31C and D). Co-transfer of Nos2-/- M1 macrophages with CD8+ T 
cells also resulted in substantially lower polarization of CD45.1+ endogenous 
macrophages towards M1-like macrophages (Figure 31C and D). In summary, iNOS+ 
macrophage co-transfer with CD8+ T cells increased the recruitment of tumor-
specific CD8+ T cells into the tumor, as well as M1 skewing of endogenous 
macrophages.          
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Figure 30: Co-transfer of iNOS+ macrophages with tumor-specific CD8+ T cells results in strong infiltration 
of leukocytes, notably tumor-specific CD8+ T cells.  
(A) CD45.2+ macrophages were isolated from wild-type and Nos2-/- mice and activated with LPS and IFN-γ (M1) 
or left untreated (M0). B16-OVA-bearing CD45.1 mice were injected i.v. with CD45.2+ macrophages 1 day before 
adoptive transfer of activated OT-I CD8+ T cells. 2 days after CD8+ T cell transfer, mice were sacrificed for 
analysis by flow cytometry. (B) Quantification of total CD45+ leukocyte infiltration, (C) lypmhocyte infiltration, 
(D) Thy1.1+ transferred OT-I CD8+ T cell infiltration and (E) innate cell infiltration into B16-OVA tumors. Data 
are shown as mean±SEM of 10 mice per group. Shown is all data from 2 independent experiments. *=p<0.05, 
*=p<0.01, *=p<0.001, ns=not statistically significant.  
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Figure 31: Co-transfer of iNOS+ macrophages with tumor-specific CD8+ T cells induces M1-like 
polarization of CD45.1+ endogenous macrophages. 
(A) CD45.2+ macrophages were isolated from wild-type and Nos2-/- mice and activated with LPS and IFN-γ (M1) 
or left untreated (M0). B16-OVA-bearing CD45.1 mice were injected i.v. with CD45.2+ macrophages 1 day before 
adoptive transfer of activated OT-I CD8+ T cells. 2 days after CD8+ T cell transfer, mice were sacrificed for 
analysis by flow cytometry.(B) Representative flow cytometric analysis of CD45.2+ transferred macrophages in 
tumors of CD45.1 mice. (C) Representative flow cytometric analysis of iNOS (M1 marker) and CD206 (MRC1) 
(M2 marker) expression on CD45.2- endogenous tumor macrophages. (D) Summary of data presented in  (B). Bars 
indicate the percentage of respective population in total tumor-infiltrating macrophages. Results are mean±SEM of 
10 mice per group. Shown is all data from 2 independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not 
statistically significant. 
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Next, tumors from mice treated with wt M1 macrophages or Nos2
-/-
 M1 
macrophages were examined by RT-PCR for the expression of the genes that take part 
in inflammation and angiogenesis. Co-transfer of CD8
+
 T cells with M1 macrophages 
was found to induce strong activation of the genes encoding Th1 response-related 
cytokines, IFN-α, IFN-β, IFN-γ, TNF-α, IL-12, IL-1, IL-2 and IL-6, Th2 response-
related cytokines, IL-10, IL-4 and IL-13, chemokines, CCL2, CCL5, CXCL9 and 
CXCL10, adhesion molecules, VCAM-1 and intercellular adhesion molecule 
(ICAM)-1, and cytotoxic molecule Granzyme B (Figure 32B). Interestingly, 
upregulation of these genes was significantly weaker when transferred macrophages 
lack iNOS activity (Figure 32B). Furthermore, the intratumoral expression of 
angiogenic factors, such as Vegf-α, Angpt2, regulator of G-protein signaling 5 (Rgs5), 
Fgf1, platelet-derived growth factor (Pdgf)-α was substantially downregulated after 
the co-transfer of M1 macrophages with OT-I CD8
+
 T cells (Figure 32B). In contrast, 
tumors, which were treated with combination of Nos2
-/-
 macrophages and OT-I CD8 
T cells, showed higher expression of these angiogenic genes (Figure 32B). In 
summary, iNOS
+
 macrophages seem to control inflammation and angiogenesis in the 
tumor. 
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Figure 32: Changes in the B16-OVA tumor microenvironment after transfer of macrophages and OT-I 
CD8+ T cells.  
(A) CD45.2+ macrophages were isolated from wild-type and Nos2-/- mice and activated with LPS and IFN-γ (M1) 
or left untreated (M0). B16-OVA-bearing CD45.1 mice were injected i.v. with CD45.2+ macrophages 1 day before 
adoptive transfer of activated OT-I CD8+ T cells. 2 days after CD8+ T cell transfer, mice were sacrificed for 
analysis. (B) qRT-PCR analysis of cytokines, chemokines, proangiogenic factors, adhesion molcules in tumors of 
the indicated mice. Data are shown as mean±SEM of 10 mice per group. Shown is all data from 2 independent 
experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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3.2.6 Adoptive transfer of iNOS+ macrophages results in 
normalization of tumor vessels 
 
The effect of macrophages on the tumor vasculature was analyzed one day 
after the macrophage transfer, when the transferred macrophages infiltrated the tumor. 
As shown before, untreated tumors are characterized by few but dilated vessels and 
low levels of VCAM-1 expression on CD31
+
 endothelial cells (ECs) (Figure 33B 
and C). The transfer of wt M1 macrophages alone resulted in formation of smaller 
vessels and higher expression of VCAM-1 on ECs whereas wt M0 and Nos2
-/-
 M1 
macrophages had no effect on tumor vasculature at all (Figure 33B and C). These 
findings demonstrate that activated macrophages can activate and normalize the 
tumor endothelium in an iNOS-dependent way.  
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Figure 33: Adoptive transfer of iNOS+ macrophages leads to normalization of the tumor vasculature.  
(A) CD45.2+ macrophages were isolated from wild-type and Nos2-/- mice and activated with LPS and IFN-γ (M1) 
or left untreated (M0). B16-OVA-bearing CD45.1 mice were injected i.v. with CD45.2+ macrophages. 1 day later, 
mice were sacrificed for analysis. (C) Representative immunofluorescence microscopy analysis of tumor vessels 
of the indicated mice stained with antibodies against CD31 (red) and VCAM-1 (green). Yellow color shows 
colocalization. Size bar indicates 100 μm. (D) Quantification of individual CD31+ tumor vessel size, number of 
CD31+ tumor vessels and VCAM-1 expression on CD31+ tumor vessels. Tumors of comparable size were 
investigated. 2 random fields were analyzed from each tumor. Results are mean±SEM of 6 mice per group. Shown 
is 1 representative experiment. *=p<0.05, *=p<0.01, *=p<0.001, ns=not statistically significant. 
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3.2.7 Macrophage-derived NO stimulates adhesion molecule 
expression on human umbilical vein endothelial cells 
(HUVECs) 
 
The observed augmentation in VCAM-1 expression on tumor endothelial 
cells (ECs) only after the transfer of iNOS-expressing macrophages raised the 
possibility that macrophage-derived nitric oxide (NO) would directly act on ECs to 
stimulate the expression of the adhesion molecules. The effect of NO produced by 
macrophages on the expression of adhesion molecules on ECs was examined in 
preliminary experiments, in which HUVECs were co-cultured with human THP-1 
macrophages, obtained after differentiation of THP-1 monocyte-like cell line by 
phorbol myristate acetate (PMA) treatment, in the presence or absence of iNOS 
inhibitor, L-NIL. Non-stimulated HUVECs displayed low expression of VCAM-1 
(Figure 34B and C). Co-culture with M1-polarized (by LPS and IFN-γ) THP-1 
macrophages resulted in enhanced expression of VCAM-1 on HUVECs, whereas M0 
macrophages failed to do so (Figure 34B and C). Interestingly, iNOS blockade by L-
NIL hampered the M1 macrophage-mediated increase in the expression of VCAM-1 
(Figure 34B and C).  
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Figure 34: Co-culture with M1-polarized THP-1 human macrophages results in induction of VCAM-1 on 
human umbilical vein endothelial cells (HUVECs).  
(A) THP-1 human monocytes were differentiated into THP-1 macrophages by phorbol 12-myristate 13-acetate 
(PMA) treatment for 24 hours. After 6 days in culture, THP-1 macrophages were activated by LPS and IFN-γ for 
18 hours (M1) or left untreated (M0). THP-1 macrophages were washed 3 times and co-cultured with HUVECs in 
the presence or absence of N6-(1-iminoethyl)-L-lysine (L-NIL) for 18 hours. (B) Representative flow cytometric 
analysis of VCAM-1 expression on vWF+ (von Willebrand Factor) HUVECs. (C) Quantification by flow 
cytometry of VCAM-1 expression on HUVECs as mean fluorescent intensity (MFI). Results are shown as 
mean±SEM of 6 samples per group. Shown is all data from 2 independent experiments. *=p<0.05, *=p<0.01, 
*=p<0.001, ns=not statistically significant.  
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In a more comprehensive study, HUVECs were co-cultured with human 
primary macrophages derived from blood monocytes. HUVECs co-cultured with M1 
macrophages exhibited enhanced expression of adhesion molecules such as VCAM-1, 
ICAM-1 and E-Selectin whereas iNOS bloackade by L-NIL partially inhibited 
expression of these adhesion molecules (Figure 35B and C). The incomplete 
inhibition obtained after L-NIL treatment suggests that additional factors are involved 
in the regulation of VCAM-1, ICAM-1 and E-Selectin expression on HUVECs. 
Together these data suggest that macrophages can directly regulate the expression of 
adhesion molecules on Ecs, probably through NO production.  
 
In order to test if NO was directly able to induce adhesion molecules in 
endothelial cells, HUVECs were cultured in the presence of the NO donor glyceryl 
trinitrate (GTN). Low levels of NO (10.7 nM and 16.5 nM) were found to induce 
VCAM-1, ICAM-1 and E-selectin expression on HUVECs whereas higher level of 
NO (22.1 nM and 29.3 nM)  failed to induce adhesion molecules (Figure 36B). When 
HUVECs were stimulated by TNF, which is known to be potent inducer of adhesion 
molecule expression on HUVECs, the addition of NO at low concentrations enhanced 
VCAM-1, ICAM-1 and E-selectin expression (Figure 36B). In contrast, NO at high 
higher concentrations suppressed the TNF-dependent expression of adhesion 
molecules (Figure 36B). These findings show that NO at low levels is able to 
stimulate VCAM-1, ICAM-1 and E-selectin  on HUVECs, explaining the observation 
that iNOS
+
 macrophages, but not iNOS
-
 macrophages, promotes VCAM-1 expression 
on the tumor endothelium. 
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Figure 35: Co-culture with M1-polarized human primary macrophages leads to induction of VCAM-1, 
ICAM-1 and E-Selectin on human umbilical vein endothelial cells (HUVECs).  
(A) Human macrophages were differentiated from blood monocytes in the presence of M-CSF.  After 7 days in 
culture, fully differentiated macrophages were activated by LPS and IFN-γ for 18 hours (M1) or left untreated 
(M0). Macrophages were washed 3 times and co-cultured with HUVECs in the presence or absence of N6-(1-
iminoethyl)-L-lysine (L-NIL) for 18 hours. (B) Representative flow cytometric analysis of VCAM-1, ICAM-1 and 
E-Selectin expression on vWF+ HUVECs. (C) Quantification by flow cytometry of VCAM-1, ICAM-1 and E-
Selectin expression on HUVECs as mean fluorescent intensity (MFI). Results are shown as mean±SEM of 6 
samples per group. Shown is all data from 2 independent experiments. *=p<0.05, *=p<0.01, *=p<0.001, ns=not 
statistically significant. 
 
RESULTS 107 
 
 
Figure 36: Treatment with low levels of NO donor glyceryl trinitrate (GTN) results in induction of VCAM-
1, ICAM-1 and E-Selectin on human umbilical vein endothelial cells (HUVECs).  
(A) HUVECs were cultured with indicated doses of NO donor glyceryl trinitrate (GTN) and TNF for 18 hours. (B) 
Quantification by flow cytometry of VCAM-1, ICAM-1 and E-Selectin expression on HUVECs as mean 
fluorescent intensity (MFI). Nitric oxide (NO) concentrations measured in the medium are shown. Results are 
shown as mean±SEM of 6 samples per group. Shown is all data from 2 independent experiments. *=p<0.05, 
*=p<0.01, *=p<0.001, ns=not statistically significant. 
 
 
The transcriptional profile of HUVECs treated with low level of NO donor 
(GTN, 100 μM) was compared to HUVECs treated with TNF (10 ng/ml), which is 
known to be a potent inducer of adhesion molecule expression on endothelial cells, by 
microarray analysis using the HumanHT-12 expression beadchip. Analysis of more 
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than 47000 genes demonstrated that 572 genes were differentially expressed between 
NO-treated HUVECs and untreated HUVECs and 589 genes were differentially 
expressed between TNF-treated HUVECs and untreated HUVECs (Figure 37). NO- 
and TNF-treated HUVECs displayed similar gene expression profiles, in which 
similar genes are upregulated or downregulated after both NO and TNF treatment 
compared to untreated samples. Many of the upregulated genes after both NO and 
TNF treatment were those that encode adhesion molecules, E-Selectin (SELE) and 
VCAM-1 (VCAM1), and chemokines, such as CX3CL1, CCL20 , CXCL10, CXCL5, 
CXCL2 and IL-8 (CXCL8) (Table 13). Computer program analysis of microarray 
data showed that both NO and TNF activate an array of pathways that involve in 
granulocyte and agranulocyte extravasation and migration (Table 14), probably by 
acting on NF-κB transcritption factor (Table 15).  
 
Figure 37: Microarray analysis of HUVECs treated with NO donor glyceryl trinitrate (GTN) and TNF.  
Total RNA was isolated from untreated HUVECs or from HUVECs treated with NO donor (GTN) or TNF, and 
hybridized to Human HT-12 v4 expression beadchip. Normalized gene expression intensities were compared, and 
genes were considered to be differentially expressed between different groups if their fold change was greater than 
2 or less than -2. Columns correspond to the experimental conditions (untreated, NO-treated and TNF-treated). 572 
genes were differentially expressed between untreated and NO-treated HUVECs. 589 genes were differentially 
expressed between untreated and TNF-treated HUVECs. 221 genes were differentially expressed between NO-
treated and TNF-treated HUVECs. 
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Table 13: Top upregulated molecules in HUVECs after NO and TNF treatment 
 
 
 
Table 14: Top activated pathways in HUVECs after NO and TNF treatment 
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Table 15: Top regulator effect networks in HUVECs after NO and TNF treatment 
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4 DISCUSSION 
 
4.1 Treg Depletion as a Model to Study Immune Rejection 
of Tumors 
 
Regulatory T cells (Tregs) are abundantly present in a wide array of human 
tumors and a high density of Tregs is often associated with a poor clinical outcome. 
Tregs have been shown to potently block anti-tumor immune responses, mainly by 
impairing the efficacy of priming of tumor-specific T cells. Therefore, selective 
depletion of these cells is an emerging therapeutic strategy for cancer, with the aim of 
generating strong anti-tumor immune responses. In this study, the effect of Tregs in 
anti-tumor immunity was intensively analyzed using mouse models of Treg depletion.    
 
4.1.1 Different levels of Treg depletion determine efficacy of tumor 
rejection 
 
The main focus of this part of the study was to investigate whether the extent 
of Treg ablation would be important for the generation of immune responses against 
tumors. In this study, two mouse models were employed to selectively deplete Tregs 
upon diphtheria toxin (DT) administration. Foxp3
DTR
 mice were generated by targeted 
insertion of the construct encoding human diphtheria toxin receptor (DTR) and 
enhanced green fluorescent protein (eGFP) at foxp3 locus
219
. This knock-in strategy 
allows depletion of almost all Foxp3
+
 Tregs because almost all Treg express the 
human DTR on their surface
219
. In previous studies, it was reported that persistent 
application of DT (every week) in these mice led to catastrophic autoimmune 
disease
219
. In contrast, limited DT application did not result in overt autoimmune 
responses, as performed in the present study probably due to an IL-2-dependent rapid 
proliferation of the remaining Tregs.  Foxp.LuciDTR4 mice were generated by 
introduction of the transgene expressing human DTR, eGFP and luciferase into the 
mouse genome using bacterial artifical chromosome (BAC) technology
220
. BACs are 
large  genomic DNA fragments theoretically containing all potential regulatory 
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elements of a gene
285
, allowing tissue specific expression of the transgene. However, 
in BAC transgenic animals, the copy number and sites of genomic integration of the 
transgene are usually unknown
285
. In addition, the local chromatin structure may 
affect the transgene expression in BAC transgenic mice
285
. Thus, BAC transgenic 
mice may exhibit different degrees of transgene expression depending on the 
integration site of BAC construct. In Foxp3.LuciDTR4 mice, about 90% of Foxp3
+
 
Tregs are ablated after DT application
220
, indicating that about 90% of Tregs express 
DTR on their surface. In another BAC transgenic mouse line, Foxp3.LuciDTR3 mice, 
the level of depletion was about 70% after DT administration
220
. Importantly, both 
strains of Foxp3.LuciDTR4 BAC transgenic mice do not show any sign of 
autoimmunity
220
 probably because remaining Tregs are sufficient to suppress 
autoimmune responses. 
 
In a previous study, our group has shown that ~70% Treg depletion in 
Foxp3.LuciDTR3 mice, or ~70% Treg depletion obtained with anti-CD25 antibody 
(PC-61) in wild-type mice, had no effect on the growth of ovalbumin-expressing B16 
melanoma (B16-OVA) and simian virus 40 large T antigen-expressing RMA 
lymphoma (RMA-Tag)
222
.  In contrast, ~90% depletion resulted in complete rejection 
of these tumors
222
. In the present study, HCmel 1274 and B16 melanoma cell lines 
were utilized to analyze the effect of different degrees of Treg depletion on the 
growth of tumors displaying lower immunogenicity. Similar to B16-OVA and RMA-
Tag, ~70% Treg depletion with PC-61 antibody in mice bearing HCmel 1274 or B16 
melanoma failed to control tumor growth. Suprisingly, ~90% depletion in 
Foxp3.LuciDTR4 mice resulted in only partial regression of HCmel 1274 tumors and 
had little effect on the growth of B16 tumors. However, when the level of Treg 
depletion was raised to ~99% using Foxp3
DTR
 mice, complete rejection of 
HCmel1274 and B16 tumors was observed. 
 
B16-OVA and RMA-Tag tumors present epitopes derived from OVA or Tag. 
These epitopes can be recognized as non-self antigens and induce robust T cell 
responses in the host. The ~10% Tregs, which are not depleted in Foxp3.LuciDTR4 
mice, apparently fail to control such strong T cell responses, explaining the complete 
rejection of tumors expressing OVA or Tag. On the other hand, HCmel 1274 and B16 
tumors produce self-proteins that may induce tolerance, thus expressing antigens that 
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can be recognized as “self” by the immune system. However, it is known that some 
melanocyte self antigens that are overexpressed in melanomas, including Melan-
A/MART-1, gp100, tyrosinase, tyrosinase-related protein-1 (TRP-1) and TRP-2 can 
induce low-avidity T cell responses due to the mechanisms of central and peripheral 
tolerance. These low-avidity T cell responses less efficiently reject tumors than high-
avidity T cell responses elicited against foreign antigens. It seems that the few 
remaining Tregs in Foxp3.LuciDTR4 mice can suppress such T cell responses 
directed against self antigens, in agreement with the observation that 
Foxp3.LuciDTR4 mice display no sign of autoimmunity after DT application. In 
contrast, when almost all Tregs are removed, peripheral tolerance mechanisms against 
self antigens appear to collapse, resulting in efficient regression of HCmel 1274 and 
B16 tumors. In agreement with this, Treg-depleted Foxp3
DTR
 mice displayed vitiligo-
like depigmentation in the tumor rejection area, similar to the depigmentation 
observed in melanoma patients receiving immunotherapy. In fact, in the clinic vitiligo 
is regarded as a positive parameter for an anti-tumor response.   
 
Adoptive reconstitution of Tregs in Foxp3
DTR
 mice after Treg depletion 
further supported the notion that few numbers of Tregs are able to control immune 
responses against tumors of lower immunogenicity. In agreement with this notion, 
intratumoral injection of low numbers of CD4
+
 CD25
+
 splenic Tregs (2x10
3
 cells) 
caused inhibition of tumor rejection.  However, it should be emphasized that 
transferred Tregs may rapidly expand in Treg-depleted mice due to IL-2 dependent 
homeostatic proliferation which has been observed in Treg-depleted mice
220
. 
 
4.1.2 Treg depletion induces drastic changes in the tumor 
microenvironment 
 
Treg depletion-mediated regression of HCmel 1274 tumors was 
accompanied by a massive infiltration of leukocytes into the tumor 4 days after Treg 
depletion. Notably, CD8
+
 T cells were particularly enriched in both Foxp3.LuciDTR4 
and Foxp3
DTR
 mice after Treg depletion but the level of CD8
+
 T cell infiltration was 
higher in Foxp3
DTR
 mice than in Foxp3.LuciDTR4 mice. Higher level of CD8
+
 T cell 
infiltration may explain why complete tumor rejection was achieved in Foxp3
DTR
, but 
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not in Foxp3.LuciDTR4 mice, since tumor rejection obtained in Foxp3
DTR 
mice after 
Treg depletion was shown to be dependent on CD8
+
 T cells. Suprisingly, Treg-
depleted tumors in Foxp3
DTR
 displayed strong infiltration of basophils, which 
represented 4% of total tumor-infiltrating leukocytes 4 days after Treg depletion. 
Tumor-infiltrating basophils were characterized as CD45
int
 FcεRI+ CD49b+ 
CD200R3
+
 c-Kit
-
 cells by flow cytometry. They were also shown to be IgE
+
, 
indicating an activated phenotype of tumor-associated basophils since IgE is a potent 
stimulator for effector functions of basophils. Sorted intratumoral CD45
+
 FcεRI+ 
CD49b
+
 cells displayed high levels of Mcpt8 mRNA, which encodes basophil-
specific mast cell protease 8, a granzyme B-like protease stored in the granules of 
basophils, now designated as Basoph8). Giemsa staining showed that the sorted cells 
exhibited a typical basophil morphology with a lobulated nucleus and basophilic 
granules.  
 
The cytokine and chemokine profile of HCmel 1274 tumors was measured 4 
days after Treg depletion in Foxp3
DTR
 mice and showed that Treg depletion resulted 
in a pro-inflammatory tumor microenvironment. The enhanced expression of genes 
encoding IFN-γ, IFN-α, IFN-β, TNF, IL-12, IL-1β in the tumor microenvironment 
indicated strong activation of both innate and adaptive immune cells. For instance, 
these cytokines are known to activate DCs and to skew macrophages towards a M1-
like phenotype, which, may promote the activation and infiltration of tumor-specific T 
cells. Expression of genes encoding Th2 response-related cytokines, such as IL-3, IL-
4, IL-5, IL-10 and IL-13 was also upregulated after Treg depletion. The elevated 
levels of Th2 cytokines may be explained byincreased infiltration of basophils and 
eosinophils into the tumor because these cells are known to be potent producers of 
Th2 cytokines upon activation with an appropriate stimuli.  
 
Similar to cytokines, intratumoral levels of chemokines such as CCL2, 
CCL3, CCL4, CCL7, CCL11, CCL20, CXCL9 and CXCL10 were substantially 
augmented 4 days following Treg depletion, Of note, the expression of CCL2, CCL3, 
CCL4, CXCL9 and CXCL10 in tumors of melanoma patients was found to correlate 
with the presence of intratumoral CD8
+
 T cells
62
. Consistently, enhanced expression 
of these chemokines in murine models of cancer has been shown to be associated with 
infiltration of tumor-specific CD8
+
 T cells
281, 286, 287, 288, 289, 290, 291, 292, 293
. Thus, the 
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observed increase in the production of these chemokines may provide an explanation 
for the particular enrichment of CD8
+
 T cells and tumor rejection after Treg depletion. 
Further analysis was carried out to identify the cell types producing these chemokines 
within the tumor microenvironment. Gene expression profiling data with cells sorted 
from Treg-depleted tumors revealed that CCL3 and CCL4 were mainly produced by 
tumor-associated basophils whereas CCL2, CXCL9 and CXCL10 were mostly 
produced by tumor-associated macrophages. In several in vitro studies, basophils 
were shown to produce CCL3 and CCL4 in response to activation by IgE
294
 or by a 
combination of IL-3, IL-18 and IL-33
257, 258
. In the present study, I confirmed that 
activation of basophils with a combination of IL-3, IL-18 and IL-33 results in 
enhanced production of CCL3 and CCL4 but not of CCL2, CXCL9 and CXCL10. 
Moreover, using a two-chamber system, activated basophils were found to induce 
migration of activated CD8
+
 T cells via production of CCL3 and CCL4. This finding 
is novel, because so far, it has not been known that basophils can induce CD8
+
 T cell 
migration.  
 
The observed production of chemokines CCL3 and CCL4 by tumor-
associated basophils raised the possibility that CD8
+
 T cells could be attracted in vivo 
to the tumor by these chemokines. The examination of early immune responses (2 
days after Treg depletion) demonstrated that basophils were the first immune cell 
population that infiltrated the tumor after Treg depletion, thereby preceding 
infiltration by CD8
+
 T cells. Basophil infiltration resulted in an increase in the 
intratumoral expression of CCL3 and CCL4 2 days following Treg depletion, 
explaining the enhanced infiltration of CD8
+
 T cells on the next day.  
 
In order to understand the mechanism underlying the selective tumor 
recruitment of basophils, gene expression profiling was performed for the presence of 
potential chemokine transcripts that are important for migration of basophils into 
tissues. 2 days after Treg depletion, the expression of basophil-derived chemokines 
CCL3 and CCL4 was found to be upregulated but not expression of other 
chemokines, suggesting that other mechanism may be involved in the recruitment 
basophils into the tumor. It has been shown that selective tissue recruitment of 
basophils can be mediated by a variety of cytokines that are implicated in homeostatis 
and activation of basophils. For example, IL-3 has been demonstrated to be a critical 
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factor for infiltration of basophils into lymph nodes following infection of mice with 
helminth
237
. Consistent with this finding, intratumoral expression of IL-3 was shown 
to be upregulated only in Foxp
DTR
 mice after Treg depletion, but not in 
Foxp3.LuciDTR4 mice. In conclusion, IL-3 seems to play a crucial role in the 
recruitment of basophils into the tumor ~99% after Treg depletion.        
 
4.1.3 Basophils play an essential role in tumor rejection after Treg 
depletion in Foxp3
DTR
 mice 
 
MAR-1, a monoclonal antibody specific to FcεRIα, was employed to study 
the role of basophils in Treg depletion-mediated tumor rejection. MAR-1 could be 
used because there was very little intratumoral infiltration of mast cells and FcεRI+ 
DCs after Treg depletion.  
 
The rejection of HCmel 1274 and B16 tumors following Treg depletion was 
drastically hampered in the absence of basophils, resulting in severely reduced 
survival of tumor-bearing mice. Analysis of the immune cell composition in Treg-
depleted HCmel 1274 and B16 tumors showed that the intratumoral infiltration of 
tumor-rejector CD8
+
 T cells was markedly decreased after basophil ablation, 
explaining the impaired tumor regression after basophil depletion. Interestingly, in 
addition to reduction in CCL3 and CCL4 expression, basophil depletion resulted in 
the diminished expression of CCL2, CXCL9 and CXCL10. The curbed expression of 
CCL3 and CCL4 is the most likely mechanism underlying reduced migration of CD8
+
 
T cells after basophil ablation.  
 
4.1.4 Basophils act on tumor-associated macrophages via 
induction of CD8
+
 T cell infiltration into the tumor 
 
Among myeloid cells, macrophages are the most prominent cell population 
in the tumor. Tumor-associated macrophages often exhibit an M2-like phenotype, 
which is characterized by low expression of the chemokines that are important for T 
cell infiltration into the tumor. Consistently, macrophages sorted from untreated 
HCmel 1274 tumors displayed low levels of CCL2, CXCL9 and CXCL10 mRNA. 
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Macrophages are amenable to changes in the tumor microenvironment and exhibit 
functional plasticity depending on the nature of environmental cues. After Treg 
depletion, macrophages underwent a change in their phenotype and produced 
increased amounts of CCL2, CXCL9 and CXCL10, thereby enhancing CD8
+
 T cell 
infiltration into the tumor. However, basophil depletion impaired the increase in the 
expression of these chemokines obtained by Treg depletion. Interestingly, these 
chemokines are IFN-γ-inducible chemokines295. IFN-γ is known to be one of the key 
effector molecules for tumor-specific CD8
+
 T cells
185
. Indeed, both CD8
+
 T cell 
depletion and IFN-γ blockade resulted in decreased expression of CCL2, CXCL9 and 
CXCL10 in Treg-depleted tumors, suggesting that reduced number of intratumoral 
CD8
+
 T cells and reduced intratumoral expression of IFN-γ are responsible for the 
reduced intratumoral expression of these chemokines after basophil depletion. These 
observations indicate a feedback mechanism in which basophils first induce CD8
+
 T 
cell migration into the tumor via production of CCL3 and CCL4, These tumor-
infiltrating IFN-γ+ CD8+ T cells caused polarization of macrophages towards M1-like 
macrophages that secrete CCL2, CXCL9 and CXCL10. These chemokines further 
enhance CD8
+
 T cell infiltrationand macrophage polarization. This feedback loop is 
further supported by the kinetic studies showing that the expression of CCL3 and 
CCL4, and the infiltration by basophils, preceded the expression of CCL2, CXCL9 
and CXCL10 and the infiltration by CD8
+
 T cells. 
 
 The observed expression of the CD8
+
 T cell-chemoattractants CCL2, 
CXCL9 and CXCL10 by tumor-associated macrophages indicate an essential role of 
macrophages in Treg depletion-mediated tumor rejection. This hypothesis was 
supported by the finding that depletion of macrophages with CLIP impeded the 
basophil-dependent rejection of HCmel 1274 tumors. Specifically, macrophage 
depletion resulted in decreased expression levels of the chemokines within the tumor 
microenvironment, such as CCL2, CXCL9 and CXCL10, and impaired the infiltration 
of CD8
+
 T cell infiltration into the tumor, demonstrating that macrophages serve as 
critical accessory cells for the attraction of tumor-specific CD8
+
 T cells. The blockade 
of IFN-γ yielded comparable results, indicating that IFN-γ production within the 
tumor microenvironment is crucial for anti-tumoral functions of macrophages. 
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In a recent study, we have reported that eosinophils were essential for the 
rejection of ovalbumin-expressing B16 tumors after Treg depletion in 
Foxp3.LuciDTR4 mice
283
. Therefore, the role of eosinophils was also investigated in 
the rejection of HCmel 1274 tumors after Treg depletion in Foxp3
DTR
 mice. However, 
depletion of eosinophils with anti-Siglec-F antibody had no influence in the rejection 
of HCmel 1274 tumors. These results show that eosinophils do not play a vital role in 
the tumor rejection in Foxp3
DTR
 mice. Comparitive studies revealed that the level of 
infiltration by eosinophils was 20-fold higher in B16-OVA tumors in 
Foxp3.LuciDTR4 mice as compared to eosinophil infiltration in HCmel 1274 tumors 
after 99% Treg depletion in Foxp3
DTR
 mice. Moreover, infiltration of CD8
+
 T cells 
into B16-OVA tumors occured 6 days after Treg depletion and 2 days after eosinophil 
infiltration
283
. In contrast, in Foxp3
DTR
 mice infiltration of CD8
+
 T cells and 
eosinophils into HCmel 1274 tumors occurred simultaneously on day 4 after Treg 
depletion, suggesting that eosinophils do not play an important role in CD8
+
 T cell 
migration into HCmel 1274 tumors. 
 
4.1.5 IL-3/antibody complex-induced basophilia improves the 
efficacy of adoptive T cell therapy in melanoma-bearing mice 
 
In the clinic, adoptive T cell therapy has emerged as a promising 
immunotherapy but its success is limited
185
. Therefore, I investigated whether or not 
experimentally induced tumor-associated basophilia would improve the efficacy of T 
cell therapy. For this purpose, I attempted to expand the number of basophils in the 
tumor. One approach was to adoptively transfer activated bone marrow-derived 
basophils into tumor-bearing mice. However, since in vitro generation of basophils 
from bone marrow is laborious and yields only small number of mature basophils, 
another method was chosen, namely injection of IL-3, which is a important 
differentiation and homeostatic factor for basophils. In a previous study, injection of 
IL-3 complexed with anti-IL-3 antibody into mice was shown to selectively increase 
the number of basophils
232
. The IL-3/antibody complex is more efficient than IL-3 
alone because the antibody will protect IL-3 from rapid degradation. B16-OVA was 
used as tumor model because OT-I TCR transgenic mice were available in the 
laboratory. These mice contain ovalbumin specific CD8
+
 T cells that can be used for 
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T cell transfer studies. 3 days after the injection of IL-3/antibody complex , 
basophilia, but not eosinophilia or mastocytosis, was observed in the tumor, lung, 
spleen and blood of B16-OVA-bearing mice. Basophilia in the tumor resulted in 
enhanced production of CCL3 and CCL4, which induced recruitment of leukocytes 
into B16-OVA tumors, notably the transferred tumor-specific OT-I CD8
+
 T cells. 
This combination therapy resulted in tumor rejection and prolonged survival of 
tumor-bearing mice. Macrophages sorted from the mice treated with a combination of 
IL-3/antibody complex and tumor-specific CD8
+
 T cells displayed an M1-like 
phenotype with higher expression of M1 markers such as CCL2, CXCL9, CXCL10, 
TNF-α and iNOS, and lower expression of M2 markers such as MRC1 and ArginaseI. 
In addition, the basophil combination therapy induced normalization of  the tumor 
vasculature and increased expression of adhesion molecules such as VCAM-1 on 
tumor endothelium. The observed normalization of the vasculature and increase in the 
expression of chemokines such as CCL2,  CXCL9 and CXCL10 by macrophages 
apparently further augment the infiltration of tumor-specific CD8
+
 T cells into the 
tumor. 
 
Together these studies show that, under particular conditions, basophils play 
a critical role in T cell mediated-tumo rejection. Basophils are usually associated with 
poor clinical outcome in cancer patients, however, our results indicate that the mere 
presence of basophils should not be used a prognostic factor for cancer patients 
without detemination of the precise activation status of basophils, as well as the status 
of T cell infiltration.  
 
4.2 Rip1-Tag5 (RT5) Model as a Model to Study Immune 
Rejection of Tumors 
 
Inefficient T cell trafficking to the tumor represents a critical problem for 
efficient cancer immunotherapy.  A major barrier for T cell migration into the tumor 
is the establishment of an aberrant vasculature by tumors that is characterized by 
dilated and tortous vessels and by low-level expression of adhesion molecules which 
are required for T cell extravasation. The effect of an aberrant tumor vasculature on T 
cell infiltration was extensively studied in our laboratory using the RT5 mouse model 
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of spontaneous pancreatic islet tumors. Adoptive T cell therapy with tumor-specific 
CD8
+
 and CD4
+
 T cells has limited effects on tumor progression in RT5 mice since 
these cells fail to penetrate into the tumor due to the presence of aberrant tumor 
vessels. In previous studies, our group has shown that induction of vasculature 
normalization with danger signals such as irradiation
275, 276
 and TLR ligands
274
 
resulted in efficient infiltration of tumor-reactive T cells into the tumor.   
 
4.2.1 CpG-ODN improves the efficacy of adoptive T cell therapy in 
RT5 mice   
 
Animal studies and clinical trials have demonstrated that CpG-ODN can 
have potent immunostimulatory effects on the immune cells and enhance the efficacy 
of a variety of immunotherapies
296
. CpG-ODN can activate innate immune cells, 
including DCs, NK cells and macrophages cells through binding to TLR9
297
, resulting 
in secretion of pro-inflammatory cytokines that promote T cell responses
298, 299
. 
Especially, the prominent effect of CpG-ODN on DCs indicates that it might be an 
useful adjuvant for vaccination strategies against cancer. Several studies have 
reported that anti-tumor vaccination with CpG-ODN was able to induce immune 
responses but was only effective in prophylactic setting
300, 301, 302, 303
. In contrast, 
Intra- and peritumoral injection of CpG-ODN was found by us and other groups to 
lead to rejection of established tumors
304, 305, 306
. This rejection was dependent on the 
activation of cytotoxic T cells and NK cells
305
. However, these studies have not 
investigated whether CpG acts as an adjuvant that enhance the priming and activation 
of T cells, or as a danger signal that directly induces changes within the tumor 
microenvironment. In a recent study, our group has shown that systemic CpG-ODN 
application can indeed function as a potent danger signal that renders RT5 tumors 
permissive for tumor-specific CD8
+
 T cells
274
.    
 
In this thesis, I have observed that systemic application of CpG-ODN in 
combination with adoptive transfer of tumor-specific CD8
+
 T cells prolonged the 
survival of RT5 mice. This combination therapy induced massive infiltration of 
leukocytes into RT5 tumors, including CD8
+
 T cells, CD4
+
 T cells, NK cells, DCs and 
macrophages. Of note, CpG-ODN was found to bind to intratumoral macrophages in 
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RT5 tumors
274
. Further analysis demonstrated that CpG-ODN ploarized tumor-
resident macrophages towards a M1-like phenotype, which is characterized by high-
level expression of the M1 marker iNOS and low-level expression of the M2 marker 
CD206 (MRC1). The combination of CpG-ODN with tumor-specific CD8
+
 T cells 
led also to normalization of the tumor vasculature and enhanced expression of 
VCAM-1 on the tumor endothelium. Both processes are known to promote T cell 
infiltration into the tumor. 
 
4.2.2 iNOS activity in tumor-infiltrating macrophages is required 
for normalization of tumor vasculature, T cell recruitment 
and RT5 tumor regression  
 
The present data showed that depletion of the M1-polarized macrophages 
with CLIP inhibited T cell recruitment and tumor rejection obtained by combination 
therapy. Macrophage depletion also prevented normalization of the tumor vasculature 
and diminished VCAM-1 expression on the tumor endothelium, thereby explaining 
the impaired recruitment of tumor-specific CD8
+ 
T cells into the tumor. Importantly, 
blockade of iNOS with L-NIL treatment impeded normalization of the tumor 
vasculature, expression of VCAM-1 on the tumor endothelium, infiltration of tumor-
specific CD8
+
 T cells and tumor regression, indicating that iNOS expression in 
macrophages is critical for anti-tumoral effects of macrophages. These observations 
were suprising and puzzling, because after NO was mainly regarded as a toxic 
molecule and iNOS, therefore, as an immunosuppressive moeity
307
.  
 
In order to study in more detail the mechanim by which iNOS activity by 
macrophages support tumor immunity, macrophages from wild-type and iNOS-
deficient mice (NOS2
-/-
 mice) were compared for their capacity to induce 
inflammation, normalization of the tumor vasculature and migration of CD8
+
 T cells 
into the tumor. After activtion with LPS and IFN-γ, wild-type and iNOS-deficient 
macrophages exhibited no difference in the expression of inflammatory cytokines and 
chemokines, including TNF-α, IL-12 and IL-1β, CCL2, CCL5, CXCL9 and CXCL10. 
In addition, both wild-type and iNOS-deficient macrophages displayed decreased 
expression of pro-angiogenic molecules, such as VEGF-α, ANG2 and FGF1. Overall, 
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these findings indicate that the lack of iNOS had no major effects on the phenotype of 
activated macrophages. When injected into tumor-bearing mice, activated wild-type 
and NOS2
-/-
 macrophages were found to migrate into the tumor with the same 
efficacy. However, only iNOS
+
 wild-type macrophages were able to induce vascular 
changes in the tumor, such as replacement of dilated vessels with a high number of 
small vessels and induction of VCAM-1 expression on CD31
+
 endothelial cells. Co-
transfer of activated wild-type M1 macrophages with tumor-specific CD8
+
 T cells 
resulted in extensive infiltration by leukocytes, including tumor-specific CD8
+
 T 
cells, NK cells, DCs and macrophages. In contrast, tumors of mice treated by co-
transfer of iNOS-deficient M1 macrophages with tumor-specific CD8
+
 T cells 
displayed restricted infiltration of leukocytes, notably tumor-specific CD8
+
 T cells. 
Furthermore, gene expression profiling of the tumor micronenvironment revealed that 
co-transfer of iNOS
+
 macrophages with CD8
+
 T cells caused strong activation of the 
genes encoding pro-inflammatory molecules, including IFN-α, IFN-β, IFN-γ, TNF-α, 
IL-12, IL-1, IL-2 and IL-6, chemokines, including CCL2, CCL5, CXCL9 and 
CXCL10, and adhesion molecules, including  VCAM-1 and ICAM-1 and strong 
suppression of the genes encoding pro-angiogenic molecules, including VEGF-α, 
ANG2, RGS5, FGF1, PDGF-α. Apparently, the lack of iNOS expression in 
macrophages hindered the augmented expression of pro-inflammatory cytokines, 
chemokines and adhesion molecules achieved after co-transfer of iNOS
+
 macrophages 
with CD8
+
 T cells. Conversely, iNOS deficiency in macrophages led to partial 
reversion of the suppression of the genes encoding proangiogenic molecules. These 
findings show that adoptive transfer of pre-activated macrophages can promote 
infiltration of T cells into the tumor in the absence of additional danger signal such as 
CpG-ODN.  
 
Suprisingly, there were no transferred macrophages left in the tumor 3 days 
after the injection, suggesting that transferred macrophages have short half-life. 
However, after co-transfer of wild-type M1 macrophages and tumor-specific CD8
+
 T 
cells, endogenous intratumoral macrophages exhibited potent M1-like phenotype with 
high expression of iNOS. On the contrary, iNOS deficieny in transferred macrophages 
resulted in impaired polarization of endogenous macrophages towards a iNOS
+
 
phenotype, suggesting that iNOS expression in transferred macrophages play a role in 
polarization of endogenous macrophages probably via induction of infiltration of 
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IFN-γ-producing CD8+ T cells into the tumor. Skewing of endogenous macrophages 
is interesting and deserves further investigation.  
 
The precise mechanisms of normalization of tumor vessels after macrophage 
transfer and the sequence of events are still elusive. Unlike normal vessels, tumor 
vessels display structural and functional abnormalities due to the incessant production 
of proangiogenic factors such as VEGF within the tumor microenvironment. Tumor-
associated macrophages (TAMs) seem to be an important source of VEGF in many 
cancers. Targeted-deletion of VEGF in macrophages was demonstrated to cause 
normalization of tumor vasculature in animal models
73
. These observations indicate 
that the level of VEGF production by macrophages is vital for formation of aberrant 
tumor vessels. Thus, macrophage skewing from a M2-like phenotype towards  a M1-
like phenotype apparently plays a critical role in normalization of tumor vasculature. 
In addition, M1-like macrophages may produce anti-angiogenic molecules, such as 
TNF, CXCL9, CXCL10 and IL-12, representing another mechanism by which M1-
like macrophages induce vascular nomalization. 
 
4.2.3 NO regulates the expression of adhesion molecules on human 
umbilical endothelial cells (HUVECs) 
 
Nitric oxide is produced from of L-arginine and molecular oxygen through 
activity of NO synthases. Neuronal NO synthase (nNOS) is found in neurons, 
endothelial NO synthase (eNOS) is expressed by endotheial cells, and inducible NO 
synthase (iNOS) is produced by myeloid cells, mainly macrophages. NO has diverse 
effects on the immune system but it is best known for its inhibitory activity on T 
cells
307
.  
 
The process of T cell extravasation involves the migration of T cells from the 
blood stream through vascular endothelium into the target tissue, where they exercise 
their effector functions. ICAM-1, VCAM-1 and E-selectin expressed on endothelial 
cells mediate the adhesion of T cells to the wall of blood vessels through interactions 
with a variety of ligands found on T cells
308
. In steady-state conditions, quiescent 
endothelial cells poorly interact with circulating T cells due to the low-level 
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expression of adhesion molecules on their surface. However, in the case of 
inflammation or infection, a variety of pro-inflammatory molecules, such as TNF, 
IFN-γ and IL-1β, are produced, which induce expression of adhesion molecules lining 
the inflammed tissue, thereby promoting T cell infiltration. Since trafficking T cells to 
the tumor is of prime importance, a better understanding of T cell extravasation 
through tumor vessels is important for the development of effective immunotherapies 
against cancer. 
 
In this thesis, iNOS expression in macrophages was found to correlate with 
enhanced expression of VCAM-1 on the tumor endothelium in RT5 mice. In order to 
study the underlying mechanism, as well as the relevance of these findings for human 
endothelial cells, HUVECs were co-cultured with the human THP-1 macrophage-like 
cell line or with primary human macrophages, which were derived from blood 
monocytes. After activation with LPS and IFN-γ, the resulting M1-polarized 
macrophages were found to stimulate the expression of adhesion molecules, including 
VCAM-1, ICAM-1 and E-Selectin on HUVECs. Blocking of iNOS with L-NIL 
inhibited the induction of adhesion molecules obtained during co-culture with M1 
macrophages. The incomplete inhibition suggested that additional factors, such as 
TNF, are involved in regulation of adhesion molecules on endothelial cells. HUVECs 
were treated with the NO donor glyceryl trinitrate (GTN). Interestingly, NO alone at 
low levels were able to augment the expression of above-mentioned adhesion 
molecules, indicating that the level of NO is a critical parameter for the expression of 
adhesion molecules. Our study also that low concentrations of NO was observed to 
potentiate TNF-induced expression of VCAM-1, ICAM-1 and E-selectin on HUVECs 
whereas high concentrations blocked TNF-induced expression of these molecules.  
 
Microarray analysis of  revealed that the genes encoding adhesion molecules, 
such as VCAM-1 and E-Selectin, and chemokines, such as CX3CL1, CCL20, 
CXCL10, CXCL5, CXCL2 and IL-8 (CXCL8), are highly upregulated in HUVECs 
treated with low level of NO. TNF-treated HUVECs displayed comparable gene 
expression pattern with increased expression of above-mentioned molecules. NO 
treatment resulted in activation of diapedesis pathways in HUVECs, indicating that 
NO-treated HUVECs exhibit enhanced capaticity for transendothelial migration of 
leukocytes. Moreover, NO acts on a variety of signaling transduction pathways in 
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HUVECs for the regulation of gene expression. Similar gene expression profiling of 
NO- and TNF-treated HUVECs suggests that NO works via NF-κB activation. 
Umansky et al.’s findings, where low level of NO was found to enhance TNF-induced 
activation of NF-κB, reinforces this hypothesis. However, more analysis should be 
carried out to identify the mechanism by which NO modulates the process of NF-κB 
activation. 
 
The role of NO in normalization of tumor vasculature and leukocyte 
extravasation is unclear. A previous study reported that inhibition of NO production 
by glioblastomas via blockade of nNOS caused normalization of the tumor 
vasculature, resulting in enhanced oxygenation of tumors and improved efficacy of 
radiation therapy
309
. Another study showed that endothelin B receptor (ETBR) 
induced upregulation of NO synthases, resulting in NO release from the 
endothelium
310
. NO in turn impeded the expression of ICAM-1 on the tumor 
endothelium, impairing T cell adhesion and, consequently, preventing T cell 
infiltration into the tumor
311
. In addition, several groups have examined the influence 
of NO on adhesion molecules expressed by HUVECs using a variety of NO donors
312, 
313, 314, 315
. In these studies, NO was found to downregulate the endothelial expression 
of VCAM-1, ICAM-1 and E-Selectin
312, 313, 314, 315
. In contrast to these findings, this 
study demonstrated that low level of NO induced the expression of adhesion 
molecules on HUVECs. In addition, iNOS activity in M1-like macrophages led to 
normalization of the tumor vasculature and increased expression of VCAM-1 on the 
tumor endothelium, indicating that M1-polarized macrophages produce low amounts 
of NO that are required for induction of adhesion molecules on endothelial cells. 
These contradictory data suggest that the source or amount of NO are key factors for 
its inhibitory or stimulatory properties within the tumor microenvironment.  It seems 
that, in order to establish the conditions under which NO upregulate or downregulate 
endothelial expression of adhesion molecules, NO levels within the immediate 
environment of endothelial cells should be determined. 
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4.3 Conclusions 
 
The results obtained in two different systems revealed a unifying mechanism 
of tumor rejection, in which M1 skewing of intratumoral macrophages plays a central 
role in T cell-mediated rejection of tumors (summarized in Figure 38).  
 
Tumor-infiltrating macrophages are mainly of an M2-like phenotype 
characterized by high-level expression of immunosuppressive molecules and pro-
angiogenic factors such as VEGF that are known to cause abnormal morphology of 
tumor vessels. The present study shows that polarization of tumor-associated 
macrophages towards an M1-like phenotype by danger signals such as CpG-ODN or 
basophilia-induced CD8
+
 T cell infiltration play a central for tumor rejection. M1-
skewed macrophages produce only low amounts of VEGF, leading to the removal of 
key driver of tumor angiogenesis and promoting normalization of the tumor 
vasculature, which is known to enhance T cell infiltration. In addition, M1-
polarization leads to production of NO by macrophages, which can enhance 
expression of adhesion molecules such as VCAM-1 on the tumor endothelium, 
thereby augmenting T cell infiltration into the tumor. M1-polarized macrophages also 
produce large amounts of CXCL9 and CXCL10, which attract tumor-reactive T cells 
into the tumor. Then, in a feedback mechanism, infiltrating T cells lead to more M1 
skewing, normalization and VCAM-1 expression, thereby to more T cell infiltration 
and tumor eradication.  
 
Despite the fact that increasing our understanding of the tumor 
microenvironment has accelerated the progress in the development of effective 
immunotherapies, including vaccination, adoptive T therapy and immune checkpoint 
inhibitors, against cancer, the clinical success is still limited. One of the major 
limitations of cancer immunotherapy is failure of T cell trafficking to the tumor due to 
low levels of inflammation and chemokines, and aberrant tumor vasculature. Based 
on the present study, targeted modulation of Tregs, basophils or macrophages 
represents a promising strategy for promoting the recruitment of tumor-specific CD8
+ 
T cells into the tumor. Moreover, adoptive transfer of pre-activated macrophages 
emerges as a promising tool for improvement of clinical cancer therapy.  
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Figure 38: Polarization of M2-like macrophages into M1-like macrophages play a central in tumor 
rejection.  
Tumor-associated macrophages (TAMs) with M2-like phenotype lead to abnormal tumor vasculature by producing 
angiogenic factors, such as VEGF, thereby impairing CD8
+
 T cell infiltration into the tumor. Basophill-derived 
CCL3 and CCL4 induces migration of IFN-γ-producing CD8
+
 T cells into the tumor. Elevated levels of IFN-γ 
polarize TAMs from M2-like phenotype to M1-like phenotype. M1 skweing of TAMs can also be achieved by 
systemic administration of CpG-ODN. M1-skewed macrophages enhance CD8
+
 infiltration into the tumor by 
several mechanisms: M1-like macrophages produce only little amount of VEGF, leading to removal of the most 
potent proangiogenic factor and promoting normalization of the tumor vasculaturecell infiltration. M1-polarized 
macrophages produce nitric oxide (NO), which enhances expression of adhesion molecules, such as VCAM-1, on 
tumor endothelial cells. M1-skewed macrophages also produce large amounts of CXCL9 and CXCL10, which are 
known to be potent chemoattractants for CD8
+
 T cells. 
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6 ABBREVIATIONS 
 
A 
 
ACT adoptive cell therapy 
AIRE autoimmune regulator 
ANGPT2 angiopoeitin 2 
APC antigen presenting cell 
ARG1 arginase 1 
 
B 
 
B16-OVA ovalbumin-expressing B16 
BAC bacterial artificial chromosome 
b-FGF basic-fibroblast growth factor 
BMCP basophil-mast cell common progenitor 
 
C 
 
C3a complement factor 3a 
C5a complement factor 5a 
CAF carcinoma-associated fibroblast 
CAR chimeric antigen receptor 
CCL2 chemokine C-C motif ligand 2 
CCL3 chemokine C-C motif ligand 3 
CCL4 chemokine C-C motif ligand 4 
CCL5 chemokine C-C motif ligand 5 
CCL7 chemokine C-C motif ligand 7 
CCL11 chemokine C-C motif ligand 11 
CCL19 chemokine C-C motif ligand 19 
CCL20 chemokine C-C motif ligand 20 
CCL22 chemokine C-C motif ligand 22 
CCL24 chemokine C-C motif ligand 24 
CCL28 chemokine C-C motif ligand 28 
CCR1 chemokine C-C motif receptor 1 
CCR2 chemokine C-C motif receptor 2 
CCR3 chemokine C-C motif receptor 3 
CCR4 chemokine C-C motif receptor 4 
CCR7 chemokine C-C motif receptor 7 
CCR10 chemokine C-C motif receptor 10 
cDNA complementary deoxyribonucleic acid 
c-Kit mast/stem cell growth factor receptor 
CLIP clodronate-loaded liposomes 
CLP common lymphoid progenitor 
CMP common myeloid progenitor 
CpG cytosine-phosphorothioate-guanine 
CTLA4 cytotoxic T lymphocyte antigen-4 
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CVID common variable immunodeficiency 
CX3CL1 chemokine C-X3-C motif ligand 1 
CXCL2 chemokine C-X-C motif ligand 2 
CXCL5 chemokine C-X-C motif ligand 5 
CXCL6 chemokine C-X-C motif ligand 6 
CXCL9 chemokine C-X-C motif ligand 9 
CXCL10 chemokine C-X-C motif ligand 10 
CXCR1 chemokine C-X-C motif receptor 1 
CXCR4 chemokine C-X-C motif receptor 1 
 
D 
 
DAMP danger-associated molecular pattern 
DARC duffy antigen/chemokine receptor 
DC dendritic cell 
DT diphtheria toxin 
DTR diphtheria toxin receptor 
 
E 
 
EBI3 Epstein-Barr virus induced gene 3 
EC endothelial cell 
ECM extracellular matrix 
eGFP enhanced green fluorescent protein 
eNOS endothelial nitric oxide synthase 
 
F 
 
FAP fibroblast-activating protein 
FasL fas ligand 
FcεRI high-affinity immunoglobulin E receptor 
FDA United States Food and Drug Administration 
FGF fibroblast growth factor 
FGF1 fibroblast growth factor 1 
fMLP N-formyl-methionine-leucine-phenylanaline 
Foxp3 forkhead box P3 
 
G 
 
GIST gastrointestinal stromal tumors 
GM-CSF granulocyte macrophage colony-stimulating factor 
GMP granulocyte-monocyte progenitor 
gp100 glycoprotein 100 
GTN glyceryl trinitrate 
 
H 
 
HB-EGF heparin-binding epidermal growth factor 
HIF-1 hypoxia-inducible factor-1 
HIF-2 hypoxia-inducible factor-2 
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HSC hematopoietic stem cell 
HUVEC human umbilical vein endothelial cell 
 
I 
 
ICAM-1 intracellular adhesion molecule-1 
ICAM-2 intracellular adhesion molecule-2 
IDO indoleamine 2,3-dioxygenase 
IFN-α interferon-alpha 
IFN-β interferon-beta 
IFN-γ interferon-gamma 
IgA immunoglobulin A 
IgD immunoglobulin D 
IgE immunoglobulin E 
IL-1β interleukin-1beta 
IL-2 interleukin-2 
IL-3 interleukin-3 
IL-4 interleukin-4 
IL-5 interleukin-5 
IL-6 interlukin-6 
IL-8 interleukin-8 
IL-9 interleukin-9 
IL-10 interleukin-10 
IL-12 interleukin-12 
IL-13 interleukin-13 
IL-17 interleukin-17 
IL-18 interleukin-18 
IL-25 interleukin-25 
IL-33 interleukin-33 
IL-35 interleukin-35 
iNOS inducible nitric oxide synthase 
iTreg inducible regulatory T cell 
 
L 
 
LAG-3 lymphocyte-activation gene-3 
LAMC2 laminin, gamma 2 
L-NIL N6-(1-iminoethyl)-L-lysine 
LPS lipopolysaccharide 
LTB lymphotoxin beta 
LTC4 leukotriene C4 
 
M 
 
M-CSF macrophage colony-stimulating factor 
MDS myelodysplastic syndrome 
MDSC myeloid-derived suppressor cell 
MHC  major histocompatibility complex 
MIF macrophage inhibitory factor 
mMCP8 mast cell protease 8 
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MMP10 matrix metallopeptidase 10 
MRC1 mannose receptor 1, c type 1 
mRNA messenger ribonucleic acid 
mTEC medullary thymic epithelial cells 
MX1 myxovirus resistance 1 
 
N 
 
NK natural killer 
NO nitric oxide 
nNOS neuronal nitric oxide synthase 
nTreg natural regulatory T cell 
 
O 
 
ODN oligodeoxynucleotide   
OVA ovalbumin 
 
P 
 
PAF platelet activating factor 
PAMP pathogen-associated molecular pattern 
PanNET pancreatic neuroendocrine tumor 
PDGF platelet-derived growth factor 
PDGF-α platelet-derived growth factor-alpha 
PD-1 programmed death receptor-1 
PD-L1 programmed death ligand-1 
PD-L2 programmed death ligand-2 
PGD2 prostagladin D2 
PGE2 prostagladin E2 
PlGF placental growth factor 
PLIP PBS-loaded liposomes 
PMA phorbol myristate acetate 
PPARG peroxisome-proliferating receptor-γ 
 
Q 
 
qRT-PCR quantitative real time-polymerase chain reaction 
 
R 
 
RAG2 recombination activating gene 2 
RGS5 regulator of G-protein signaling 5 
RIP rat insulin promoter 
RMA-Tag simian virus 40 large T antigen-expressing RMA 
RNA ribonucleic acid 
RNS reactive nitrogen species 
RT5 Rip1-Tag5 
RT-PCR real time-polymerase chain reaction 
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S 
 
SELE E-Selectin 
SEMA4D semaphoring 4D 
SLC7A2 solute carrier family 7(cationic amino acid transporter,y+system), member 2 
SOD2 superoxide dismutase 2 
SV40-Tag simian virus 40 large T antigen 
 
T 
 
TAM tumor-associated macrophage 
TCR T cell receptor 
Th-1 T-helper 1 
Th-2 T-helper 2 
TGF-β transforming growth factor-beta 
TIM-3 T cell immunoglobulin mucin-3 
TLR toll-like receptor 
TLR9 toll-like receptor 9 
TNF tumor necrosis factor 
TNF-α tumor necrosis factor-alpha 
TRAIL tumor necrosis factor-related apoptosis-inducing ligand 
Treg regulatory T cell 
TRP-1 tyrosinase related protein-1 
TRP-2 tyrosinase related protein-2 
TSLP thymic stromal lymphopoietin 
 
U 
 
UBD ubiquitin D 
 
V 
 
VCAM-1 vascular cell adhesion molecule-1  
VEGF vascular endothelial growth factor 
VEGF-α vascular endothelial growth factor-alpha 
 
 
